U.S. patent application number 16/391738 was filed with the patent office on 2020-03-19 for immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines.
This patent application is currently assigned to Genentech, Inc.. The applicant listed for this patent is Genentech, Inc.. Invention is credited to Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski.
Application Number | 20200085840 16/391738 |
Document ID | / |
Family ID | 54293331 |
Filed Date | 2020-03-19 |
View All Diagrams
United States Patent
Application |
20200085840 |
Kind Code |
A1 |
Chen; Xiaocheng ; et
al. |
March 19, 2020 |
Immunoconjugates Comprising Anti-HER2 Antibodies and
Pyrrolobenzodiazepines
Abstract
The invention provides immunoconjugates comprising anti-HER2
antibodies and methods of using the same.
Inventors: |
Chen; Xiaocheng;
(Burlingame, CA) ; Dennis; Mark; (San Carlos,
CA) ; Junutula; Jagath Reddy; (Fremont, CA) ;
Phillips; Gail Lewis; (San Carlos, CA) ; Pillow;
Thomas Harden; (San Francisco, CA) ; Sliwkowski; Mark
X.; (San Carlos, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Genentech, Inc. |
South San Francisco |
CA |
US |
|
|
Assignee: |
Genentech, Inc.
South San Francisco
CA
|
Family ID: |
54293331 |
Appl. No.: |
16/391738 |
Filed: |
April 23, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15438418 |
Feb 21, 2017 |
10314846 |
|
|
16391738 |
|
|
|
|
PCT/US2015/050382 |
Sep 16, 2015 |
|
|
|
15438418 |
|
|
|
|
62051562 |
Sep 17, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/24 20130101;
A61K 39/39558 20130101; A61K 47/6869 20170801; C07K 16/005
20130101; A61K 47/6803 20170801; A61P 35/04 20180101; A61K 31/5517
20130101; A61K 47/6855 20170801; A61P 35/00 20180101; A61P 43/00
20180101; C07K 16/32 20130101; C07K 2317/92 20130101 |
International
Class: |
A61K 31/5517 20060101
A61K031/5517; A61K 47/68 20060101 A61K047/68; A61K 39/395 20060101
A61K039/395; C07K 16/00 20060101 C07K016/00; C07K 16/32 20060101
C07K016/32 |
Claims
1. An immunoconjugate comprising an antibody and a cytotoxic agent,
wherein the immunoconjugate has the formula Ab-(L-D)p, wherein: (a)
Ab is the antibody; (b) L is a linker; (c) D is a cytotoxic agent;
and (d) p ranges from 1-8; and wherein D is a pyrrolobenzodiazepine
and L-D comprises the structure: ##STR00033## wherein: Y has the
formula: ##STR00034## G is a linker connected to the antibody; n is
an integer selected in the range of 0 to 48; and wherein the
antibody is a humanized monoclonal antibody that binds HER2
comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO: 15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
16; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17;
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (f)
HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.
2. The immunoconjugate of claim 1, wherein the antibody comprises a
heavy chain variable region comprising the sequence of SEQ ID NO:
11 and a light chain variable region comprising the sequence of SEQ
ID NO: 10.
3. (canceled)
4. (canceled)
5. The immunoconjugate of claim 1, which is an antibody fragment
that binds HER2.
6. The immunoconjugate of claim 1, wherein HER2 is human HER2
comprising amino acids 23 to 1255 of SEQ ID NO: 1.
7. The immunoconjugate of an claim 1, wherein the antibody binds to
extracellular domain I of HER2.
8. The immunoconjugate of claim 7, wherein extracellular domain I
of HER2 has the sequence of SEQ ID NO: 35.
9. The immunoconjugate of claim 4, which is an IgG1, IgG2a or IgG2b
antibody.
10. The immunoconjugate of claim 1, wherein the antibody comprises
one or more engineered free cysteine amino acids residues.
11. The immunoconjugate of claim 10, wherein the one or more
engineered free cysteine amino acids residues are located in the
heavy chain.
12. The immunoconjugate of claim 10, wherein the one or more
engineered free cysteine amino acids residues are located in the
light chain.
13. The immunoconjugate of claim 11, wherein the antibody comprises
at least one mutation in the heavy chain constant region selected
from A118C and S400C.
14. The immunoconjugate of claim 12, wherein the antibody comprises
at least one mutation in the light chain constant region selected
from K149C and V205C.
15. The immunoconjugate of claim 1, wherein the antibody comprises:
a) a heavy chain comprising the sequence of SEQ ID NO: 19 and a
light chain comprising the sequence of SEQ ID NO: 18; or b) a heavy
chain comprising the sequence of SEQ ID NO: 19 and a light chain
comprising the sequence of SEQ ID NO: 23; or c) a heavy chain
comprising the sequence of SEQ ID NO: 24 and a light chain
comprising the sequence of SEQ ID NO: 18.
16. The immunoconjugate of claim 1, wherein the antibody comprises
the heavy chain constant region of SEQ ID NO: 28.
17. The immunoconjugate of claim 1, wherein the antibody comprises
the light chain constant region of SEQ ID NO: 25.
18.-32. (canceled)
33. The immunoconjugate of claim 1, comprising the structure:
##STR00035##
34. The immunoconjugate of claim 1, wherein p ranges from 1.3-2 or
from 2-5.
35. A pharmaceutical formulation comprising the immunoconjugate of
claim 1 and a pharmaceutically acceptable carrier.
36. The pharmaceutical formulation of claim 35, further comprising
an additional therapeutic agent.
37. The pharmaceutical formulation of claim 36, wherein the
additional therapeutic agent is an antibody or immunoconjugate that
binds HER2.
38. The pharmaceutical formulation of claim 37, wherein the
additional therapeutic agent is (i) an antibody or immunoconjugate
that binds to domain II of HER2, and/or (ii) an antibody or
immunoconjugate that binds to domain IV or HER2.
39. The pharmaceutical formulation of claim 38, wherein the
additional therapeutic agent is (i) an antibody or immunoconjugate
that binds to epitope 2C4, and/or (ii) an antibody or
immunoconjugate that binds to epitope 4D5.
40. The pharmaceutical formulation of claim 36, wherein the
additional therapeutic agent is trastuzumab, trastuzumab-MCC-DM1
(T-DM1), and/or pertuzumab.
41. The pharmaceutical formulation of claim 36, further comprising
(1) trastuzumab or T-DM1, and (2) pertuzumab.
42. A method of treating an individual having a HER2-positive
cancer, the method comprising administering to the individual an
effective amount of the immunoconjugate of claim 1.
43. The method of claim 42, wherein the HER2-positive cancer is
breast cancer or gastric cancer.
44. The method of claim 43, wherein the HER2-positive breast cancer
is early-stage breast cancer.
45. The method of claim 43, wherein the HER2-positive breast cancer
is metastatic breast cancer.
46. The method of claim 42, further comprising administering an
additional therapeutic agent to the individual.
47. A method of treating an individual having a HER2-positive
cancer, the method comprising administering to the individual an
effective amount of the immunoconjugate of claim 1 and at least one
additional therapeutic agent to the individual.
48. The method of claim 47, wherein the additional therapeutic
agent is an antibody or immunoconjugate that binds HER2.
49. The method of claim 48, wherein the additional therapeutic
agent is (i) an antibody or immunoconjugate that binds to domain II
of HER2, and/or (ii) an antibody or immunoconjugate that binds to
domain IV or HER2.
50. The method of claim 49, wherein the additional therapeutic
agent is (i) an antibody or immunoconjugate that binds to epitope
2C4, and/or (ii) an antibody or immunoconjugate that binds to
epitope 4D5.
51. The method of claim 47, wherein the additional therapeutic
agent is selected from trastuzumab, trastuzumab-MCC-DM1 (T-DM1),
and pertuzumab.
52. The method of claim 47, wherein the additional therapeutic
agents are (1) trastuzumab or T-DM1, and (2) pertuzumab.
53. The method of claim 47, wherein the HER2-positive cancer is
breast cancer or gastric cancer.
54. The method of claim 53, wherein the HER2-positive breast cancer
is metastatic breast cancer.
55. The method of claim 53, wherein the HER2-positive breast cancer
is early-stage breast cancer.
56. The method of claim 42, wherein the HER2-positive cancer is
recurrent cancer.
57. The method of claim 56, wherein the recurrent cancer is locally
recurrent cancer.
58. The method of claim 42, wherein the HER2-positive cancer is
advanced cancer.
59. The method of claim 42, wherein the HER2-positive cancer is
non-resectable.
60. A method of treating an individual having a HER2-positive
cancer, comprising: a) subjecting the individual to neoadjuvant
treatment with the immunoconjugate claim 1, b) removing the cancer
by definitive surgery, and c) subjecting the individual to adjuvant
treatment with the immunoconjugate of claim 1.
61. The method of claim 60, wherein the HER2-positive cancer is
breast cancer or gastric cancer.
62. The method of claim 61, wherein the HER2-positive cancer is
breast cancer.
63. A method of inhibiting proliferation of a HER2-positive cell,
the method comprising exposing the cell to the immunoconjugate of
claim 1 under conditions permissive for binding of the
immunoconjugate to HER2 on the surface of the cell, thereby
inhibiting proliferation of the cell.
64. The method of claim 63, wherein the cell is a breast cancer
cell or a gastric cancer cell.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S.
application Ser. No. 15/438,418, filed Feb. 21, 2017, which is a
continuation of International Application No. PCT/US2015/050382,
filed Sep. 16, 2015, which claims the benefit of priority of U.S.
Provisional Application No. 62/051,562, filed Sep. 17, 2014, each
of which is incorporated by reference herein in its entirety for
any purpose.
SEQUENCE LISTING
[0002] The present application is filed with a Sequence Listing in
electronic format. The Sequence Listing is provided as a file
entitled "2019-04-22_01146-0039-01US_Sequence_Listing_ST25.txt"
created on Feb. 14, 2017, which is 76,260 bytes in size. The
information in the electronic format of the sequence listing is
incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0003] The present invention relates to immunoconjugates comprising
anti-HER2 antibodies and methods of using the same.
BACKGROUND
[0004] Breast cancer is a highly significant cause of morbidity and
mortality worldwide. There are over 1.3 million cases of breast
cancer diagnosed globally each year with more than 450,000 deaths
related to the disease (Jemal A, Bray F, Center M, et al. Global
cancer statistics. CA Cancer J Clin, 2011; 61(2):69-90).
[0005] The HER2 (ErbB2) receptor tyrosine kinase is a member of the
epidermal growth factor receptor (EGFR) family of transmembrane
receptors. Overexpression of HER2 is observed in approximately 20%
of human breast cancers and is implicated in the aggressive growth
and poor clinical outcomes associated with these tumors (Slamon et
al (1987) Science 235:177-182). HER2 protein overexpression can be
determined using an immunohistochemistry based assessment of fixed
tumor blocks (Press M F, et al (1993) Cancer Res 53:4960-70).
[0006] Trastuzumab (CAS 180288-69-1, HERCEPTIN.RTM., huMAb4D5-8,
rhuMAb HER2, Genentech) is a recombinant DNA-derived, IgG1 kappa,
monoclonal antibody that is a humanized version of a murine
anti-HER2 antibody (4D5) that selectively binds with high affinity
in a cell-based assay (Kd=5 nM) to the extracellular domain of HER2
(U.S. Pat. Nos. 5,677,171; 5,821,337; 6,054,297; 6,165,464;
6,339,142; 6,407,213; 6,639,055; 6,719,971; 6,800,738; 7,074,404;
Coussens et al (1985) Science 230:1132-9; Slamon et al (1989)
Science 244:707-12; Slamon et al (2001) New Engl. J. Med.
344:783-792). Trastuzumab has been shown, in both in vitro assays
and in animals, to inhibit the proliferation of human tumor cells
that overexpress HER2 (Hudziak et al (1989) Mol Cell Biol
9:1165-72; Lewis et al (1993) Cancer Immunol Immunother; 37:255-63;
Baselga et al (1998) Cancer Res. 58:2825-2831). Trastuzumab is a
mediator of antibody-dependent cellular cytotoxicity, ADCC (Lewis
et al (1993) Cancer Immunol Immunother 37(4):255-263; Hotaling et
al (1996) [abstract]. Proc. Annual Meeting Am Assoc Cancer Res;
37:471; Pegram M D, et al (1997) [abstract]. Proc Am Assoc Cancer
Res; 38:602; Sliwkowski et al (1999) Seminars in Oncology 26(4),
Suppl 12:60-70; Yarden Y. and Sliwkowski, M. (2001) Nature Reviews:
Molecular Cell Biology, Macmillan Magazines, Ltd., Vol.
2:127-137).
[0007] HERCEPTIN.RTM. was approved in 1998 for the treatment of
patients with HER2-overexpressing metastatic breast cancers
(Baselga et al, (1996) J. Clin. Oncol. 14:737-744) that have
received extensive prior anti-cancer therapy, and has since been
used in over 300,000 patients (Slamon D J, et al. N Engl J Med
2001; 344:783-92; Vogel C L, et al. J Clin Oncol 2002; 20:719-26;
Marty M, et al. J Clin Oncol 2005; 23:4265-74; Romond E H, et al. T
N Engl J Med 2005; 353:1673-84; Piccart-Gebhart M J, et al. N Engl
J Med 2005; 353:1659-72; Slamon D, et al. [abstract]. Breast Cancer
Res Treat 2006, 100 (Suppl 1): 52). In 2006, the FDA approved
HERCEPTIN.RTM. (trastuzumab, Genentech Inc.) as part of a treatment
regimen containing doxorubicin, cyclophosphamide and paclitaxel for
the adjuvant treatment of patients with HER2-positive,
node-positive breast cancer.
[0008] Trastuzumab-MCC-DM1 (T-DM1, trastuzumab emtansine,
ado-trastuzumab emtansine, KADCYLA.RTM.), a novel antibody-drug
conjugate (ADC) for the treatment of HER2-positive breast cancer,
is composed of the cytotoxic agent DM1 (a thiol-containing
maytansinoid anti-microtubule agent) conjugated to trastuzumab at
lysine side chains via an MCC linker, with an average drug load
(drug to antibody ratio) of about 3.5. After binding to HER2
expressed on tumor cells, T-DM1 undergoes receptor-mediated
internalization, resulting in intracellular release of cytotoxic
catabolites containing DM1 and subsequent cell death.
[0009] The U.S. Food and Drug Administration approved
ado-trastuzumab emtansine, marketed under the tradename
KADCYLA.RTM., on Feb. 22, 2013 for the treatment of patients with
HER2-positive, metastatic breast cancer who previously received
treatment with trastuzumab and a taxane.
[0010] Pertuzumab (also known as recombinant humanized monoclonal
antibody 2C4, rhuMAb 2C4, PERJETA.RTM., Genentech, Inc, South San
Francisco) represents the first in a new class of agents known as
HER dimerization inhibitors (HDI) and functions to inhibit the
ability of HER2 to form active heterodimers or homodimers with
other HER receptors (such as EGFR/HER1, HER2, HER3 and HER4). See,
for example, Harari and Yarden Oncogene 19:6102-14 (2000); Yarden
and Sliwkowski. Nat Rev Mol Cell Biol 2:127-37 (2001); Sliwkowski
Nat Struct Biol 10:158-9 (2003); Cho et al. Nature 421:756-60
(2003); and Malik et al. Pro Am Soc Cancer Res 44:176-7 (2003)
[0011] Pertuzumab blockade of the formation of HER2-HER 3
heterodimers in tumor cells has been demonstrated to inhibit
critical cell signaling, which results in reduced tumor
proliferation and survival (Agus et al. Cancer Cell 2:127-37
(2002)).
[0012] Pertuzumab has been evaluated in Phase II studies in
combination with trastuzumab in patients with HER2-positive
metastatic breast cancer who have previously received trastuzumab
for metastatic disease. One study, conducted by the National cancer
Institute (NC1), enrolled 11 patients with previously treated
HER2-positive metastatic breast cancer. Two out of the 11 patients
exhibited a partial response (PR) (Baselga et al., J Clin Oncol
2007 ASCO Annual Meeting Proceedings; 25:18 S (June 20 Supplement):
1004. The results of a Phase II neoadjuvant study evaluating the
effect of a novel combination regimen of pertuzumab and trastuzumab
plus chemotherapy (Docetaxel) in women with early-stage
HER2-positive breast cancer, presented at the CTRC-AACR San Antonio
Breast Cancer Symposium (SABCS), Dec. 8-12, 2010, showed that the
two HER2 antibodies plus Docetaxel given in the neoadjuvant setting
prior to surgery significantly improved the rate of complete tumor
disappearance (pathological complete response rate, pCR, of 45.8
percent) in the breast by more than half compared to trastuzumab
plus Docetaxel (pCR of 29.0 percent), p=0.014.
[0013] Pertuzumab, marketed under the tradename PERJETA.RTM., was
approved in 2012 for the treatment of patients with advanced or
late-stage (metastatic) HER2-positive breast cancer. HER2-positive
breast cancers have increased amounts of the HER2 protein that
contributes to cancer cell growth and survival.
[0014] On Sep. 30, 2013, the U.S. Food and Drug Administration
granted accelerated approval to PERJETA.RTM. (pertuzumab) as part
of a complete treatment regimen for patients with early stage
breast cancer (EBC) before surgery (neoadjuvant setting).
PERJETA.RTM. is the first FDA-approved drug for the neoadjuvant
treatment of breast cancer.
[0015] There is a need in the art for additional safe and effective
agents that target HER2 for treatment of HER2-associated
conditions, such as breast cancer, for use in monotherapy and
combination therapy. The invention fulfills that need and provides
other benefits.
SUMMARY
[0016] The invention provides immunoconjugates comprising anti-HER2
antibodies and methods of using the same.
[0017] In some embodiments, an immunoconjugate is provided, which
comprises an antibody and a cytotoxic agent, wherein the cytotoxic
agent is a center-linked pyrrolobenzodiazepine. In some
embodiments, the immunoconjugate has the formula Ab-(L-D)p,
wherein: [0018] a) Ab is the antibody of any one of claim 1 to 16;
[0019] b) L is a linker; [0020] c) D is a center-linked
pyrrolobenzodiazepine; and [0021] d) p ranges from 1-8. In some
embodiments, L-D is of Formula A:
##STR00001##
[0021] wherein:
[0022] R.sup.2 is
##STR00002##
where R.sup.36a and R.sup.36b are independently selected from H, F,
C.sub.1-4 saturated alkyl, C.sub.2-3 alkenyl, which alkyl and
alkenyl groups are optionally substituted by a group selected from
C.sub.1-4 alkyl amido and C.sub.1-4 alkyl ester; or, when one of
R.sup.36a and R.sup.36b is H, the other is selected from nitrile
and a C.sub.1-4 alkyl ester;
[0023] R.sup.6 and R.sup.9 are independently selected from H, R,
OH, OR, SH, SR, NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and
halo;
[0024] R.sup.7 is independently selected from H, R, OH, OR, SH, SR,
NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and halo;
[0025] Y has the formula:
##STR00003##
[0026] G is a linker connected to the antibody;
[0027] n is an integer selected in the range of 0 to 48;
[0028] R.sup.A4 is a C.sub.1-6 alkylene group;
[0029] either: [0030] (a) R.sup.10 is H, and R.sup.11 is OH,
OR.sup.A, where R.sup.A is C.sub.1-4 alkyl; or [0031] (b) R.sup.0
and R.sup.11 form a nitrogen-carbon double bond between the
nitrogen and carbon atoms to which they are bound; or [0032] (c)
R.sup.0 is H and R.sup.11 is OSO.sub.zM, where z is 2 or 3 and M is
a monovalent pharmaceutically acceptable cation;
[0033] R and R' are each independently selected from optionally
substituted C.sub.1-12 alkyl, C.sub.3-20 heterocyclyl and
C.sub.5-20 aryl groups, and optionally in relation to the group
NRR', R and R' together with the nitrogen atom to which they are
attached form an optionally substituted 4-, 5-, 6- or 7-membered
heterocyclic ring;
[0034] R.sup.6, R.sup.17, R.sup.19, R.sup.20, R.sup.21 and R.sup.22
are as defined for R.sup.6, R.sup.7, R.sup.9, R.sup.10, R.sup.11
and R.sup.2 respectively;
[0035] Z is CH or N;
[0036] T and T'' are independently selected from a single bond or a
C.sub.1-9 alkylene, which chain may be interrupted by one or more
heteroatoms, e.g., O, S, N(H), NMe, provided that the number of
atoms in the shortest chain of atoms between X and X' is 3 to 12
atoms; and
[0037] X and X' are independently selected from O, S and N(H);
and
[0038] wherein the antibody binds to HER2 and comprises (a) HVR-H1
comprising the amino acid sequence of SEQ ID NO: 15; (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO: 16; (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO: 17; (d) HVR-L1
comprising the amino acid sequence of SEQ ID NO: 12; (e) HVR-L2
comprising the amino acid sequence of SEQ ID NO: 13; and (f) HVR-L3
comprising the amino acid sequence of SEQ ID NO: 14. In some
embodiments, the antibody comprises a heavy chain variable region
comprising the sequence of SEQ ID NO: 11 and a light chain variable
region comprising the sequence of SEQ ID NO: 10. In some
embodiments, the antibody is a monoclonal antibody. In some
embodiments, the antibody is a humanized or chimeric antibody. In
some embodiments, the antibody is an antibody fragment that binds
HER2.
[0039] In some embodiments, HER2 is human HER2 comprising amino
acids 23 to 1255 of SEQ ID NO: 1. In some embodiments, the antibody
binds to extracellular domain I of HER2. In some embodiments,
extracellular domain I of HER2 has the sequence of SEQ ID NO: 35.
In some embodiments, the antibody binds to loop 163-189 and loop
185-189 of extracellular domain I (e.g., a first loop defined by
amino acids 163-189 and a second loop defined by amino acids
185-189 of extracellular domain I). In some embodiments, the
antibody contacts His171, Ser186, Ser187 and Glu188 of
extracellular domain I.
[0040] In some embodiments, the antibody is an IgG1, IgG2a or IgG2b
antibody. In any of the embodiments described herein, the antibody
may comprise one or more engineered free cysteine amino acids
residues. In any of the embodiments described herein, the one or
more engineered free cysteine amino acids residues may be located
in the heavy chain. In any of the embodiments described herein, the
one or more engineered free cysteine amino acids residues may be
located in the light chain. In some embodiments, the antibody
comprises at least one mutation in the heavy chain constant region
selected from A118C and S400C. In some embodiments, the antibody
comprises at least one mutation in the light chain constant region
selected from K149C and V205C.
[0041] In some embodiments, the antibody comprises: [0042] a) a
heavy chain comprising the sequence of SEQ ID NO: 19 and a light
chain comprising the sequence of SEQ ID NO: 18; or [0043] b) a
heavy chain comprising the sequence of SEQ ID NO: 19 and a light
chain comprising the sequence of SEQ ID NO: 23; or [0044] c) a
heavy chain comprising the sequence of SEQ ID NO: 24 and a light
chain comprising the sequence of SEQ ID NO: 18.
[0045] In some embodiments, the antibody comprises the heavy chain
constant region of SEQ ID NO: 28.
[0046] In some embodiments, the antibody comprises the light chain
constant region of SEQ ID NO: 25.
[0047] In some embodiments, the immunoconjugate comprises an
antibody that binds to HER2, wherein the antibody comprises a heavy
chain comprising the sequence of SEQ ID NO: 19 and a light chain
comprising the sequence of SEQ ID NO: 23. In some embodiments, an
isolated antibody that binds to HER2 is provided, wherein the
antibody comprises a heavy chain comprising the sequence of SEQ ID
NO: 24 and a light chain comprising the sequence of SEQ ID NO:
18.
[0048] In some embodiments of the immunoconjugate, R.sup.9 is H. In
some embodiments, R.sup.6 is H. In some embodiments, R.sup.7 is
OR.sup.7A, where R.sup.7A is optionally substituted C.sub.1-4
alkyl. In some embodiments, R.sup.7A is Me. In some embodiments, X
is O. In some embodiments, T is selected from a single bond,
C.sub.1, and a C.sub.2 alkylene group. In some embodiments, T is a
C.sub.1 alkylene group. In some embodiments, R.sup.36a and
R.sup.36b are both H. In some embodiments, R.sup.36a and R.sup.36b
are both methyl. In some embodiments, one of R.sup.36a and
R.sup.36b is H, and the other is selected from C.sub.1-4 saturated
alkyl, C.sub.2-3 alkenyl, which alkyl and alkenyl groups are
optionally substituted. In some embodiments, the group of R.sup.36a
and R.sup.36b which is not H is selected from methyl and ethyl. In
some embodiments, R.sup.10 is H, and R.sup.11 is OH. In some
embodiments, R.sup.10 and R.sup.11 form a nitrogen-carbon double
bond between the nitrogen and carbon atoms to which they are bound.
In some embodiments, R.sup.16, R.sup.17, R.sup.19, R.sup.20,
R.sup.21, R.sup.22, X' and T' are the same as R.sup.6, R.sup.7,
R.sup.9, R.sup.10, R.sup.11, R.sup.2, X and T, respectively.
[0049] In some embodiments, an immunoconjugate comprises the
structure:
##STR00004##
wherein Y is defined as above. In some embodiments, the
immunoconjugate comprises the structure:
##STR00005##
wherein Ab is an antibody that binds HER2 described herein.
[0050] In any of the immunoconjugates described herein, p may range
from 1.3-2, 1.4-2, 1.5-2, or 2-5.
[0051] In some embodiments, a pharmaceutical formulation is
provided, comprising an immunoconjugate described herein and a
pharmaceutically acceptable carrier. In some embodiments, the
pharmaceutical formulation further comprises an additional
therapeutic agent. In some embodiments, the additional therapeutic
agent is an antibody or immunoconjugate that binds to HER2. In some
embodiments, the additional therapeutic agent is (i) an antibody or
immunoconjugate that binds to domain II of HER2, and/or (ii) an
antibody or immunoconjugate that binds to domain IV or HER2. In
some embodiments, the additional therapeutic agent is (i) an
antibody or immunoconjugate that binds to epitope 2C4, and/or (ii)
an antibody or immunoconjugate that binds to epitope 4D5. In some
embodiments, the additional therapeutic agent is selected from
trastuzumab, trastuzumab-MCC-DM1 (T-DM1), and pertuzumab. In some
embodiments, the pharmaceutical formulation further comprises (1)
trastuzumab or T-DM1, and (2) pertuzumab.
[0052] In some embodiments, methods of treating an individual
having a HER2-positive cancer are provided. In some embodiments, a
method comprises administering to the individual an effective
amount of an immunoconjugate described herein, or a pharmaceutical
composition described herein. In some embodiments, the
HER2-positive cancer is breast cancer or gastric cancer. In some
embodiments, the HER2-positive breast cancer is early-stage breast
cancer. In some embodiments, the HER2-positive breast cancer is
metastatic breast cancer. In some embodiments, the HER2-positive
cancer is recurrent cancer. In some embodiments, the recurrent
cancer is locally recurrent cancer. In some embodiments, the
HER2-positive cancer is advanced cancer. In some embodiments, the
HER2-positive cancer is non-resectable. In some embodiments, the
method further comprises administering an additional therapeutic
agent to the individual.
[0053] In some embodiments, a method of treating an individual
having a HER2-positive cancer comprises administering to the
individual an effective amount of an immunoconjugate described
herein and at least one additional therapeutic agent to the
individual. In some embodiments, the additional therapeutic agent
is an antibody or immunoconjugate that binds to HER2. In some
embodiments, the additional therapeutic agent is (i) an antibody or
immunoconjugate that binds to domain II of HER2, and/or (ii) an
antibody or immunoconjugate that binds to domain IV or HER2. In
some embodiments, the additional therapeutic agent is (i) an
antibody or immunoconjugate that binds to epitope 2C4, and/or (ii)
an antibody or immunoconjugate that binds to epitope 4D5. In some
embodiments, the additional therapeutic agent is selected from
trastuzumab, trastuzumab-MCC-DM1 (T-DM1), and pertuzumab. In some
embodiments, the additional therapeutic agents are (1) trastuzumab
or T-DM1, and (2) pertuzumab. In some embodiments, the
HER2-positive cancer is breast cancer or gastric cancer. In some
embodiments, the HER2-positive breast cancer is early-stage breast
cancer. In some embodiments, the HER2-positive breast cancer is
metastatic breast cancer. In some embodiments, the HER2-positive
cancer is recurrent cancer. In some embodiments, the recurrent
cancer is locally recurrent cancer. In some embodiments, the
HER2-positive cancer is advanced cancer. In some embodiments, the
HER2-positive cancer is non-resectable.
[0054] In some embodiments, a method of treating an individual
having a HER2-positive cancer comprises: [0055] a) subjecting the
individual to neoadjuvant treatment with an immunoconjugate
described herein or a pharmaceutical formulation described herein,
[0056] b) removing the cancer by definitive surgery, and [0057] c)
subjecting the individual to adjuvant treatment with an
immunoconjugate described herein or a pharmaceutical formulation
described herein.
[0058] In some embodiments, the HER2-positive cancer is breast
cancer or gastric cancer.
[0059] In some embodiments, methods of inhibiting proliferation of
a HER2-positive cell are provided. In some embodiments a method
comprises exposing the cell to an immunoconjugate described herein
under conditions permissive for binding of the immunoconjugate to
HER2 on the surface of the cell, thereby inhibiting proliferation
of the cell. In some embodiments, the cell is a breast cancer cell
of a gastric cancer cell.
BRIEF DESCRIPTION OF THE FIGURES
[0060] FIG. 1 shows an alignment of the human VH subgroup I
(VH.sub.I) consensus sequence and heavy chain variable region
sequences of murine 7C2.B9 ("7C2") and humanized 7C2.v2.2.LA, as
described in Example 1.
[0061] FIG. 2 shows an alignment of the human VL kappa IV
(VL.sub.KIV) consensus sequence and light chain variable region
sequences of murine 7C2.B9 ("7C2") and humanized 7C2.v2.2.LA, as
described in Example 1.
[0062] FIG. 3 shows the Her2 extracellular domain structure, with
domains I to IV indicated, and the domains to which anti-Her2
antibodies trastuzumab, pertuzumab, and 7C2 bind.
[0063] FIG. 4 shows change in tumor volume (mm3) over time upon
treatment with hu7C2.v2.2.LA antibody-drug conjugates (ADCs), as
described in Example 3.
[0064] FIG. 5 shows change in tumor volume (mm3) over time upon
treatment with hu7C2.v2.2.LA antibody-drug conjugates (ADCs), as
described in Example 4.
[0065] FIG. 6 show the structures for certain antibody-drug
conjugates used in the examples herein.
[0066] FIGS. 7A-B show the pertuzumab main species antibody light
chain (A) and heavy chain (B) amino acid sequences.
[0067] FIGS. 8A-B show exemplary pertuzumab variant species
antibody light chain (A) and heavy chain (B) amino acid
sequences.
[0068] FIGS. 9A-B show the trastuzumab antibody light chain (A) and
heavy chain (B) amino acid sequences.
[0069] FIG. 10 shows a schematic of the Her2 receptor and the
sequences for domains I to IV.
[0070] FIGS. 11A-D show (A) crystal structure of the complex
between HER2 ECD (surface shaded by domain and shown as a
space-filling model) and 7C2 Fab. The 7C2 Fab binds to domain I of
HER2, which is different from the binding epitopes of the
trastuzumab Fab (Tmab, PDB code: 1N8Z) and the pertuzumab Fab
(Pmab, PDB code: 1S78). (B) Superposition of the structures of HER2
ECD within the trastuzumab/HER2 complex, pertuzumab/HER2 complex,
and 7C2/HER2 complex. (C) The 7C2/HER2 complex interface. The side
chains of the residues involved in the 7C2/HER2 interaction are
shown as sticks. Some of the potential intermolecular hydrogen
bonds are shown as dashed lines. (D) The 7C2 binding epitope is
partially overlapped with the chA21 single-chain Fv (scFv).
Superposition of the structure of the chA21 scFv/HER2 complex (PDB
code: 3H3B) with the 7C2/HER2 complex.
DETAILED DESCRIPTION
[0071] Reference will now be made in detail to certain embodiments
of the invention, examples of which are illustrated in the
accompanying structures and formulas. While the invention will be
described in conjunction with the enumerated embodiments, it will
be understood that they are not intended to limit the invention to
those embodiments. On the contrary, the invention is intended to
cover all alternatives, modifications, and equivalents which may be
included within the scope of the present invention as defined by
the claims. One skilled in the art will recognize many methods and
materials similar or equivalent to those described herein, which
could be used in the practice of the present invention. The present
invention is in no way limited to the methods and materials
described.
[0072] All references cited throughout the disclosure are expressly
incorporated by reference herein in their entirety. In the event
that one or more of the incorporated literature, patents, and
similar materials differs from or contradicts this application,
including but not limited to defined terms, term usage, described
techniques, or the like, this application controls.
I. DEFINITIONS
[0073] The words "comprise," "comprising," "include," "including,"
and "includes" when used in this specification and claims are
intended to specify the presence of stated features, integers,
components, or steps, but they do not preclude the presence or
addition of one or more other features, integers, components,
steps, or groups thereof.
[0074] An "acceptor human framework" for the purposes herein is a
framework comprising the amino acid sequence of a light chain
variable domain (VL) framework or a heavy chain variable domain
(VH) framework derived from a human immunoglobulin framework or a
human consensus framework, as defined below. An acceptor human
framework "derived from" a human immunoglobulin framework or a
human consensus framework may comprise the same amino acid sequence
thereof, or it may contain amino acid sequence changes. In some
embodiments, the number of amino acid changes are 10 or less, 9 or
less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or
less, or 2 or less. In some embodiments, the VL acceptor human
framework is identical in sequence to the VL human immunoglobulin
framework sequence or human consensus framework sequence.
[0075] "Affinity" refers to the strength of the sum total of
noncovalent interactions between a single binding site of a
molecule (e.g., an antibody) and its binding partner (e.g., an
antigen). Unless indicated otherwise, as used herein, "binding
affinity" refers to intrinsic binding affinity which reflects a 1:1
interaction between members of a binding pair (e.g., antibody and
antigen). The affinity of a molecule X for its partner Y can
generally be represented by the dissociation constant (Kd).
Affinity can be measured by common methods known in the art,
including those described herein. Specific illustrative and
exemplary embodiments for measuring binding affinity are described
in the following.
[0076] An "affinity matured" antibody refers to an antibody with
one or more alterations in one or more hypervariable regions
(HVRs), compared to a parent antibody which does not possess such
alterations, such alterations resulting in an improvement in the
affinity of the antibody for antigen.
[0077] The terms "anti-HER2 antibody" and "an antibody that binds
to HER2" refer to an antibody that is capable of binding HER2 with
sufficient affinity such that the antibody is useful as a
diagnostic and/or therapeutic agent in targeting HER2. In one
embodiment, the extent of binding of an anti-HER2 antibody to an
unrelated, non-HER2 protein is less than about 10% of the binding
of the antibody to HER2 as measured, e.g., by a radioimmunoassay
(RIA). In certain embodiments, an antibody that binds to HER2 has a
dissociation constant (Kd) of .ltoreq.1 .mu.M, .ltoreq.100 nM,
.ltoreq.10 nM, .ltoreq.5 nm, .ltoreq.4 nM, .ltoreq.3 nM, .ltoreq.2
nM, .ltoreq.1 nM, .ltoreq.0.1 nM, .ltoreq.0.01 nM, or .ltoreq.0.001
nM (e.g., 10.sup.-8 M or less, e.g. from 10.sup.-8 M to 10.sup.-13
M, e.g., from 10.sup.-9 M to 10.sup.-13 M). In certain embodiments,
an anti-HER2 antibody binds to an epitope of HER2 that is conserved
among HER2 from different species.
[0078] The term "antibody" is used herein in the broadest sense and
encompasses various antibody structures, including but not limited
to monoclonal antibodies, polyclonal antibodies, multispecific
antibodies (e.g., bispecific antibodies), and antibody fragments so
long as they exhibit the desired antigen-binding activity.
[0079] An "antibody fragment" refers to a molecule other than an
intact antibody that comprises a portion of an intact antibody and
that binds the antigen to which the intact antibody binds. Examples
of antibody fragments include but are not limited to Fv, Fab, Fab',
Fab'-SH, F(ab').sub.2; diabodies; linear antibodies; single-chain
antibody molecules (e.g. scFv); and multispecific antibodies formed
from antibody fragments.
[0080] An "antibody that binds to the same epitope" as a reference
antibody refers to an antibody that blocks binding of the reference
antibody to its antigen in a competition assay by 50% or more, and
conversely, the reference antibody blocks binding of the antibody
to its antigen in a competition assay by 50% or more. An exemplary
competition assay is provided herein.
[0081] The terms "cancer" and "cancerous" refer to or describe the
physiological condition in mammals that is typically characterized
by unregulated cell growth/proliferation. Examples of cancer
include, but are not limited to, carcinoma, lymphoma, blastoma,
sarcoma, and leukemia. In some embodiments, the cancer is breast
cancer or gastric cancer. In some embodiments, a cancer is any
HER2-positive cancer.
[0082] A "HER2-positive" cancer comprises cancer cells which have
higher than normal levels of HER2. Examples of HER2-positive cancer
include HER2-positive breast cancer and HER2-positive gastric
cancer. Optionally, HER2-positive cancer has an
immunohistochemistry (IHC) score of 2+ or 3+ and/or an in situ
hybridization (ISH) amplification ratio .gtoreq.2.0.
[0083] The term "early stage breast cancer (EBC)" or "early breast
cancer" is used herein to refer to breast cancer that has not
spread beyond the breast or the axillary lymph nodes. This includes
ductal carcinoma in situ and stage I, stage IIA, stage IIB, and
stage IIIA breast cancers.
[0084] Reference to a tumor or cancer as a "Stage 0," "Stage I,"
"Stage II," "Stage III," or "Stage IV", and various sub-stages
within this classification, indicates classification of the tumor
or cancer using the Overall Stage Grouping or Roman Numeral Staging
methods known in the art. Although the actual stage of the cancer
is dependent on the type of cancer, in general, a Stage 0 cancer is
an in situ lesion, a Stage I cancer is small localized tumor, a
Stage II and III cancer is a local advanced tumor which exhibits
involvement of the local lymph nodes, and a Stage IV cancer
represents metastatic cancer. The specific stages for each type of
tumor is known to the skilled clinician.
[0085] The term "metastatic breast cancer" means the state of
breast cancer where the cancer cells are transmitted from the
original site to one or more sites elsewhere in the body, by the
blood vessels or lymphatics, to form one or more secondary tumors
in one or more organs besides the breast.
[0086] An "advanced" cancer is one which has spread outside the
site or organ of origin, either by local invasion or metastasis.
Accordingly, the term "advanced" cancer includes both locally
advanced and metastatic disease.
[0087] A "recurrent" cancer is one which has regrown, either at the
initial site or at a distant site, after a response to initial
therapy, such as surgery.
[0088] A "locally recurrent" cancer is cancer that returns after
treatment in the same place as a previously treated cancer.
[0089] An "operable" or "resectable" cancer is cancer which is
confined to the primary organ and suitable for surgery
(resection).
[0090] A "non-resectable" or "unresectable" cancer is not able to
be removed (resected) by surgery.
[0091] The term "chimeric" antibody refers to an antibody in which
a portion of the heavy and/or light chain is derived from a
particular source or species, while the remainder of the heavy
and/or light chain is derived from a different source or
species.
[0092] The "class" of an antibody refers to the type of constant
domain or constant region possessed by its heavy chain. There are
five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and
several of these may be further divided into subclasses (isotypes),
e.g., IgG.sub.1, IgG.sub.2, IgG.sub.3, IgG.sub.4, IgA.sub.1, and
IgA.sub.2. The heavy chain constant domains that correspond to the
different classes of immunoglobulins are called .alpha., .delta.,
.epsilon., .gamma., and .mu., respectively.
[0093] The term "cytotoxic agent" as used herein refers to a
substance that inhibits or prevents a cellular function and/or
causes cell death or destruction. Cytotoxic agents include, but are
not limited to, radioactive isotopes (e.g., At.sup.211, I.sup.131,
I.sup.125, Y.sup.90, Re.sup.186, Re.sup.188, Sm.sup.153,
Bi.sup.212, P.sup.32, Pb.sup.212 and radioactive isotopes of Lu);
chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin,
vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin,
melphalan, mitomycin C, chlorambucil, daunorubicin or other
intercalating agents); growth inhibitory agents; enzymes and
fragments thereof such as nucleolytic enzymes; antibiotics; toxins
such as small molecule toxins or enzymatically active toxins of
bacterial, fungal, plant or animal origin, including fragments
and/or variants thereof; and the various antitumor or anticancer
agents disclosed below.
[0094] "Effector functions" refer to those biological activities
attributable to the Fc region of an antibody, which vary with the
antibody isotype. Examples of antibody effector functions include:
Clq binding and complement dependent cytotoxicity (CDC); Fc
receptor binding; antibody-dependent cell-mediated cytotoxicity
(ADCC); phagocytosis; down regulation of cell surface receptors
(e.g. B cell receptor); and B cell activation.
[0095] An "effective amount" of an agent, e.g., a pharmaceutical
formulation, refers to an amount effective, at dosages and for
periods of time necessary, to achieve the desired therapeutic or
prophylactic result. The effective amount of the drug for treating
cancer may reduce the number of cancer cells; reduce the tumor
size; inhibit (i.e., slow to some extent and preferably stop)
cancer cell infiltration into peripheral organs; inhibit (i.e.,
slow to some extent and preferably stop) tumor metastasis; inhibit,
to some extent, tumor growth; and/or relieve to some extent one or
more of the symptoms associated with the cancer. To the extent the
drug may prevent growth and/or kill existing cancer cells, it may
be cytostatic and/or cytotoxic. The effective amount may extend
progression free survival (e.g. as measured by Response Evaluation
Criteria for Solid Tumors, RECIST, or CA-125 changes), result in an
objective response (including a partial response, PR, or complete
response, CR), increase overall survival time, and/or improve one
or more symptoms of cancer (e.g. as assessed by FOSI).
[0096] The term "epitope" refers to the particular site on an
antigen molecule to which an antibody binds.
[0097] The "epitope 4D5" or "4D5 epitope" or "4D5" is the region in
the extracellular domain of HER2 to which the antibody 4D5 (ATCC
CRL 10463) and trastuzumab bind. This epitope is close to the
transmembrane domain of HER2, and within domain IV of HER2. To
screen for antibodies which bind to the 4D5 epitope, a routine
cross-blocking assay such as that described in Antibodies, A
Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and
David Lane (1988), can be performed. Alternatively, epitope mapping
can be performed to assess whether the antibody binds to the 4D5
epitope of HER2 (e.g. any one or more residues in the region from
about residue 550 to about residue 610, inclusive, of HER2 (SEQ ID
NO: 39).
[0098] The "epitope 2C4" or "2C4 epitope" is the region in the
extracellular domain of HER2 to which the antibody 2C4 binds. In
order to screen for antibodies which bind to the 2C4 epitope, a
routine cross-blocking assay such as that described in Antibodies,
A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and
David Lane (1988), can be performed. Alternatively, epitope mapping
can be performed to assess whether the antibody binds to the 2C4
epitope of HER2.
[0099] Epitope 2C4 comprises residues from domain II in the
extracellular domain of HER2. The 2C4 antibody and pertuzumab bind
to the extracellular domain of HER2 at the junction of domains I,
II and III (Franklin et al. Cancer Cell 5:317-328 (2004)).
[0100] The term "Fc region" herein is used to define a C-terminal
region of an immunoglobulin heavy chain that contains at least a
portion of the constant region. The term includes native sequence
Fc regions and variant Fc regions. In one embodiment, a human IgG
heavy chain Fc region extends from Cys226, or from Pro230, to the
carboxyl-terminus of the heavy chain. However, the C-terminal
lysine (Lys447) of the Fc region may or may not be present. Unless
otherwise specified herein, numbering of amino acid residues in the
Fc region or constant region is according to the EU numbering
system, also called the EU index, as described in Kabat et al.,
Sequences of Proteins of Immunological Interest, 5th Ed. Public
Health Service, National Institutes of Health, Bethesda, Md.,
1991.
[0101] "Framework" or "FR" refers to variable domain residues other
than hypervariable region (HVR) residues. The FR of a variable
domain generally consists of four FR domains: FR1, FR2, FR3, and
FR4. Accordingly, the HVR and FR sequences generally appear in the
following sequence in VH (or VL):
FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0102] The terms "full length antibody," "intact antibody," and
"whole antibody" are used herein interchangeably to refer to an
antibody having a structure substantially similar to a native
antibody structure or having heavy chains that contain an Fc region
as defined herein.
[0103] The term "glycosylated forms of HER2" refers to naturally
occurring forms of HER2 that are post-translationally modified by
the addition of carbohydrate residues.
[0104] The terms "host cell," "host cell line," and "host cell
culture" are used interchangeably and refer to cells into which
exogenous nucleic acid has been introduced, including the progeny
of such cells. Host cells include "transformants" and "transformed
cells," which include the primary transformed cell and progeny
derived therefrom without regard to the number of passages. Progeny
may not be completely identical in nucleic acid content to a parent
cell, but may contain mutations.
[0105] Mutant progeny that have the same function or biological
activity as screened or selected for in the originally transformed
cell are included herein.
[0106] A "human antibody" is one which possesses an amino acid
sequence which corresponds to that of an antibody produced by a
human or a human cell or derived from a non-human source that
utilizes human antibody repertoires or other human
antibody-encoding sequences. This definition of a human antibody
specifically excludes a humanized antibody comprising non-human
antigen-binding residues.
[0107] A "human consensus framework" is a framework which
represents the most commonly occurring amino acid residues in a
selection of human immunoglobulin VL or VH framework sequences.
Generally, the selection of human immunoglobulin VL or VH sequences
is from a subgroup of variable domain sequences. Generally, the
subgroup of sequences is a subgroup as in Kabat et al., Sequences
of Proteins of Immunological Interest, Fifth Edition, NIH
Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In one
embodiment, for the VL, the subgroup is subgroup kappa I as in
Kabat et al., supra. In one embodiment, for the VH, the subgroup is
subgroup III as in Kabat et al., supra.
[0108] A "humanized" antibody refers to a chimeric antibody
comprising amino acid residues from non-human HVRs and amino acid
residues from human FRs. In certain embodiments, a humanized
antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all
of the HVRs (e.g., CDRs) correspond to those of a non-human
antibody, and all or substantially all of the FRs correspond to
those of a human antibody. A humanized antibody optionally may
comprise at least a portion of an antibody constant region derived
from a human antibody. A "humanized form" of an antibody, e.g., a
non-human antibody, refers to an antibody that has undergone
humanization.
[0109] The term "hypervariable region" or "HVR," as used herein,
refers to each of the regions of an antibody variable domain which
are hypervariable in sequence and/or form structurally defined
loops ("hypervariable loops"). Generally, native four-chain
antibodies comprise six HVRs; three in the VH (H1, H2, H3), and
three in the VL (L1, L2, L3). HVRs generally comprise amino acid
residues from the hypervariable loops and/or from the
"complementarity determining regions" (CDRs), the latter being of
highest sequence variability and/or involved in antigen
recognition. Exemplary hypervariable loops occur at amino acid
residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55
(H2), and 96-101 (H3). (Chothia and Lesk, J. Mol. Biol. 196:901-917
(1987).) Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2,
and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2,
89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3. (Kabat et
al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, Md.
(1991).) With the exception of CDR1 in VH, CDRs generally comprise
the amino acid residues that form the hypervariable loops. CDRs
also comprise "specificity determining residues," or "SDRs," which
are residues that contact antigen. SDRs are contained within
regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary
a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and
a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2,
89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3. (See
Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008).) Unless
otherwise indicated, HVR residues and other residues in the
variable domain (e.g., FR residues) are numbered herein according
to Kabat et al., supra.
[0110] An "immunoconjugate" is an antibody conjugated to one or
more heterologous molecule(s), including but not limited to a
cytotoxic agent.
[0111] A "patient" or "individual" or "subject" is a mammal.
Mammals include, but are not limited to, domesticated animals
(e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans
and non-human primates such as monkeys), rabbits, and rodents
(e.g., mice and rats). In certain embodiments, the patient,
individual, or subject is a human. In some embodiments, the patient
may be a "cancer patient," i.e. one who is suffering or at risk for
suffering from one or more symptoms of cancer, in particular
gastric or breast cancer.
[0112] A "patient population" refers to a group of cancer patients.
Such populations can be used to demonstrate statistically
significant efficacy and/or safety of a drug.
[0113] A "relapsed" patient is one who has signs or symptoms of
cancer after remission.
[0114] Optionally, the patient has relapsed after adjuvant or
neoadjuvant therapy.
[0115] A cancer or biological sample which "displays HER
expression, amplification, or activation" is one which, in a
diagnostic test, expresses (including overexpresses) a HER
receptor, has amplified HER gene, and/or otherwise demonstrates
activation or phosphorylation of a HER receptor.
[0116] "Neoadjuvant therapy" or "preoperative therapy" herein
refers to therapy given prior to surgery. The goal of neoadjuvant
therapy is to provide immediate systemic treatment, potentially
eradicating micrometastases that would otherwise proliferate if the
standard sequence of surgery followed by systemic therapy were
followed. Neoadjuvant therapy may also help to reduce tumor size
thereby allowing complete resection of initially unresectable
tumors or preserving portions of the organ and its functions.
Furthermore, neoadjuvant therapy permits an in vivo assessment of
drug efficacy, which may guide the choice of subsequent
treatments.
[0117] "Adjuvant therapy" herein refers to therapy given after
definitive surgery, where no evidence of residual disease can be
detected, so as to reduce the risk of disease recurrence. The goal
of adjuvant therapy is to prevent recurrence of the cancer, and
therefore to reduce the chance of cancer-related death. Adjuvant
therapy herein specifically excludes neoadjuvant therapy.
[0118] "Definitive surgery" is used as that term is used within the
medical community. Definitive surgery includes, for example,
procedures, surgical or otherwise, that result in removal or
resection of the tumor, including those that result in the removal
or resection of all grossly visible tumor. Definitive surgery
includes, for example, complete or curative resection or complete
gross resection of the tumor. Definitive surgery includes
procedures that occur in one or more stages, and includes, for
example, multi-stage surgical procedures where one or more surgical
or other procedures are performed prior to resection of the tumor.
Definitive surgery includes procedures to remove or resect the
tumor including involved organs, parts of organs and tissues, as
well as surrounding organs, such as lymph nodes, parts of organs,
or tissues. Removal may be incomplete such that tumor cells might
remain even though undetected.
[0119] "Survival" refers to the patient remaining alive, and
includes disease free survival (DFS), progression free survival
(PFS) and overall survival (OS). Survival can be estimated by the
Kaplan-Meier method, and any differences in survival are computed
using the stratified log-rank test.
[0120] "Progression-Free Survival" (PFS) is the time from the first
day of treatment to documented disease progression (including
isolated CNS progression) or death from any cause on study,
whichever occurs first.
[0121] "Disease free survival (DFS)" refers to the patient
remaining alive, without return of the cancer, for a defined period
of time such as about 1 year, about 2 years, about 3 years, about 4
years, about 5 years, about 10 years, etc., from initiation of
treatment or from initial diagnosis. In one aspect, DFS is analyzed
according to the intent-to-treat principle, i.e., patients are
evaluated on the basis of their assigned therapy. The events used
in the analysis of DFS can include local, regional and distant
recurrence of cancer, occurrence of secondary cancer, and death
from any cause in patients without a prior event (e.g., breast
cancer recurrence or second primary cancer).
[0122] "Overall survival" refers to the patient remaining alive for
a defined period of time, such as about 1 year, about 2 years,
about 3 years, about 4 years, about 5 years, about 10 years, etc.,
from initiation of treatment or from initial diagnosis. In the
studies underlying the invention the event used for survival
analysis was death from any cause.
[0123] By "extending survival" is meant increasing DFS and/or OS in
a treated patient relative to an untreated patient, or relative to
a control treatment protocol. Survival is monitored for at least
about six months, or at least about 1 year, or at least about 2
years, or at least about 3 years, or at least about 4 years, or at
least about 5 years, or at least about 10 years, etc., following
the initiation of treatment or following the initial diagnosis.
[0124] By "monotherapy" is meant a therapeutic regimen that
includes only a single therapeutic agent for the treatment of the
cancer or tumor during the course of the treatment period.
[0125] By "maintenance therapy" is meant a therapeutic regimen that
is given to reduce the likelihood of disease recurrence or
progression. Maintenance therapy can be provided for any length of
time, including extended time periods up to the life-span of the
subject. Maintenance therapy can be provided after initial therapy
or in conjunction with initial or additional therapies. Dosages
used for maintenance therapy can vary and can include diminished
dosages as compared to dosages used for other types of therapy.
[0126] As defined herein, the terms "trastuzumab", "HERCEPTIN.RTM."
and "huMAb4D5-8" are used interchangeably. Such antibody preferably
comprises the light and heavy chain amino acid sequences shown in
SEQ ID NO: 30 and SEQ ID NO. 29, respectively.
[0127] For the purposes herein, "pertuzumab", "PERJETA.RTM." and
"rhuMAb 2C4", are used interchangeably. Such antibody comprises a
main species antibody having the light and heavy chain amino acid
sequences in SEQ ID NOs: 32 and 31, respectively (FIGS. 7A and B).
In some embodiments, pertuzumab comprises a variant species
antibody with an amino-terminal leader extension, e.g., comprising
a light chain amino acid sequence of SEQ ID NO: 34, and a heavy
chain amino acid sequence of SEQ ID NO: 33. The antibody is
optionally produced by recombinant Chinese Hamster Ovary (CHO)
cells.
[0128] As defined herein, the terms "T-DM1," "trastuzumab-MCC-DM1,"
"ado-trastuzumab emtansine," "trastuzumab emtansine," and
"KADCYLA.RTM." are used interchangeably, and refer to trastuzumab
linked through the linker moiety MCC to the maytansinoid drug
moiety DM1, including all mixtures of variously loaded and attached
antibody-drug conjugates where 1, 2, 3, 4, 5, 6, 7, and 8 drug
moieties are covalently attached to the antibody trastuzumab (U.S.
Pat. Nos. 7,097,840; 8,337,856; US 2005/0276812; US
2005/0166993).
[0129] An "isolated antibody" is one which has been separated from
a component of its natural environment. In some embodiments, an
antibody is purified to greater than 95% or 99% purity as
determined by, for example, electrophoretic (e.g., SDS-PAGE,
isoelectric focusing (IEF), capillary electrophoresis) or
chromatographic (e.g., ion exchange or reverse phase HPLC). For
review of methods for assessment of antibody purity, see, e.g.,
Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0130] An "isolated nucleic acid" refers to a nucleic acid molecule
that has been separated from a component of its natural
environment. An isolated nucleic acid includes a nucleic acid
molecule contained in cells that ordinarily contain the nucleic
acid molecule, but the nucleic acid molecule is present
extrachromosomally or at a chromosomal location that is different
from its natural chromosomal location.
[0131] "Isolated nucleic acid encoding an anti-HER2 antibody"
refers to one or more nucleic acid molecules encoding antibody
heavy and light chains (or fragments thereof), including such
nucleic acid molecule(s) in a single vector or separate vectors,
and such nucleic acid molecule(s) present at one or more locations
in a host cell.
[0132] The term "HER2," as used herein, refers to any native,
mature HER2 which results from processing of a HER2 precursor
protein in a cell. The term includes HER2 from any vertebrate
source, including mammals such as primates (e.g. humans and
cynomolgus monkeys) and rodents (e.g., mice and rats), unless
otherwise indicated. The term also includes naturally occurring
variants of HER2, e.g., splice variants or allelic variants. The
amino acid sequence of an exemplary human HER2 precursor protein,
with signal sequence (with signal sequence, amino acids 1-22) is
shown in SEQ ID NO: 1. The amino acid sequence of an exemplary
mature human HER2 is amino acids 23-1255 of SEQ ID NO: 1.
[0133] The term "HER2-positive cell" refers to a cell that
expresses HER2 on its surface.
[0134] The term "monoclonal antibody" as used herein refers to an
antibody obtained from a population of substantially homogeneous
antibodies, i.e., the individual antibodies comprising the
population are identical and/or bind the same epitope, except for
possible variant antibodies, e.g., containing naturally occurring
mutations or arising during production of a monoclonal antibody
preparation, such variants generally being present in minor
amounts. In contrast to polyclonal antibody preparations, which
typically include different antibodies directed against different
determinants (epitopes), each monoclonal antibody of a monoclonal
antibody preparation is directed against a single determinant on an
antigen. Thus, the modifier "monoclonal" indicates the character of
the antibody as being obtained from a substantially homogeneous
population of antibodies, and is not to be construed as requiring
production of the antibody by any particular method. For example,
the monoclonal antibodies to be used in accordance with the present
invention may be made by a variety of techniques, including but not
limited to the hybridoma method, recombinant DNA methods,
phage-display methods, and methods utilizing transgenic animals
containing all or part of the human immunoglobulin loci, such
methods and other exemplary methods for making monoclonal
antibodies being described herein.
[0135] A "naked antibody" refers to an antibody that is not
conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or
radiolabel. The naked antibody may be present in a pharmaceutical
formulation.
[0136] "Native antibodies" refer to naturally occurring
immunoglobulin molecules with varying structures. For example,
native IgG antibodies are heterotetrameric glycoproteins of about
150,000 daltons, composed of two identical light chains and two
identical heavy chains that are disulfide-bonded. From N- to
C-terminus, each heavy chain has a variable region (VH), also
called a variable heavy domain or a heavy chain variable domain,
followed by three constant domains (CH1, CH2, and CH3). Similarly,
from N- to C-terminus, each light chain has a variable region (VL),
also called a variable light domain or a light chain variable
domain, followed by a constant light (CL) domain. The light chain
of an antibody may be assigned to one of two types, called kappa
(.kappa.) and lambda (.lamda.), based on the amino acid sequence of
its constant domain.
[0137] A "vial" is a container suitable for holding a liquid or
lyophilized preparation. In one embodiment, the vial is a
single-use vial, e.g. a 20-cc single-use vial with a stopper.
[0138] The term "package insert" is used to refer to instructions
customarily included in commercial packages of therapeutic
products, that contain information about the indications, usage,
dosage, administration, combination therapy, contraindications
and/or warnings concerning the use of such therapeutic
products.
[0139] "Percent (%) amino acid sequence identity" with respect to a
reference polypeptide sequence is defined as the percentage of
amino acid residues in a candidate sequence that are identical with
the amino acid residues in the reference polypeptide sequence,
after aligning the sequences and introducing gaps, if necessary, to
achieve the maximum percent sequence identity, and not considering
any conservative substitutions as part of the sequence identity.
Alignment for purposes of determining percent amino acid sequence
identity can be achieved in various ways that are within the skill
in the art, for instance, using publicly available computer
software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software. Those skilled in the art can determine appropriate
parameters for aligning sequences, including any algorithms needed
to achieve maximal alignment over the full length of the sequences
being compared. For purposes herein, however, % amino acid sequence
identity values are generated using the sequence comparison
computer program ALIGN-2. The ALIGN-2 sequence comparison computer
program was authored by Genentech, Inc., and the source code has
been filed with user documentation in the U.S. Copyright Office,
Washington D.C., 20559, where it is registered under U.S. Copyright
Registration No. TXU510087. The ALIGN-2 program is publicly
available from Genentech, Inc., South San Francisco, Calif., or may
be compiled from the source code. The ALIGN-2 program should be
compiled for use on a UNIX operating system, including digital UNIX
V4.0D. All sequence comparison parameters are set by the ALIGN-2
program and do not vary.
[0140] In situations where ALIGN-2 is employed for amino acid
sequence comparisons, the % amino acid sequence identity of a given
amino acid sequence A to, with, or against a given amino acid
sequence B (which can alternatively be phrased as a given amino
acid sequence A that has or comprises a certain % amino acid
sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows: [0141] 100 times the fraction X/Y
where X is the number of amino acid residues scored as identical
matches by the sequence alignment program ALIGN-2 in that program's
alignment of A and B, and where Y is the total number of amino acid
residues in B. It will be appreciated that where the length of
amino acid sequence A is not equal to the length of amino acid
sequence B, the % amino acid sequence identity of A to B will not
equal the % amino acid sequence identity of B to A. Unless
specifically stated otherwise, all % amino acid sequence identity
values used herein are obtained as described in the immediately
preceding paragraph using the ALIGN-2 computer program.
[0142] The term "pharmaceutical formulation" refers to a
preparation which is in such form as to permit the biological
activity of an active ingredient contained therein to be effective,
and which contains no additional components which are unacceptably
toxic to a subject to which the formulation would be
administered.
[0143] A "pharmaceutically acceptable carrier" refers to an
ingredient in a pharmaceutical formulation, other than an active
ingredient, which is nontoxic to a subject. A pharmaceutically
acceptable carrier includes, but is not limited to, a buffer,
excipient, stabilizer, or preservative.
[0144] As used herein, "treatment" (and grammatical variations
thereof such as "treat" or "treating") refers to clinical
intervention in an attempt to alter the natural course of the
individual being treated, and can be performed either for
prophylaxis or during the course of clinical pathology.
[0145] Desirable effects of treatment include, but are not limited
to, preventing occurrence or recurrence of disease, alleviation of
symptoms, diminishment of any direct or indirect pathological
consequences of the disease, preventing metastasis, decreasing the
rate of disease progression, amelioration or palliation of the
disease state, and remission or improved prognosis. In some
embodiments, antibodies of the invention are used to delay
development of a disease or to slow the progression of a
disease.
[0146] By "co-administering" is meant intravenously administering
two (or more) drugs during the same administration, rather than
sequential infusions of the two or more drugs. Generally, this will
involve combining the two (or more) drugs into the same IV bag
prior to co-administration thereof.
[0147] A drug that is administered "concurrently" with one or more
other drugs is administered during the same treatment cycle, on the
same day of treatment as the one or more other drugs, and,
optionally, at the same time as the one or more other drugs. For
instance, for cancer therapies given every 3 weeks, the
concurrently administered drugs are each administered on day-1 of a
3-week cycle.
[0148] A "chemotherapy" is use of a chemotherapeutic agent useful
in the treatment of cancer.
[0149] A "chemotherapeutic agent" is a chemical compound useful in
the treatment of cancer, regardless of mechanism of action. Classes
of chemotherapeutic agents include, but are not limited to:
alkylating agents, antimetabolites, spindle poison plant alkaloids,
cytotoxic/antitumor antibiotics, topoisomerase inhibitors,
antibodies, photosensitizers, and kinase inhibitors. Examples of
chemotherapeutic agents include: anthracyclines, such as epirubicin
or doxorubicin (ADRIAMYCIN.RTM.), cyclophosphamide (CYTOXAN.RTM.,
NEOSAR.RTM.), anthracycline and cyclophosphamide in combination
("AC"); a taxane, e.g., docetaxel (TAXOTERE.RTM.) or paclitaxel
(TAXOL.RTM.), 5-FU (fluorouracil, 5-fluorouracil, CAS No. 51-21-8),
lapatinib (TYKERB.RTM.), capecitabine (XELODA.RTM.), gemcitabine
(GEMZAR.RTM., Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer),
cisplatin (cis-diamine,dichloroplatinum(II), CAS No. 15663-27-1),
carboplatin (CAS No. 41575-94-4), temozolomide
(4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo [4.3.0]
nona-2,7,9-triene-9-carboxamide, CAS No. 85622-93-1, TEMODAR.RTM.,
TEMODAL.RTM., Schering Plough), tamoxifen
((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethyl-ethanamine,
NOLVADEX.RTM., ISTUBAL.RTM., VALODEX.RTM.).
[0150] More examples of chemotherapeutic agents include:
oxaliplatin (ELOXATIN.RTM., Sanofi), bortezomib (VELCADE.RTM.,
Millennium Pharm.), sutent (SUNITINIB.RTM., SU11248, Pfizer),
letrozole (FEMARA.RTM., Novartis), imatinib mesylate (GLEEVEC.RTM.,
Novartis), XL-518 (MEK inhibitor, Exelixis, WO 2007/044515),
ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, Astra Zeneca),
SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K
inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787/ZK
222584 (Novartis), fulvestrant (FASLODEX.RTM., AstraZeneca),
leucovorin (folinic acid), rapamycin (sirolimus, RAPAMUNE.RTM.,
Wyeth), lonafarnib (SARASAR.TM., SCH 66336, Schering Plough),
sorafenib (NEXAVAR.RTM., BAY43-9006, Bayer Labs), gefitinib
(IRESSA.RTM., AstraZeneca), irinotecan (CAMPTOSAR.RTM., CPT-11,
Pfizer), tipifarnib (ZARNESTRA.TM., Johnson & Johnson),
ABRAXANE.TM. (Cremophor-free), albumin-engineered nanoparticle
formulations of paclitaxel (American Pharmaceutical Partners,
Schaumberg, Ill.), vandetanib (rINN, ZD6474, ZACTIMA.RTM.,
AstraZeneca), chloranmbucil, AG1478, AG1571 (SU 5271; Sugen),
temsirolimus (TORISEL.RTM., Wyeth), pazopanib (GlaxoSmithKline),
canfosfamide (TELCYTA.RTM., Telik), thiotepa and cyclosphosphamide
(CYTOXAN.RTM., NEOSAR.RTM.); alkyl sulfonates such as busulfan,
improsulfan and piposulfan; aziridines such as benzodopa,
carboquone, meturedopa, and uredopa; ethylenimines and
methylamelamines including altretamine, triethylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide and
trimethylomelamine; acetogenins (especially bullatacin and
bullatacinone); a camptothecin (including the synthetic analog
topotecan); bryostatin; callystatin; CC-1065 (including its
adozelesin, carzelesin and bizelesin synthetic analogs);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8);
dolastatin; duocarmycin (including the synthetic analogs, KW-2189
and CB1-TM 1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil,
chlornaphazine, chlorophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
novembichin, phenesterine, prednimustine, trofosfamide, uracil
mustard; nitrosoureas such as carmustine, chlorozotocin,
fotemustine, lomustine, nimustine, and ranimnustine; antibiotics
such as the enediyne antibiotics (e.g., calicheamicin,
calicheamicin gammalI, calicheamicin omegaIl (Angew Chem. Intl. Ed.
Engl. (1994) 33:183-186); dynemicin, dynemicin A; bisphosphonates,
such as clodronate; an esperamicin; as well as neocarzinostatin
chromophore and related chromoprotein enediyne antibiotic
chromophores), aclacinomysins, actinomycin, authramycin, azaserine,
bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin,
chromomycinis, dactinomycin, daunorubicin, detorubicin,
6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin,
cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and
deoxydoxorubicin), epirubicin, esorubicin, idarubicin,
marcellomycin, mitomycins such as mitomycin C, mycophenolic acid,
nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin,
quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,
ubenimex, zinostatin, zorubicin; anti-metabolites such as
methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as
denopterin, methotrexate, pteropterin, trimetrexate; purine analogs
such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;
pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine,
carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine,
floxuridine; androgens such as calusterone, dromostanolone
propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals
such as aminoglutethimide, mitotane, trilostane; folic acid
replenisher such as frolinic acid; aceglatone; aldophosphamide
glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil;
bisantrene; edatraxate; defofamine; demecolcine; diaziquone;
elfornithine; elliptinium acetate; an epothilone; etoglucid;
gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids
such as maytansine and ansamitocins; mitoguazone; mitoxantrone;
mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin;
losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine;
PSK.RTM. polysaccharide complex (JHS Natural Products, Eugene,
Oreg.); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic
acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes
(T-2 toxin, verracurin A, roridin A and anguidine); urethan;
vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol;
pipobroman; gacytosine; arabinoside (Ara-C); cyclophosphamide;
thiotepa; 6-thioguanine; mercaptopurine; methotrexate; platinum
analogs such as cisplatin and carboplatin; vinblastine; etoposide
(VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine
(NAVELBINE.RTM.); novantrone; teniposide; edatrexate; daunomycin;
aminopterin; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000;
difluoromethylornithine (DMFO); retinoids such as retinoic acid;
and pharmaceutically acceptable salts, acids and derivatives of any
of the above.
[0151] A "fixed" or "flat" dose of a therapeutic agent herein
refers to a dose that is administered to a human patient without
regard for the weight (WT) or body surface area (BSA) of the
patient. The fixed or flat dose is therefore not provided as a
mg/kg dose or a mg/m2 dose, but rather as an absolute amount of the
therapeutic agent.
[0152] A "loading" dose herein generally comprises an initial dose
of a therapeutic agent administered to a patient, and is followed
by one or more maintenance dose(s) thereof. Generally, a single
loading dose is administered, but multiple loading doses are
contemplated herein. Usually, the amount of loading dose(s)
administered exceeds the amount of the maintenance dose(s)
administered and/or the loading dose(s) are administered more
frequently than the maintenance dose(s), so as to achieve the
desired steady-state concentration of the therapeutic agent earlier
than can be achieved with the maintenance dose(s).
[0153] A "maintenance" dose herein refers to one or more doses of a
therapeutic agent administered to the patient over a treatment
period. Usually, the maintenance doses are administered at spaced
treatment intervals, such as approximately every week,
approximately every 2 weeks, approximately every 3 weeks, or
approximately every 4 weeks, preferably every 3 weeks.
[0154] "Infusion" or "infusing" refers to the introduction of a
drug-containing solution into the body through a vein for
therapeutic purposes. Generally, this is achieved via an
intravenous (IV) bag.
[0155] An "intravenous bag" or "IV bag" is a bag that can hold a
solution which can be administered via the vein of a patient. In
one embodiment, the solution is a saline solution (e.g. about 0.9%
or about 0.45% NaCl). Optionally, the IV bag is formed from
polyolefin or polyvinal chloride.
[0156] The term "variable region" or "variable domain" refers to
the domain of an antibody heavy or light chain that is involved in
binding the antibody to antigen. The variable domains of the heavy
chain and light chain (VH and VL, respectively) of a native
antibody generally have similar structures, with each domain
comprising four conserved framework regions (FRs) and three
hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby
Immunology, 6.sup.th ed., W.H. Freeman and Co., page 91 (2007).) A
single VH or VL domain may be sufficient to confer antigen-binding
specificity. Furthermore, antibodies that bind a particular antigen
may be isolated using a VH or VL domain from an antibody that binds
the antigen to screen a library of complementary VL or VH domains,
respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887
(1993); Clarkson et al., Nature 352:624-628 (1991).
[0157] The term "vector," as used herein, refers to a nucleic acid
molecule capable of propagating another nucleic acid to which it is
linked. The term includes the vector as a self-replicating nucleic
acid structure as well as the vector incorporated into the genome
of a host cell into which it has been introduced. Certain vectors
are capable of directing the expression of nucleic acids to which
they are operatively linked. Such vectors are referred to herein as
"expression vectors."
[0158] "Alkyl" is C.sub.1-C.sub.18 hydrocarbon containing normal,
secondary, tertiary or cyclic carbon atoms. Examples are methyl
(Me, --CH.sub.3), ethyl (Et, --CH.sub.2CH.sub.3), 1-propyl (n-Pr,
n-propyl, --CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr, i-propyl,
--CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (i-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
2-methyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3.
[0159] The term "C.sub.1-C.sub.8 alkyl," as used herein refers to a
straight chain or branched, saturated or unsaturated hydrocarbon
having from 1 to 8 carbon atoms. Representative "C.sub.1-C.sub.8
alkyl" groups include, but are not limited to, -methyl, -ethyl,
-n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl,
-n-nonyl and -n-decyl; while branched C.sub.1-C.sub.8 alkyls
include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl,
-tert-butyl, -isopentyl, 2-methylbutyl, unsaturated C.sub.1-C.sub.8
alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl,
-2-butenyl, -isobutylenyl, -1-pentenyl, -2-pentenyl,
-3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl,
1-hexyl, 2-hexyl, 3-hexyl, -acetylenyl, -propynyl, -1-butynyl,
-2-butynyl, -1-pentynyl, -2-pentynyl, -3-methyl-1 butynyl. A
C.sub.1-C.sub.8 alkyl group can be unsubstituted or substituted
with one or more groups including, but not limited to,
--C.sub.1-C.sub.8 alkyl, --O--(C.sub.1-C.sub.8 alkyl), -aryl,
--C(O)R', --OC(O)R', --C(O)OR', --C(O)NH.sub.2, --C(O)NHR',
--C(O)N(R').sub.2--NHC(O)R', --SO.sub.3R', --S(O).sub.2R',
--S(O)R', --OH, -halogen, --N.sub.3, --NH.sub.2, --NH(R'),
--N(R').sub.2 and --CN; where each R' is independently selected
from H, --C.sub.1-C.sub.8 alkyl and aryl.
[0160] The term "C.sub.1-C.sub.12 alkyl," as used herein refers to
a straight chain or branched, saturated or unsaturated hydrocarbon
having from 1 to 12 carbon atoms. A C.sub.1-C.sub.12 alkyl group
can be unsubstituted or substituted with one or more groups
including, but not limited to, --C.sub.1-C.sub.8 alkyl,
--O--(C.sub.1-C.sub.8 alkyl), -aryl, --C(O)R', --OC(O)R',
--C(O)OR', --C(O)NH.sub.2, --C(O)NHR', --C(O)N(R').sub.2--NHC(O)R',
--SO.sub.3R', --S(O).sub.2R', --S(O)R', --OH, -halogen, --N.sub.3,
--NH.sub.2, --NH(R'), --N(R').sub.2 and --CN; where each R' is
independently selected from H, --C.sub.1-C.sub.8 alkyl and
aryl.
[0161] The term "C.sub.1-C.sub.6 alkyl," as used herein refers to a
straight chain or branched, saturated or unsaturated hydrocarbon
having from 1 to 6 carbon atoms. Representative "C.sub.1-C.sub.6
alkyl" groups include, but are not limited to, -methyl, -ethyl,
-n-propyl, -n-butyl, -n-pentyl, -and n-hexyl; while branched
C.sub.1-C.sub.6 alkyls include, but are not limited to, -isopropyl,
-sec-butyl, -isobutyl, -tert-butyl, -isopentyl, and 2-methylbutyl;
unsaturated C.sub.1-C.sub.6 alkyls include, but are not limited to,
-vinyl, -allyl, -1-butenyl, -2-butenyl, and -isobutylenyl,
-1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl,
-2,3-dimethyl-2-butenyl, 1-hexyl, 2-hexyl, and 3-hexyl. A
C.sub.1-C.sub.6 alkyl group can be unsubstituted or substituted
with one or more groups, as described above for C.sub.1-C.sub.8
alkyl group.
[0162] The term "C.sub.1-C.sub.4 alkyl," as used herein refers to a
straight chain or branched, saturated or unsaturated hydrocarbon
having from 1 to 4 carbon atoms. Representative "C.sub.1-C.sub.4
alkyl" groups include, but are not limited to, -methyl, -ethyl,
-n-propyl, -n-butyl; while branched C.sub.1-C.sub.4 alkyls include,
but are not limited to, -isopropyl, -sec-butyl, -isobutyl,
-tert-butyl; unsaturated C.sub.1-C.sub.4 alkyls include, but are
not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, and
-isobutylenyl. A C.sub.1-C.sub.4 alkyl group can be unsubstituted
or substituted with one or more groups, as described above for
C.sub.1-C.sub.8 alkyl group.
[0163] "Alkoxy" is an alkyl group singly bonded to an oxygen.
Exemplary alkoxy groups include, but are not limited to, methoxy
(--OCH.sub.3) and ethoxy (--OCH.sub.2CH.sub.3). A "C.sub.1-C.sub.8
alkoxy" is an alkoxy group with 1 to 5 carbon atoms. Alkoxy groups
may can be unsubstituted or substituted with one or more groups, as
described above for alkyl groups.
[0164] "Alkenyl" is C.sub.2-C.sub.18 hydrocarbon containing normal,
secondary, tertiary or cyclic carbon atoms with at least one site
of unsaturation, i.e. a carbon-carbon, sp.sup.2 double bond.
Examples include, but are not limited to: ethylene or vinyl
(--CH.dbd.CH.sub.2), allyl (--CH.sub.2CH.dbd.CH.sub.2),
cyclopentenyl (--C.sub.5H7), and 5-hexenyl (--CH.sub.2
CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH.sub.2). A "C.sub.2-C.sub.8
alkenyl" is a hydrocarbon containing 2 to 8 normal, secondary,
tertiary or cyclic carbon atoms with at least one site of
unsaturation, i.e. a carbon-carbon, sp.sup.2 double bond.
[0165] "Alkynyl" is C.sub.2-C.sub.18 hydrocarbon containing normal,
secondary, tertiary or cyclic carbon atoms with at least one site
of unsaturation, i.e. a carbon-carbon, sp triple bond. Examples
include, but are not limited to: acetylenic (--C.dbd.CH) and
propargyl (--CH.sub.2C.dbd.CH). A "C.sub.2-C.sub.8 alkynyl" is a
hydrocarbon containing 2 to 8 normal, secondary, tertiary or cyclic
carbon atoms with at least one site of unsaturation, i.e. a
carbon-carbon, sp triple bond.
[0166] "Alkylene" refers to a saturated, branched or straight chain
or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two
monovalent radical centers derived by the removal of two hydrogen
atoms from the same or two different carbon atoms of a parent
alkane. Typical alkylene radicals include, but are not limited to:
methylene (--CH.sub.2--) 1,2-ethyl (--CH.sub.2CH.sub.2--),
1,3-propyl (--CH.sub.2CH.sub.2CH.sub.2--), 1,4-butyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--), and the like.
[0167] "Alkenylene" refers to an unsaturated, branched or straight
chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and
having two monovalent radical centers derived by the removal of two
hydrogen atoms from the same or two different carbon atoms of a
parent alkene. Typical alkenylene radicals include, but are not
limited to: 1,2-ethylene (--CH.dbd.CH--).
[0168] "Alkynylene" refers to an unsaturated, branched or straight
chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and
having two monovalent radical centers derived by the removal of two
hydrogen atoms from the same or two different carbon atoms of a
parent alkyne. Typical alkynylene radicals include, but are not
limited to: acetylene (--C.ident.C--), propargyl
(--CH.sub.2C.dbd.C--), and 4-pentynyl
(--CH.sub.2CH.sub.2CH.sub.2C.ident.C--).
[0169] "Aryl" refers to a carbocyclic aromatic group. Examples of
aryl groups include, but are not limited to, phenyl, naphthyl and
anthracenyl. A carbocyclic aromatic group or a heterocyclic
aromatic group can be unsubstituted or substituted with one or more
groups including, but not limited to, --C.sub.1-C.sub.8 alkyl,
--O--(C.sub.1-C.sub.8 alkyl), -aryl, --C(O)R', --OC(O)R',
--C(O)OR', --C(O)NH.sub.2, --C(O)NHR', --C(O)N(R').sub.2--NHC(O)R',
--S(O).sub.2R', --S(O)R', --OH, -halogen, --N.sub.3, --NH.sub.2,
--NH(R'), --N(R').sub.2 and --CN; wherein each R' is independently
selected from H, --C.sub.1-C.sub.8 alkyl and aryl.
[0170] A "C.sub.5-C.sub.20 aryl" is an aryl group with 5 to 20
carbon atoms in the carbocyclic aromatic rings. Examples of
C.sub.5-C.sub.20 aryl groups include, but are not limited to,
phenyl, naphthyl and anthracenyl. A C.sub.5-C.sub.20 aryl group can
be substituted or unsubstituted as described above for aryl groups.
A "C.sub.5-C.sub.14 aryl" is an aryl group with 5 to 14 carbon
atoms in the carbocyclic aromatic rings. Examples of
C.sub.5-C.sub.14 aryl groups include, but are not limited to,
phenyl, naphthyl and anthracenyl. A C.sub.5-C.sub.14 aryl group can
be substituted or unsubstituted as described above for aryl
groups.
[0171] An "arylene" is an aryl group which has two covalent bonds
and can be in the ortho, meta, or para configurations as shown in
the following structures:
##STR00006##
in which the phenyl group can be unsubstituted or substituted with
up to four groups including, but not limited to, --C.sub.1-C.sub.8
alkyl, --O--(C.sub.1-C.sub.8 alkyl), -aryl, --C(O)R', --OC(O)R',
--C(O)OR', --C(O)NH.sub.2, --C(O)NHR', --C(O)N(R').sub.2--NHC(O)R',
--S(O).sub.2R', --S(O)R', --OH, -halogen, --N.sub.3, --NH.sub.2,
--NH(R'), --N(R').sub.2 and --CN; wherein each R' is independently
selected from H, --C.sub.1-C.sub.8 alkyl and aryl.
[0172] "Arylalkyl" refers to an acyclic alkyl radical in which one
of the hydrogen atoms bonded to a carbon atom, typically a terminal
or sp.sup.3 carbon atom, is replaced with an aryl radical. Typical
arylalkyl groups include, but are not limited to, benzyl,
2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl,
2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl,
2-naphthophenylethan-1-yl and the like. The arylalkyl group
comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including
alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to
6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.
[0173] "Heteroarylalkyl" refers to an acyclic alkyl radical in
which one of the hydrogen atoms bonded to a carbon atom, typically
a terminal or sp.sup.3 carbon atom, is replaced with a heteroaryl
radical. Typical heteroarylalkyl groups include, but are not
limited to, 2-benzimidazolylmethyl, 2-furylethyl, and the like. The
heteroarylalkyl group comprises 6 to 20 carbon atoms, e.g. the
alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the
heteroarylalkyl group is 1 to 6 carbon atoms and the heteroaryl
moiety is 5 to 14 carbon atoms and 1 to 3 heteroatoms selected from
N, O, P, and S. The heteroaryl moiety of the heteroarylalkyl group
may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms
or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1
to 3 heteroatoms selected from N, O, P, and S), for example: a
bicyclo [4,5], [5,5], [5,6], or [6,6] system.
[0174] "Substituted alkyl," "substituted aryl," and "substituted
arylalkyl" mean alkyl, aryl, and arylalkyl respectively, in which
one or more hydrogen atoms are each independently replaced with a
substituent. Typical substituents include, but are not limited to,
--X, --R, --O--, --OR, --SR, --S.sup.-, --NR.sub.2, --NR.sub.3,
.dbd.NR, --CX.sub.3, --CN, --OCN, --SCN, --N.dbd.C.dbd.O, --NCS,
--NO, --NO.sub.2, .dbd.N.sub.2, --N.sub.3, NC(.dbd.O)R,
--C(.dbd.O)R, --C(.dbd.O)NR.sub.2, --SO.sub.3.sup.-, --SO.sub.3H,
--S(.dbd.O).sub.2R, --OS(.dbd.O).sub.2OR, --S(.dbd.O).sub.2NR,
--S(.dbd.O)R, --OP(.dbd.O)(OR).sub.2, --P(.dbd.O)(OR).sub.2,
--PO.sup.-.sub.3, --PO.sub.3H.sub.2, --C(.dbd.O)R, --C(.dbd.O)X,
--C(.dbd.S)R, --CO.sub.2R, --CO.sub.2.sup.-, --C(.dbd.S)OR,
--C(.dbd.O)SR, --C(.dbd.S)SR, --C(.dbd.O)NR.sub.2,
--C(.dbd.S)NR.sub.2, --C(.dbd.NR)NR.sub.2, where each X is
independently a halogen: F, Cl, Br, or I; and each R is
independently --H, C.sub.2-C.sub.18 alkyl, C.sub.6-C.sub.20 aryl,
C.sub.3-C.sub.14 heterocycle, protecting group or prodrug moiety.
Alkylene, alkenylene, and alkynylene groups as described above may
also be similarly substituted.
[0175] "Heteroaryl" and "heterocycle" refer to a ring system in
which one or more ring atoms is a heteroatom, e.g. nitrogen,
oxygen, and sulfur. The heterocycle radical comprises 3 to 20
carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. A
heterocycle may be a monocycle having 3 to 7 ring members (2 to 6
carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S)
or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1
to 3 heteroatoms selected from N, O, P, and S), for example: a
bicyclo [4,5], [5,5], [5,6], or [6,6] system.
[0176] Exemplary heterocycles are described, e.g., in Paquette, Leo
A., "Principles of Modern Heterocyclic Chemistry" (W. A. Benjamin,
New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The
Chemistry of Heterocyclic Compounds, A series of Monographs" (John
Wiley & Sons, New York, 1950 to present), in particular Volumes
13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566.
[0177] Examples of heterocycles include by way of example and not
limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl),
thiazolyl, tetrahydrothiophenyl, sulfur oxidized
tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl,
pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl,
indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl,
piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl,
pyrrolinyl, tetrahydrofuranyl, bis-tetrahydrofuranyl,
tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, decahydroquinolinyl,
octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl,
2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl,
isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl,
isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl,
isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl,
phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl,
cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl,
.beta.-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl,
phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl,
imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl,
isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl,
benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and
isatinoyl.
[0178] By way of example and not limitation, carbon bonded
heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine,
position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a
pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4,
or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or
tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or
thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or
isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4
of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or
position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more
typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl,
4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl,
5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl,
5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl,
5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or
5-thiazolyl.
[0179] By way of example and not limitation, nitrogen bonded
heterocycles are bonded at position 1 of an aziridine, azetidine,
pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole,
imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline,
2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole,
indoline, 1H-indazole, position 2 of a isoindole, or isoindoline,
position 4 of a morpholine, and position 9 of a carbazole, or
.beta.-carboline. Still more typically, nitrogen bonded
heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl,
1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
[0180] A "C.sub.3-C.sub.8 heterocycle" refers to an aromatic or
non-aromatic C.sub.3-C.sub.8 carbocycle in which one to four of the
ring carbon atoms are independently replaced with a heteroatom from
the group consisting of O, S and N. Representative examples of a
C.sub.3-C.sub.8 heterocycle include, but are not limited to,
benzofuranyl, benzothiophene, indolyl, benzopyrazolyl, coumarinyl,
isoquinolinyl, pyrrolyl, thiophenyl, furanyl, thiazolyl,
imidazolyl, pyrazolyl, triazolyl, quinolinyl, pyrimidinyl,
pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, isothiazolyl,
isoxazolyl and tetrazolyl. A C.sub.3-C.sub.8 heterocycle can be
unsubstituted or substituted with up to seven groups including, but
not limited to, --C.sub.1-C.sub.8 alkyl, --O--(C.sub.1-C.sub.8
alkyl), -aryl, --C(O)R', --OC(O)R', --C(O)OR', --C(O)NH.sub.2,
--C(O)NHR', --C(O)N(R').sub.2--NHC(O)R', --S(O).sub.2R', --S(O)R',
--OH, -halogen, --N.sub.3, --NH.sub.2, --NH(R'), --N(R').sub.2 and
--CN; wherein each R' is independently selected from H,
--C.sub.1-C.sub.8 alkyl and aryl.
[0181] "C.sub.3-C.sub.8 heterocyclo" refers to a C.sub.3-C.sub.8
heterocycle group defined above wherein one of the heterocycle
group's hydrogen atoms is replaced with a bond. A C.sub.3-C.sub.8
heterocyclo can be unsubstituted or substituted with up to six
groups including, but not limited to, --C.sub.1-C.sub.8 alkyl,
--O--(C.sub.1-C.sub.5 alkyl), -aryl, --C(O)R', --OC(O)R',
--C(O)OR', --C(O)NH.sub.2, --C(O)NHR', --C(O)N(R').sub.2--NHC(O)R',
--S(O).sub.2R', --S(O)R', --OH, -halogen, --N.sub.3, --NH.sub.2,
--NH(R'), --N(R').sub.2 and --CN; wherein each R' is independently
selected from H, --C.sub.1-C.sub.8 alkyl and aryl.
[0182] A "C.sub.3-C.sub.20 heterocycle" refers to an aromatic or
non-aromatic C.sub.3-C.sub.8 carbocycle in which one to four of the
ring carbon atoms are independently replaced with a heteroatom from
the group consisting of O, S and N. A C.sub.3-C.sub.20 heterocycle
can be unsubstituted or substituted with up to seven groups
including, but not limited to, --C.sub.1-C.sub.8 alkyl,
--O--(C.sub.1-C.sub.8 alkyl), -aryl, --C(O)R', --OC(O)R',
--C(O)OR', --C(O)NH.sub.2, --C(O)NHR', --C(O)N(R').sub.2--NHC(O)R',
--S(O).sub.2R', --S(O)R', --OH, -halogen, --N.sub.3, --NH.sub.2,
--NH(R'), --N(R').sub.2 and --CN; wherein each R' is independently
selected from H, --C.sub.1-C.sub.8 alkyl and aryl.
[0183] "C.sub.3-C.sub.20 heterocyclo" refers to a C.sub.3-C.sub.20
heterocycle group defined above wherein one of the heterocycle
group's hydrogen atoms is replaced with a bond.
[0184] "Carbocycle" means a saturated or unsaturated ring having 3
to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a
bicycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more
typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring
atoms, e.g. arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6]
system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6]
system. Examples of monocyclic carbocycles include cyclopropyl,
cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl,
1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl,
1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cycloheptyl, and
cyclooctyl.
[0185] A "C.sub.3-C.sub.8 carbocycle" is a 3-, 4-, 5-, 6-, 7- or
8-membered saturated or unsaturated non-aromatic carbocyclic ring.
Representative C.sub.3-C.sub.8 carbocycles include, but are not
limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl,
-cyclopentadienyl, -cyclohexyl, -cyclohexenyl,
-1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl,
-1,3-cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl, and
-cyclooctadienyl. A C.sub.3-C.sub.8 carbocycle group can be
unsubstituted or substituted with one or more groups including, but
not limited to, --C.sub.1-C.sub.8 alkyl, --O--(C.sub.1-C.sub.8
alkyl), -aryl, --C(O)R', --OC(O)R', --C(O)OR', --C(O)NH.sub.2,
--C(O)NHR', --C(O)N(R').sub.2--NHC(O)R', --S(O).sub.2R', --S(O)R',
--OH, -halogen, --N.sub.3, --NH.sub.2, --NH(R'), --N(R').sub.2 and
--CN; where each R' is independently selected from H,
--C.sub.1-C.sub.8 alkyl and aryl.
[0186] A "C.sub.3-C.sub.8 carbocyclo" refers to a C.sub.3-C.sub.8
carbocycle group defined above wherein one of the carbocycle
groups' hydrogen atoms is replaced with a bond.
[0187] "Linker" refers to a chemical moiety comprising a covalent
bond or a chain of atoms that covalently attaches an antibody to a
drug moiety. In various embodiments, linkers include a divalent
radical such as an alkyldiyl, an aryldiyl, a heteroaryldiyl,
moieties such as: --(CR.sub.2).sub.nO(CR.sub.2).sub.n--, repeating
units of alkyloxy (e.g. polyethylenoxy, PEG, polymethyleneoxy) and
alkylamino (e.g. polyethyleneamino, Jeffamine.TM.); and diacid
ester and amides including succinate, succinamide, diglycolate,
malonate, and caproamide. In various embodiments, linkers can
comprise one or more amino acid residues, such as valine,
phenylalanine, lysine, and homolysine.
[0188] The term "chiral" refers to molecules which have the
property of non-superimposability of the mirror image partner,
while the term "achiral" refers to molecules which are
superimposable on their mirror image partner.
[0189] The term "stereoisomers" refers to compounds which have
identical chemical constitution, but differ with regard to the
arrangement of the atoms or groups in space.
[0190] "Diastereomer" refers to a stereoisomer with two or more
centers of chirality and whose molecules are not mirror images of
one another. Diastereomers have different physical properties, e.g.
melting points, boiling points, spectral properties, and
reactivities. Mixtures of diastereomers may separate under high
resolution analytical procedures such as electrophoresis and
chromatography.
[0191] "Enantiomers" refer to two stereoisomers of a compound which
are non-superimposable mirror images of one another.
[0192] Stereochemical definitions and conventions used herein
generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of
Chemical Terms (1984) McGraw-Hill Book Company, New York; and
Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds
(1994) John Wiley & Sons, Inc., New York. Many organic
compounds exist in optically active forms, i.e., they have the
ability to rotate the plane of plane-polarized light. In describing
an optically active compound, the prefixes D and L, or R and S, are
used to denote the absolute configuration of the molecule about its
chiral center(s). The prefixes d and 1 or (+) and (-) are employed
to designate the sign of rotation of plane-polarized light by the
compound, with (-) or 1 meaning that the compound is levorotatory.
A compound prefixed with (+) or d is dextrorotatory. For a given
chemical structure, these stereoisomers are identical except that
they are mirror images of one another. A specific stereoisomer may
also be referred to as an enantiomer, and a mixture of such isomers
is often called an enantiomeric mixture. A 50:50 mixture of
enantiomers is referred to as a racemic mixture or a racemate,
which may occur where there has been no stereoselection or
stereospecificity in a chemical reaction or process. The terms
"racemic mixture" and "racemate" refer to an equimolar mixture of
two enantiomeric species, devoid of optical activity.
[0193] "Leaving group" refers to a functional group that can be
substituted by another functional group. Certain leaving groups are
well known in the art, and examples include, but are not limited
to, a halide (e.g., chloride, bromide, iodide), methanesulfonyl
(mesyl), p-toluenesulfonyl (tosyl), trifluoromethylsulfonyl
(triflate), and trifluoromethylsulfonate.
[0194] The term "protecting group" refers to a substituent that is
commonly employed to block or protect a particular functionality
while reacting other functional groups on the compound. For
example, an "amino-protecting group" is a substituent attached to
an amino group that blocks or protects the amino functionality in
the compound. Suitable amino-protecting groups include, but are not
limited to, acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC),
benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc).
For a general description of protecting groups and their use, see
T. W. Greene, Protective Groups in Organic Synthesis, John Wiley
& Sons, New York, 1991, or a later edition.
II. COMPOSITIONS AND METHODS
[0195] In one aspect, the invention is based, in part, on
antibodies that bind to HER2 and immunoconjugates comprising such
antibodies. Antibodies and immunoconjugates of the invention are
useful, e.g., for the diagnosis or treatment of HER2-positive
cancers.
[0196] A. Exemplary Anti-HER2 Antibodies
[0197] Provided herein are isolated antibodies that bind to domain
I of HER2. In some embodiments, the antibodies do not interfere
with trastuzumab and/or pertuzumab binding to HER2.
[0198] In some embodiments, the antibodies do not interfere with
trastuzumab binding to HER2 and do not interfere with pertuzumab
binding to HER2. In any of the embodiments described herein, the
antibodies may be monoclonal antibodies. In some embodiments, the
antibodies may be human antibodies, humanized antibodies, or
chimeric antibodies.
[0199] An exemplary naturally occurring human HER2 precursor
protein sequence, with signal sequence (amino acids 1-22) is
provided in SEQ ID NO: 1, and the corresponding mature HER2 protein
sequence corresponds to amino acids 23-1255 of SEQ ID NO: 1. In
some embodiments, domain I of HER2 has the amino acid sequence of
SEQ ID NO: 35, domain II has the amino acid sequence of SEQ ID NO:
36, domain III has the amino acid sequence of SEQ ID NO: 37, and
domain IV has the amino acid sequence of SEQ ID NO: 38 (see FIG.
10).
[0200] Antibody hu7C2 and Other Embodiments
[0201] In some embodiments, an anti-HER2 antibody is provided that
comprises at least one, two, three, four, five, or six HVRs
selected from (a) HVR-H1 comprising the amino acid sequence of SEQ
ID NO: 15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO: 16; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14. In
some embodiments, an anti-HER2 antibody is provided that comprises
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 16 and
at least one, two, three, four, or five HVRs selected from (a)
HVR-H1 comprising the amino acid sequence of SEQ ID NO: 15; (b)
HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17; (c)
HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (d)
HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (e)
HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.
[0202] In one aspect, an antibody is provided that comprises at
least one, at least two, or all three VH HVR sequences selected
from (a) HVR-H 1 comprising the amino acid sequence of SEQ ID NO:
15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 16;
and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17.
In one embodiment, the antibody comprises HVR-H3 comprising the
amino acid sequence of SEQ ID NO: 17. In one embodiment, the
antibody comprises HVR-H2 comprising the amino acid sequence of SEQ
ID NO: 16. In another embodiment, the antibody comprises HVR-H3
comprising the amino acid sequence of SEQ ID NO: 17 and HVR-L3
comprising the amino acid sequence of SEQ ID NO: 14. In a further
embodiment, the antibody comprises HVR-H3 comprising the amino acid
sequence of SEQ ID NO: 17, HVR-L3 comprising the amino acid
sequence of SEQ ID NO: 14, and HVR-H2 comprising the amino acid
sequence of SEQ ID NO: 16. In a further embodiment, the antibody
comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID
NO: 15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
16; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17.
[0203] In another aspect, an antibody is provided that comprises at
least one, at least two, or all three VL HVR sequences selected
from (a) HVR-L 1 comprising the amino acid sequence of SEQ ID NO:
12; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13;
and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.
In one embodiment, the antibody comprises (a) HVR-L1 comprising the
amino acid sequence of SEQ ID NO: 12; (b) HVR-L2 comprising the
amino acid sequence of SEQ ID NO: 13; and (c) HVR-L3 comprising the
amino acid sequence of SEQ ID NO: 14.
[0204] In another aspect, an antibody comprises (a) a VH domain
comprising at least one, at least two, or all three VH HVR
sequences selected from (i) HVR-H 1 comprising the amino acid
sequence of SEQ ID NO: 15, (ii) HVR-H2 comprising the amino acid
sequence of SEQ ID NO: 16, and (iii) HVR-H3 comprising an amino
acid sequence selected from SEQ ID NO: 17; and (b) a VL domain
comprising at least one, at least two, or all three VL HVR
sequences selected from (i) HVR-L1 comprising the amino acid
sequence of SEQ ID NO: 12, (ii) HVR-L2 comprising the amino acid
sequence of SEQ ID NO: 13, and (c) HVR-L3 comprising the amino acid
sequence of SEQ ID NO: 14.
[0205] In another aspect, an antibody is provided that comprises
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 15; (b)
HVR-H2 comprising the amino acid sequence of SEQ ID NO: 16; (c)
HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17; (d)
HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (f)
HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.
[0206] In any of the above embodiments, an anti-HER2 antibody is
humanized. In one embodiment, an anti-HER2 antibody comprises HVRs
as in any of the above embodiments, and further comprises a human
acceptor framework, e.g. a human immunoglobulin framework or a
human consensus framework. In certain embodiments, the human
acceptor framework is the human VL kappa IV consensus (VL.sub.KIV)
framework and/or the VH framework VH.sub.I. In certain embodiments,
the human acceptor framework is the human VL kappa IV consensus
(VL.sub.KIV) framework and/or the VH framework VH.sub.1 comprising
any one of the mutations described herein.
[0207] In another aspect, an anti-HER2 antibody comprises a heavy
chain variable domain (VH) sequence having at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the
amino acid sequence of SEQ ID NO: 11. In certain embodiments, a VH
sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identity to the amino acid sequence of SEQ ID NO: 11
contains substitutions (e.g., conservative substitutions),
insertions, or deletions relative to the reference sequence, but an
anti-HER2 antibody comprising that sequence retains the ability to
bind to HER2. In certain embodiments, a total of 1 to 10 amino
acids have been substituted, inserted and/or deleted in SEQ ID NO:
11. In certain embodiments, a total of 1 to 5 amino acids have been
substituted, inserted and/or deleted in SEQ ID NO: 11. In certain
embodiments, substitutions, insertions, or deletions occur in
regions outside the HVRs (i.e., in the FRs). Optionally, the
anti-HER2 antibody comprises the VH sequence of SEQ ID NO: 11,
including post-translational modifications of that sequence. In a
particular embodiment, the VH comprises one, two or three HVRs
selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ
ID NO: 15, (b) HVR-H2 comprising the amino acid sequence of SEQ ID
NO: 16, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID
NO: 17.
[0208] In another aspect, an anti-HER2 antibody is provided,
wherein the antibody comprises a light chain variable domain (VL)
having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
or 100% sequence identity to the amino acid sequence of SEQ ID NO:
10. In certain embodiments, a VL sequence having at least 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino
acid sequence of SEQ ID NO: 10 contains substitutions (e.g.,
conservative substitutions), insertions, or deletions relative to
the reference sequence, but an anti-HER2 antibody comprising that
sequence retains the ability to bind to HER2. In certain
embodiments, a total of 1 to 10 amino acids have been substituted,
inserted and/or deleted in SEQ ID NO: 10. In certain embodiments, a
total of 1 to 5 amino acids have been substituted, inserted and/or
deleted in SEQ ID NO: 10. In certain embodiments, the
substitutions, insertions, or deletions occur in regions outside
the HVRs (i.e., in the FRs). Optionally, the anti-HER2 antibody
comprises the VL sequence of SEQ ID NO: 10, including
post-translational modifications of that sequence. In a particular
embodiment, the VL comprises one, two or three HVRs selected from
(a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (b)
HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13; and (c)
HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.
[0209] In another aspect, an anti-HER2 antibody is provided,
wherein the antibody comprises a VH as in any of the embodiments
provided above, and a VL as in any of the embodiments provided
above.
[0210] In one embodiment, the antibody comprises the VH and VL
sequences in SEQ ID NO: 11 and SEQ ID NO: 10, respectively,
including post-translational modifications of those sequences.
[0211] In a further aspect, provided are herein are antibodies that
bind to the same epitope as an anti-HER2 antibody provided herein.
For example, in certain embodiments, an antibody is provided that
binds to the same epitope as an anti-HER2 antibody comprising a VH
sequence of SEQ ID NO: 11 and a VL sequence of SEQ ID NO: 10,
respectively.
[0212] In another aspect, an anti-HER2 antibody comprises a heavy
chain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, or 100% sequence identity to the amino acid sequence
of SEQ ID NO: 19. In certain embodiments, a heavy chain sequence
having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity to the amino acid sequence of SEQ ID NO: 19 contains
substitutions (e.g., conservative substitutions), insertions, or
deletions relative to the reference sequence, but an anti-HER2
antibody comprising that sequence retains the ability to bind to
HER2. In certain embodiments, a total of 1 to 10 amino acids have
been substituted, inserted and/or deleted in SEQ ID NO: 19. In
certain embodiments, a total of 1 to 5 amino acids have been
substituted, inserted and/or deleted in SEQ ID NO: 19. In certain
embodiments, substitutions, insertions, or deletions occur in
regions outside the HVRs (i.e., in the FRs). Optionally, the
anti-HER2 antibody comprises the heavy chain sequence of SEQ ID NO:
19, including post-translational modifications of that sequence. In
a particular embodiment, the heavy chain comprises one, two or
three HVRs selected from: (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO: 15, (b) HVR-H2 comprising the amino acid
sequence of SEQ ID NO: 16, and (c) HVR-H3 comprising the amino acid
sequence of SEQ ID NO: 17.
[0213] In another aspect, an anti-HER2 antibody is provided,
wherein the antibody comprises a light chain having at least 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to the amino acid sequence of SEQ ID NO: 18. In certain
embodiments, a light chain sequence having at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid
sequence of SEQ ID NO: 18 contains substitutions (e.g.,
conservative substitutions), insertions, or deletions relative to
the reference sequence, but an anti-HER2 antibody comprising that
sequence retains the ability to bind to HER2. In certain
embodiments, a total of 1 to 10 amino acids have been substituted,
inserted and/or deleted in SEQ ID NO: 18. In certain embodiments, a
total of 1 to 5 amino acids have been substituted, inserted and/or
deleted in SEQ ID NO: 18. In certain embodiments, the
substitutions, insertions, or deletions occur in regions outside
the HVRs (i.e., in the FRs). Optionally, the anti-HER2 antibody
comprises the light chain sequence of SEQ ID NO: 18, including
post-translational modifications of that sequence. In a particular
embodiment, the light chain comprises one, two or three HVRs
selected from (a) HVR-L 1 comprising the amino acid sequence of SEQ
ID NO: 12; (b) HVR-L2 comprising the amino acid sequence of SEQ ID
NO: 13; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID
NO: 14.
[0214] In another aspect, an anti-HER2 antibody is provided,
wherein the antibody comprises a heavy chain as in any of the
embodiments provided above, and a light chain as in any of the
embodiments provided above.
[0215] In one embodiment, the antibody comprises the heavy chain
and light chain sequences in SEQ ID NO: 19 and SEQ ID NO: 18,
respectively, including post-translational modifications of those
sequences.
[0216] In a further aspect, provided are herein are antibodies that
bind to the same epitope as an anti-HER2 antibody provided herein.
For example, in certain embodiments, an antibody is provided that
binds to the same epitope as an anti-HER2 antibody comprising a
heavy chain sequence of SEQ ID NO: 19 and a light chain sequence of
SEQ ID NO: 18, respectively.
[0217] Provided herein are antibodies comprising a light chain
variable domain comprising the HVR1-LC, HVR2-LC and HVR3-LC
sequence according to Kabat numbering as depicted in FIG. 1 and a
heavy chain variable domain comprising the HVR1-HC, HVR2-HC and
HVR3-HC sequence according to Kabat numbering as depicted in FIG.
2. In some embodiments, the antibody comprises a light chain
variable domain comprising the HVR1-LC, HVR2-LC and/or HVR3-LC
sequence, and the FR1-LC, FR2-LC, FR3-LC and/or FR4-LC sequence as
depicted in FIG. 1. In some embodiments, the antibody comprises a
heavy chain variable domain comprising the HVR1-HC, HVR2-HC and/or
HVR3-HC sequence, and the FR1-HC, FR2-HC, FR3-HC and/or FR4-HC
sequence as depicted in FIG. 2.
[0218] In a further aspects, an anti-HER2 antibody according to any
of the above embodiments is a monoclonal antibody, including a
human antibody. In one embodiment, an anti-HER2 antibody is an
antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or
F(ab').sub.2 fragment. In another embodiment, the antibody is a
substantially full length antibody, e.g., an IgG1 antibody, IgG2a
antibody or other antibody class or isotype as defined herein.
[0219] In a further aspect, an anti-HER2 antibody according to any
of the above embodiments may incorporate any of the features,
singly or in combination, as described below.
[0220] 1. Antibody Affinity
[0221] In certain embodiments, an antibody provided herein has a
dissociation constant (Kd) of .ltoreq.1 .mu.M, .ltoreq.100 nM,
.ltoreq.50 nM, .ltoreq.10 nM, .ltoreq.5 nM, .ltoreq.1 nM,
.ltoreq.0.1 nM, .ltoreq.0.01 nM, or .ltoreq.0.001 nM, and
optionally is .gtoreq.10.sup.-13 M. (e.g. 10.sup.-8 M or less, e.g.
from 10.sup.-8 M to 10.sup.-13 M, e.g., from 10.sup.-9 M to
10.sup.-13 M).
[0222] In one embodiment, Kd is measured by a radiolabeled antigen
binding assay (RIA) performed with the Fab version of an antibody
of interest and its antigen as described by the following assay.
Solution binding affinity of Fabs for antigen is measured by
equilibrating Fab with a minimal concentration of
(.sup.125I)-labeled antigen in the presence of a titration series
of unlabeled antigen, then capturing bound antigen with an anti-Fab
antibody-coated plate (see, e.g., Chen et al., J. Mol. Biol.
293:865-881(1999)). To establish conditions for the assay,
MICROTITER.RTM. multi-well plates (Thermo Scientific) are coated
overnight with 5 .mu.g/ml of a capturing anti-Fab antibody (Cappel
Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked
with 2% (w/v) bovine serum albumin in PBS for two to five hours at
room temperature (approximately 23.degree. C.). In a non-adsorbent
plate (Nunc #269620), 100 pM or 26 pM [.sup.125I]-antigen are mixed
with serial dilutions of a Fab of interest (e.g., consistent with
assessment of the anti-VEGF antibody, Fab-12, in Presta et al.,
Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then
incubated overnight; however, the incubation may continue for a
longer period (e.g., about 65 hours) to ensure that equilibrium is
reached. Thereafter, the mixtures are transferred to the capture
plate for incubation at room temperature (e.g., for one hour). The
solution is then removed and the plate washed eight times with 0.1%
polysorbate 20 (TWEEN-20.RTM.) in PBS. When the plates have dried,
150 .mu.l/well of scintillant (MICROSCINT-20.TM.; Packard) is
added, and the plates are counted on a TOPCOUNT.TM. gamma counter
(Packard) for ten minutes. Concentrations of each Fab that give
less than or equal to 20% of maximal binding are chosen for use in
competitive binding assays.
[0223] According to another embodiment, Kd is measured using
surface plasmon resonance assays using a BIACORE.RTM.-2000 or a
BIACORE.RTM.-3000 (BIAcore, Inc., Piscataway, N.J.) at 25.degree.
C. with immobilized antigen CM5 chips at .about.10 response units
(RU). Briefly, carboxymethylated dextran biosensor chips (CM5,
BIACORE, Inc.) are activated with
N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC)
and N-hydroxysuccinimide (NHS) according to the supplier's
instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8,
to 5 .mu.g/ml (.about.0.2 .mu.M) before injection at a flow rate of
5 .mu.l/minute to achieve approximately 10 response units (RU) of
coupled protein. Following the injection of antigen, 1 M
ethanolamine is injected to block unreacted groups. For kinetics
measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM)
are injected in PBS with 0.05% polysorbate 20 (TWEEN-20.TM.)
surfactant (PBST) at 25.degree. C. at a flow rate of approximately
25 .mu.l/min. Association rates (k.sub.on) and dissociation rates
(k.sub.off) are calculated using a simple one-to-one Langmuir
binding model (BIACORE.RTM. Evaluation Software version 3.2) by
simultaneously fitting the association and dissociation
sensorgrams. The equilibrium dissociation constant (Kd) is
calculated as the ratio k.sub.off/k.sub.on. See, e.g., Chen et al.,
J. Mol. Biol. 293:865-881 (1999). If the on-rate exceeds 10.sup.6
M.sup.-1 s.sup.-1 by the surface plasmon resonance assay above,
then the on-rate can be determined by using a fluorescent quenching
technique that measures the increase or decrease in fluorescence
emission intensity (excitation=295 nm; emission=340 nm, 16 nm
band-pass) at 25.degree. C. of a 20 nM anti-antigen antibody (Fab
form) in PBS, pH 7.2, in the presence of increasing concentrations
of antigen as measured in a spectrometer, such as a stop-flow
equipped spectrophometer (Aviv Instruments) or a 8000-series
SLM-AMINCO.TM. spectrophotometer (ThermoSpectronic) with a stirred
cuvette.
[0224] 2. Antibody Fragments
[0225] In certain embodiments, an antibody provided herein is an
antibody fragment. Antibody fragments include, but are not limited
to, Fab, Fab', Fab'-SH, F(ab').sub.2, Fv, and scFv fragments, and
other fragments described below. For a review of certain antibody
fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a
review of scFv fragments, see, e.g., Pluckthun, in The Pharmacology
of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds.,
(Springer-Verlag, New York), pp. 269-315 (1994); see also WO
93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For
discussion of Fab and F(ab').sub.2 fragments comprising salvage
receptor binding epitope residues and having increased in vivo
half-life, see U.S. Pat. No. 5,869,046.
[0226] Diabodies are antibody fragments with two antigen-binding
sites that may be bivalent or bispecific. See, for example, EP
404,097; WO 1993/01161; Hudson et al., Nat. Med. 9:129-134 (2003);
and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448
(1993). Triabodies and tetrabodies are also described in Hudson et
al., Nat. Med. 9:129-134 (2003).
[0227] Single-domain antibodies are antibody fragments comprising
all or a portion of the heavy chain variable domain or all or a
portion of the light chain variable domain of an antibody. In
certain embodiments, a single-domain antibody is a human
single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g.,
U.S. Pat. No. 6,248,516 B1).
[0228] Antibody fragments can be made by various techniques,
including but not limited to proteolytic digestion of an intact
antibody as well as production by recombinant host cells (e.g. E.
coli or phage), as described herein.
[0229] 3. Chimeric and Humanized Antibodies
[0230] In certain embodiments, an antibody provided herein is a
chimeric antibody. Certain chimeric antibodies are described, e.g.,
in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad.
Sci. USA, 81:6851-6855 (1984)). In one example, a chimeric antibody
comprises a non-human variable region (e.g., a variable region
derived from a mouse, rat, hamster, rabbit, or non-human primate,
such as a monkey) and a human constant region. In a further
example, a chimeric antibody is a "class switched" antibody in
which the class or subclass has been changed from that of the
parent antibody. Chimeric antibodies include antigen-binding
fragments thereof.
[0231] In certain embodiments, a chimeric antibody is a humanized
antibody. Typically, a non-human antibody is humanized to reduce
immunogenicity to humans, while retaining the specificity and
affinity of the parental non-human antibody. Generally, a humanized
antibody comprises one or more variable domains in which HVRs,
e.g., CDRs, (or portions thereof) are derived from a non-human
antibody, and FRs (or portions thereof) are derived from human
antibody sequences. A humanized antibody optionally will also
comprise at least a portion of a human constant region. In some
embodiments, some FR residues in a humanized antibody are
substituted with corresponding residues from a non-human antibody
(e.g., the antibody from which the HVR residues are derived), e.g.,
to restore or improve antibody specificity or affinity.
[0232] Humanized antibodies and methods of making them are
reviewed, e.g., in Almagro and Fransson, Front. Biosci.
13:1619-1633 (2008), and are further described, e.g., in Riechmann
et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad.
Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337,
7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods
36:25-34 (2005) (describing SDR (a-CDR) grafting); Padlan, Mol.
Immunol. 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua
et al., Methods 36:43-60 (2005) (describing "FR shuffling"); and
Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J.
Cancer, 83:252-260 (2000) (describing the "guided selection"
approach to FR shuffling).
[0233] Human framework regions that may be used for humanization
include but are not limited to: framework regions selected using
the "best-fit" method (see, e.g., Sims et al. J. Immunol. 151:2296
(1993)); framework regions derived from the consensus sequence of
human antibodies of a particular subgroup of light or heavy chain
variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci.
USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623
(1993)); human mature (somatically mutated) framework regions or
human germline framework regions (see, e.g., Almagro and Fransson,
Front. Biosci. 13:1619-1633 (2008)); and framework regions derived
from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem.
272:10678-10684 (1997) and Rosok et al., J. Biol. Chem.
271:22611-22618 (1996)).
[0234] 4. Human Antibodies
[0235] In certain embodiments, an antibody provided herein is a
human antibody. Human antibodies can be produced using various
techniques known in the art. Human antibodies are described
generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:
368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459
(2008).
[0236] Human antibodies may be prepared by administering an
immunogen to a transgenic animal that has been modified to produce
intact human antibodies or intact antibodies with human variable
regions in response to antigenic challenge. Such animals typically
contain all or a portion of the human immunoglobulin loci, which
replace the endogenous immunoglobulin loci, or which are present
extrachromosomally or integrated randomly into the animal's
chromosomes. In such transgenic mice, the endogenous immunoglobulin
loci have generally been inactivated. For review of methods for
obtaining human antibodies from transgenic animals, see Lonberg,
Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Pat. Nos.
6,075,181 and 6,150,584 describing XENOMOUSE.TM. technology; U.S.
Pat. No. 5,770,429 describing HUMAB.RTM. technology; U.S. Pat. No.
7,041,870 describing K-M MOUSE.RTM. technology, and U.S. Patent
Application Publication No. US 2007/0061900, describing
VELOCIMOUSE.RTM. technology). Human variable regions from intact
antibodies generated by such animals may be further modified, e.g.,
by combining with a different human constant region.
[0237] Human antibodies can also be made by hybridoma-based
methods. Human myeloma and mouse-human heteromyeloma cell lines for
the production of human monoclonal antibodies have been described.
(See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al.,
Monoclonal Antibody Production Techniques and Applications, pp.
51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J.
Immunol., 147: 86 (1991).) Human antibodies generated via human
B-cell hybridoma technology are also described in Li et al., Proc.
Natl. Acad. Sci. USA, 103:3557-3562 (2006). Additional methods
include those described, for example, in U.S. Pat. No. 7,189,826
(describing production of monoclonal human IgM antibodies from
hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268
(2006) (describing human-human hybridomas). Human hybridoma
technology (Trioma technology) is also described in Vollmers and
Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and
Vollmers and Brandlein, Methods and Findings in Experimental and
Clinical Pharmacology, 27(3): 185-91 (2005).
[0238] Human antibodies may also be generated by isolating Fv clone
variable domain sequences selected from human-derived phage display
libraries. Such variable domain sequences may then be combined with
a desired human constant domain. Techniques for selecting human
antibodies from antibody libraries are described below.
[0239] 5. Library-Derived Antibodies
[0240] Antibodies of the invention may be isolated by screening
combinatorial libraries for antibodies with the desired activity or
activities. For example, a variety of methods are known in the art
for generating phage display libraries and screening such libraries
for antibodies possessing the desired binding characteristics. Such
methods are reviewed, e.g., in Hoogenboom et al. in Methods in
Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press,
Totowa, N.J., 2001) and further described, e.g., in the McCafferty
et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628
(1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and
Bradbury, in Methods in Molecular Biology 248:161-175 (Lo, ed.,
Human Press, Totowa, N.J., 2003); Sidhu et al., J. Mol. Biol.
338(2): 299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073-1093
(2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472
(2004); and Lee et al., J. Immunol. Methods 284(1-2):
119-132(2004).
[0241] In certain phage display methods, repertoires of VH and VL
genes are separately cloned by polymerase chain reaction (PCR) and
recombined randomly in phage libraries, which can then be screened
for antigen-binding phage as described in Winter et al., Ann. Rev.
Immunol., 12: 433-455 (1994). Phage typically display antibody
fragments, either as single-chain Fv (scFv) fragments or as Fab
fragments. Libraries from immunized sources provide high-affinity
antibodies to the immunogen without the requirement of constructing
hybridomas. Alternatively, the naive repertoire can be cloned
(e.g., from human) to provide a single source of antibodies to a
wide range of non-self and also self antigens without any
immunization as described by Griffiths et al., EMBO J, 12: 725-734
(1993). Finally, naive libraries can also be made synthetically by
cloning unrearranged V-gene segments from stem cells, and using PCR
primers containing random sequence to encode the highly variable
CDR3 regions and to accomplish rearrangement in vitro, as described
by Hoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992).
Patent publications describing human antibody phage libraries
include, for example: U.S. Pat. No. 5,750,373, and US Patent
Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000,
2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and
2009/0002360.
[0242] Antibodies or antibody fragments isolated from human
antibody libraries are considered human antibodies or human
antibody fragments herein.
[0243] 6. Multispecific Antibodies
[0244] In certain embodiments, an antibody provided herein is a
multispecific antibody, e.g. a bispecific antibody. Multispecific
antibodies are monoclonal antibodies that have binding
specificities for at least two different sites. In certain
embodiments, one of the binding specificities is for HER2 and the
other is for any other antigen. In certain embodiments, one of the
binding specificities is for HER2 and the other is for CD3. See,
e.g., U.S. Pat. No. 5,821,337. In certain embodiments, bispecific
antibodies may bind to two different epitopes of HER2. Bispecific
antibodies may also be used to localize cytotoxic agents to cells
which express HER2. Bispecific antibodies can be prepared as full
length antibodies or antibody fragments.
[0245] Techniques for making multispecific antibodies include, but
are not limited to, recombinant co-expression of two immunoglobulin
heavy chain-light chain pairs having different specificities (see
Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and
Traunecker et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole"
engineering (see, e.g., U.S. Pat. No. 5,731,168). The term
"knob-into-hole" or "KnH" technology as used herein refers to the
technology directing the pairing of two polypeptides together in
vitro or in vivo by introducing a protuberance (knob) into one
polypeptide and a cavity (hole) into the other polypeptide at an
interface in which they interact. For example, KnHs have been
introduced in the Fc:Fc binding interfaces, CL:CH1 interfaces or
VH/VL interfaces of antibodies (see, e.g., US 2011/0287009,
US2007/0178552, WO 96/027011, WO 98/050431, Zhu et al., 1997,
Protein Science 6:781-788, and WO2012/106587). In some embodiments,
KnHs drive the pairing of two different heavy chains together
during the manufacture of multispecific antibodies. For example,
multispecific antibodies having KnH in their Fc regions can further
comprise single variable domains linked to each Fc region, or
further comprise different heavy chain variable domains that pair
with similar or different light chain variable domains. KnH
technology can be also be used to pair two different receptor
extracellular domains together or any other polypeptide sequences
that comprises different target recognition sequences (e.g.,
including affibodies, peptibodies and other Fc fusions).
[0246] The term "knob mutation" as used herein refers to a mutation
that introduces a protuberance (knob) into a polypeptide at an
interface in which the polypeptide interacts with another
polypeptide. In some embodiments, the other polypeptide has a hole
mutation.
[0247] The term "hole mutation" as used herein refers to a mutation
that introduces a cavity (hole) into a polypeptide at an interface
in which the polypeptide interacts with another polypeptide. In
some embodiments, the other polypeptide has a knob mutation.
[0248] A brief nonlimiting discussion is provided below.
[0249] A "protuberance" refers to at least one amino acid side
chain which projects from the interface of a first polypeptide and
is therefore positionable in a compensatory cavity in the adjacent
interface (i.e. the interface of a second polypeptide) so as to
stabilize the heteromultimer, and thereby favor heteromultimer
formation over homomultimer formation, for example. The
protuberance may exist in the original interface or may be
introduced synthetically (e.g., by altering nucleic acid encoding
the interface). In some embodiments, nucleic acid encoding the
interface of the first polypeptide is altered to encode the
protuberance. To achieve this, the nucleic acid encoding at least
one "original" amino acid residue in the interface of the first
polypeptide is replaced with nucleic acid encoding at least one
"import" amino acid residue which has a larger side chain volume
than the original amino acid residue. It will be appreciated that
there can be more than one original and corresponding import
residue. The side chain volumes of the various amino residues are
shown, for example, in Table 1 of US2011/0287009. A mutation to
introduce a "protuberance" may be referred to as a "knob
mutation."
[0250] In some embodiments, import residues for the formation of a
protuberance are naturally occurring amino acid residues selected
from arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan
(W). In some embodiments, an import residue is tryptophan or
tyrosine. In some embodiment, the original residue for the
formation of the protuberance has a small side chain volume, such
as alanine, asparagine, aspartic acid, glycine, serine, threonine
or valine.
[0251] A "cavity" refers to at least one amino acid side chain
which is recessed from the interface of a second polypeptide and
therefore accommodates a corresponding protuberance on the adjacent
interface of a first polypeptide. The cavity may exist in the
original interface or may be introduced synthetically (e.g. by
altering nucleic acid encoding the interface). In some embodiments,
nucleic acid encoding the interface of the second polypeptide is
altered to encode the cavity. To achieve this, the nucleic acid
encoding at least one "original" amino acid residue in the
interface of the second polypeptide is replaced with DNA encoding
at least one "import" amino acid residue which has a smaller side
chain volume than the original amino acid residue. It will be
appreciated that there can be more than one original and
corresponding import residue. In some embodiments, import residues
for the formation of a cavity are naturally occurring amino acid
residues selected from alanine (A), serine (S), threonine (T) and
valine (V). In some embodiments, an import residue is serine,
alanine or threonine. In some embodiments, the original residue for
the formation of the cavity has a large side chain volume, such as
tyrosine, arginine, phenylalanine or tryptophan. A mutation to
introduce a "cavity" may be referred to as a "hole mutation."
[0252] The protuberance is "positionable" in the cavity which means
that the spatial location of the protuberance and cavity on the
interface of a first polypeptide and second polypeptide
respectively and the sizes of the protuberance and cavity are such
that the protuberance can be located in the cavity without
significantly perturbing the normal association of the first and
second polypeptides at the interface. Since protuberances such as
Tyr, Phe and Trp do not typically extend perpendicularly from the
axis of the interface and have preferred conformations, the
alignment of a protuberance with a corresponding cavity may, in
some instances, rely on modeling the protuberance/cavity pair based
upon a three-dimensional structure such as that obtained by X-ray
crystallography or nuclear magnetic resonance (NMR). This can be
achieved using widely accepted techniques in the art.
[0253] In some embodiments, a knob mutation in an IgG1 constant
region is T366W (EU numbering). In some embodiments, a hole
mutation in an IgG1 constant region comprises one or more mutations
selected from T366S, L368A and Y407V (EU numbering). In some
embodiments, a hole mutation in an IgG1 constant region comprises
T366S, L368A and Y407V (EU numbering).
[0254] In some embodiments, a knob mutation in an IgG4 constant
region is T366W (EU numbering). In some embodiments, a hole
mutation in an IgG4 constant region comprises one or more mutations
selected from T366S, L368A, and Y407V (EU numbering). In some
embodiments, a hole mutation in an IgG4 constant region comprises
T366S, L368A, and Y407V (EU numbering).
[0255] Multi-specific antibodies may also be made by engineering
electrostatic steering effects for making antibody Fc-heterodimeric
molecules (WO 2009/089004A 1); cross-linking two or more antibodies
or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et
al., Science, 229: 81 (1985)); using leucine zippers to produce
bi-specific antibodies (see, e.g., Kostelny et al., J. Immunol.,
148(5): 1547-1553 (1992)); using "diabody" technology for making
bispecific antibody fragments (see, e.g., Hollinger et al., Proc.
Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain
Fv (sFv) dimers (see, e.g. Gruber et al., J. Immunol., 152:5368
(1994)); and preparing trispecific antibodies as described, e.g.,
in Tutt et al. J. Immunol. 147: 60 (1991).
[0256] Engineered antibodies with three or more functional antigen
binding sites, including "Octopus antibodies," are also included
herein (see, e.g. US 2006/0025576A1).
[0257] The antibody or fragment herein also includes a "Dual Acting
FAb" or "DAF" comprising an antigen binding site that binds to HER2
as well as another, different antigen (see, US 2008/0069820, for
example).
[0258] 7. Antibody Variants
[0259] In certain embodiments, amino acid sequence variants of the
antibodies provided herein are contemplated. For example, it may be
desirable to improve the binding affinity and/or other biological
properties of the antibody. Amino acid sequence variants of an
antibody may be prepared by introducing appropriate modifications
into the nucleotide sequence encoding the antibody, or by peptide
synthesis. Such modifications include, for example, deletions from,
and/or insertions into and/or substitutions of residues within the
amino acid sequences of the antibody. Any combination of deletion,
insertion, and substitution can be made to arrive at the final
construct, provided that the final construct possesses the desired
characteristics, e.g., antigen-binding.
[0260] a) Substitution, Insertion, and Deletion Variants
[0261] In certain embodiments, antibody variants having one or more
amino acid substitutions are provided. Sites of interest for
substitutional mutagenesis include the HVRs and FRs. Conservative
substitutions are shown in Table 1 under the heading of "preferred
substitutions." More substantial changes are provided in Table 1
under the heading of "exemplary substitutions," and as further
described below in reference to amino acid side chain classes.
Amino acid substitutions may be introduced into an antibody of
interest and the products screened for a desired activity, e.g.,
retained/improved antigen binding, decreased immunogenicity, or
improved ADCC or CDC.
TABLE-US-00001 TABLE 1 Original Exemplary Preferred Residue
Substitutions Substitutions Ala (A) Val; Leu; Ile Val Arg (R) Lys;
Gln; Asn Lys Asn (N) Gln; His; Asp, Lys; Arg Gln Asp (D) Glu; Asn
Glu Cys (C) Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp
Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val;
Met; Ala; Phe; Norleucine Leu Leu (L) Norleucine; Ile; Val; Met;
Ala; Phe Ile Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu
Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser (S)
Thr Thr Thr (T) Val; Ser Ser Trp (W) Tyr; Phe Tyr Tyr (Y) Trp; Phe;
Thr; Ser Phe Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu
[0262] Amino acids may be grouped according to common side-chain
properties:
[0263] (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
[0264] (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
[0265] (3) acidic: Asp, Glu;
[0266] (4) basic: His, Lys, Arg;
[0267] (5) residues that influence chain orientation: Gly, Pro;
[0268] (6) aromatic: Trp, Tyr, Phe.
[0269] Non-conservative substitutions will entail exchanging a
member of one of these classes for another class.
[0270] One type of substitutional variant involves substituting one
or more hypervariable region residues of a parent antibody (e.g. a
humanized or human antibody). Generally, the resulting variant(s)
selected for further study will have modifications (e.g.,
improvements) in certain biological properties (e.g., increased
affinity, reduced immunogenicity) relative to the parent antibody
and/or will have substantially retained certain biological
properties of the parent antibody.
[0271] An exemplary substitutional variant is an affinity matured
antibody, which may be conveniently generated, e.g., using phage
display-based affinity maturation techniques such as those
described herein. Briefly, one or more HVR residues are mutated and
the variant antibodies displayed on phage and screened for a
particular biological activity (e.g. binding affinity).
[0272] Alterations (e.g., substitutions) may be made in HVRs, e.g.,
to improve antibody affinity. Such alterations may be made in HVR
"hotspots," i.e., residues encoded by codons that undergo mutation
at high frequency during the somatic maturation process (see, e.g.,
Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or SDRs
(a-CDRs), with the resulting variant VH or VL being tested for
binding affinity. Affinity maturation by constructing and
reselecting from secondary libraries has been described, e.g., in
Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien
et al., ed., Human Press, Totowa, N.J., (2001).) In some
embodiments of affinity maturation, diversity is introduced into
the variable genes chosen for maturation by any of a variety of
methods (e.g., error-prone PCR, chain shuffling, or
oligonucleotide-directed mutagenesis). A secondary library is then
created. The library is then screened to identify any antibody
variants with the desired affinity. Another method to introduce
diversity involves HVR-directed approaches, in which several HVR
residues (e.g., 4-6 residues at a time) are randomized. HVR
residues involved in antigen binding may be specifically
identified, e.g., using alanine scanning mutagenesis or modeling.
CDR-H3 and CDR-L3 in particular are often targeted.
[0273] In certain embodiments, substitutions, insertions, or
deletions may occur within one or more HVRs so long as such
alterations do not substantially reduce the ability of the antibody
to bind antigen. For example, conservative alterations (e.g.,
conservative substitutions as provided herein) that do not
substantially reduce binding affinity may be made in HVRs. Such
alterations may be outside of HVR "hotspots" or SDRs. In certain
embodiments of the variant VH and VL sequences provided above, each
HVR either is unaltered, or contains no more than one, two or three
amino acid substitutions.
[0274] A useful method for identification of residues or regions of
an antibody that may be targeted for mutagenesis is called "alanine
scanning mutagenesis" as described by Cunningham and Wells (1989)
Science, 244:1081-1085. In this method, a residue or group of
target residues (e.g., charged residues such as arg, asp, his, lys,
and glu) are identified and replaced by a neutral or negatively
charged amino acid (e.g., alanine or polyalanine) to determine
whether the interaction of the antibody with antigen is affected.
Further substitutions may be introduced at the amino acid locations
demonstrating functional sensitivity to the initial substitutions.
Alternatively, or additionally, a crystal structure of an
antigen-antibody complex is used to identify contact points between
the antibody and antigen. Such contact residues and neighboring
residues may be targeted or eliminated as candidates for
substitution. Variants may be screened to determine whether they
contain the desired properties.
[0275] Amino acid sequence insertions include amino- and/or
carboxyl-terminal fusions ranging in length from one residue to
polypeptides containing a hundred or more residues, as well as
intrasequence insertions of single or multiple amino acid residues.
Examples of terminal insertions include an antibody with an
N-terminal methionyl residue. Other insertional variants of the
antibody molecule include the fusion to the N- or C-terminus of the
antibody to an enzyme (e.g. for ADEPT) or a polypeptide which
increases the serum half-life of the antibody.
[0276] b) Glycosylation Variants
[0277] In certain embodiments, an antibody provided herein is
altered to increase or decrease the extent to which the antibody is
glycosylated. Addition or deletion of glycosylation sites to an
antibody may be conveniently accomplished by altering the amino
acid sequence such that one or more glycosylation sites is created
or removed.
[0278] Where the antibody comprises an Fc region, the carbohydrate
attached thereto may be altered. Native antibodies produced by
mammalian cells typically comprise a branched, biantennary
oligosaccharide that is generally attached by an N-linkage to
Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al.
TIBTECH 15:26-32 (1997). The oligosaccharide may include various
carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc),
galactose, and sialic acid, as well as a fucose attached to a
GlcNAc in the "stem" of the biantennary oligosaccharide structure.
In some embodiments, modifications of the oligosaccharide in an
antibody of the invention may be made in order to create antibody
variants with certain improved properties.
[0279] In one embodiment, antibody variants are provided having a
carbohydrate structure that lacks fucose attached (directly or
indirectly) to an Fc region. For example, the amount of fucose in
such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65%
or from 20% to 40%. The amount of fucose is determined by
calculating the average amount of fucose within the sugar chain at
Asn297, relative to the sum of all glycostructures attached to Asn
297 (e.g. complex, hybrid and high mannose structures) as measured
by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for
example. Asn297 refers to the asparagine residue located at about
position 297 in the Fc region (Eu numbering of Fc region residues);
however, Asn297 may also be located about +3 amino acids upstream
or downstream of position 297, i.e., between positions 294 and 300,
due to minor sequence variations in antibodies. Such fucosylation
variants may have improved ADCC function. See, e.g., US Patent
Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621
(Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to
"defucosylated" or "fucose-deficient" antibody variants include: US
2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US
2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US
2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO
2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki
et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al.
Biotech. Bioeng. 87: 614 (2004). Examples of cell lines capable of
producing defucosylated antibodies include Lecl3 CHO cells
deficient in protein fucosylation (Ripka et al. Arch. Biochem.
Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 A1,
Presta, L; and WO 2004/056312 A1, Adams et al., especially at
Example 11), and knockout cell lines, such as
alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see,
e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda,
Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and
WO2003/085107).
[0280] Antibodies variants are further provided with bisected
oligosaccharides, e.g., in which a biantennary oligosaccharide
attached to the Fc region of the antibody is bisected by GlcNAc.
Such antibody variants may have reduced fucosylation and/or
improved ADCC function. Examples of such antibody variants are
described, e.g., in WO 2003/011878 (Jean-Mairet et al.); U.S. Pat.
No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.).
Antibody variants with at least one galactose residue in the
oligosaccharide attached to the Fc region are also provided. Such
antibody variants may have improved CDC function. Such antibody
variants are described, e.g., in WO 1997/30087 (Patel et al.); WO
1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).
[0281] c) Fe Region Variants
[0282] In certain embodiments, one or more amino acid modifications
may be introduced into the Fc region of an antibody provided
herein, thereby generating an Fc region variant. The Fc region
variant may comprise a human Fc region sequence (e.g., a human
IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid
modification (e.g. a substitution) at one or more amino acid
positions.
[0283] In certain embodiments, the invention contemplates an
antibody variant that possesses some but not all effector
functions, which make it a desirable candidate for applications in
which the half life of the antibody in vivo is important yet
certain effector functions (such as complement and ADCC) are
unnecessary or deleterious. In vitro and/or in vivo cytotoxicity
assays can be conducted to confirm the reduction/depletion of CDC
and/or ADCC activities. For example, Fc receptor (FcR) binding
assays can be conducted to ensure that the antibody lacks
Fc.gamma.R binding (hence likely lacking ADCC activity), but
retains FcRn binding ability. The primary cells for mediating ADCC,
NK cells, express Fc(RIII only, whereas monocytes express Fc(RI,
Fc(RII and Fc(RIII. FcR expression on hematopoietic cells is
summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev.
Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays
to assess ADCC activity of a molecule of interest is described in
U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc. Nat'l
Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc.
Nat'l Acad. Sci. USA 82:1499-1502 (1985); U.S. Pat. No. 5,821,337
(see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)).
Alternatively, non-radioactive assays methods may be employed (see,
for example, ACTI.TM. non-radioactive cytotoxicity assay for flow
cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox
96.RTM. non-radioactive cytotoxicity assay (Promega, Madison,
Wis.). Useful effector cells for such assays include peripheral
blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
Alternatively, or additionally, ADCC activity of the molecule of
interest may be assessed in vivo, e.g., in a animal model such as
that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA
95:652-656 (1998). Clq binding assays may also be carried out to
confirm that the antibody is unable to bind Clq and hence lacks CDC
activity. See, e.g., Clq and C3c binding ELISA in WO 2006/029879
and WO 2005/100402. To assess complement activation, a CDC assay
may be performed (see, for example, Gazzano-Santoro et al., J.
Immunol. Methods 202:163 (1996); Cragg, M. S. et al., Blood
101:1045-1052 (2003); and Cragg, M. S. and M. J. Glennie, Blood
103:2738-2743 (2004)). FcRn binding and in vivo clearance/half life
determinations can also be performed using methods known in the art
(see, e.g., Petkova, S. B. et al., Int'l. Immunol. 18(12):1759-1769
(2006)).
[0284] In some embodiments, one or more amino acid modifications
may be introduced into the Fc portion of the antibody provided
herein in order to increase IgG binding to the neonatal Fc
receptor. In certain embodiments, the antibody comprises the
following three mutations according to EU numbering: M252Y, S254T,
and T256E (the "YTE mutation") (U.S. Pat. No. 8,697,650; see also
Dall'Acqua et al., Journal of Biological Chemistry
281(33):23514-23524 (2006). In certain embodiments, the YTE
mutation does not affect the ability of the antibody to bind to its
cognate antigen. In certain embodiments, the YTE mutation increases
the antibody's serum half-life compared to the native (i.e.,
non-YTE mutant) antibody. In some embodiments, the YTE mutation
increases the serum half-life of the antibody by 3-fold compared to
the native (i.e., non-YTE mutant) antibody. In some embodiments,
the YTE mutation increases the serum half-life of the antibody by
2-fold compared to the native (i.e., non-YTE mutant) antibody. In
some embodiments, the YTE mutation increases the serum half-life of
the antibody by 4-fold compared to the native (i.e., non-YTE
mutant) antibody. In some embodiments, the YTE mutation increases
the serum half-life of the antibody by at least 5-fold compared to
the native (i.e., non-YTE mutant) antibody. In some embodiments,
the YTE mutation increases the serum half-life of the antibody by
at least 10-fold compared to the native (i.e., non-YTE mutant)
antibody. See, e.g., U.S. Pat. No. 8,697,650; see also Dall'Acqua
et al., Journal of Biological Chemistry 281(33):23514-23524
(2006).
[0285] In certain embodiments, the YTE mutant provides a means to
modulate antibody-dependent cell-mediated cytotoxicity (ADCC)
activity of the antibody. In certain embodiments, the YTEO mutant
provides a means to modulate ADCC activity of a humanized IgG
antibody directed against a human antigen. See, e.g., U.S. Pat. No.
8,697,650; see also Dall'Acqua et al., Journal of Biological
Chemistry 281(33):23514-23524 (2006).
[0286] In certain embodiments, the YTE mutant allows the
simultaneous modulation of serum half-life, tissue distribution,
and antibody activity (e.g., the ADCC activity of an IgG antibody).
See, e.g., U.S. Pat. No. 8,697,650; see also Dall'Acqua et al.,
Journal of Biological Chemistry 281(33):23514-23524 (2006).
[0287] Antibodies with reduced effector function include those with
substitution of one or more of Fc region residues 238, 265, 269,
270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants
include Fc mutants with substitutions at two or more of amino acid
positions 265, 269, 270, 297 and 327, including the so-called
"DANA" Fc mutant with substitution of residues 265 and 297 to
alanine (U.S. Pat. No. 7,332,581).
[0288] In certain embodiments, the proline at position 329 (EU
numbering) (P329) of a wild-type human Fc region is substituted
with glycine or arginine or an amino acid residue large enough to
destroy the proline sandwich within the Fc/Fc.quadrature. receptor
interface, that is formed between the P329 of the Fc and
tryptophane residues W87 and W110 of FcgRIII (Sondermann et al.:
Nature 406, 267-273 (20 Jul. 2000)). In a further embodiment, at
least one further amino acid substitution in the Fc variant is
S228P, E233P, L234A, L235A, L235E, N297A, N297D, or P331S and still
in another embodiment said at least one further amino acid
substitution is L234A and L235A of the human IgG1 Fc region or
S228P and L235E of the human IgG4 Fc region, all according to EU
numbering (U.S. Pat. No. 8,969,526 which is incorporated by
reference in its entirety).
[0289] In certain embodiments, a polypeptide comprises the Fc
variant of a wild-type human IgG Fc region wherein the polypeptide
has P329 of the human IgG Fc region substituted with glycine and
wherein the Fc variant comprises at least two further amino acid
substitutions at L234A and L235A of the human IgG1 Fc region or
S228P and L235E of the human IgG4 Fc region, and wherein the
residues are numbered according to the EU numbering (U.S. Pat. No.
8,969,526 which is incorporated by reference in its entirety). In
certain embodiments, the polypeptide comprising the P329G, L234A
and L235A (EU numbering) substitutions exhibit a reduced affinity
to the human Fc.gamma.RIIIA and Fc.gamma.RIIA, for down-modulation
of ADCC to at least 20% of the ADCC induced by the polypeptide
comprising the wildtype human IgG Fc region, and/or for
down-modulation of ADCP (U.S. Pat. No. 8,969,526 which is
incorporated by reference in its entirety).
[0290] In a specific embodiment the polypeptide comprising an Fc
variant of a wildtype human Fc polypeptide comprises a triple
mutation: an amino acid substitution at position Pro329, a L234A
and a L235A mutation according to EU numbering (P329/LALA) (U.S.
Pat. No. 8,969,526 which is incorporated by reference in its
entirety). In specific embodiments, the polypeptide comprises the
following amino acid substitutions: P329G, L234A, and L235A
according to EU numbering.
[0291] Certain antibody variants with improved or diminished
binding to FcRs are described. (See, e.g., U.S. Pat. No. 6,737,056;
WO 2004/056312, and Shields et al., J. Biol. Chem. 9(2): 6591-6604
(2001).)
[0292] In certain embodiments, an antibody variant comprises an Fc
region with one or more amino acid substitutions which improve
ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the
Fc region (EU numbering of residues).
[0293] In some embodiments, alterations are made in the Fc region
that result in altered (i.e., either improved or diminished) Clq
binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as
described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et
al. J. Immunol. 164: 4178-4184 (2000).
[0294] Antibodies with increased half lives and improved binding to
the neonatal Fc receptor (FcRn), which is responsible for the
transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol.
117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are
described in US2005/0014934A1 (Hinton et al.). Those antibodies
comprise an Fc region with one or more substitutions therein which
improve binding of the Fc region to FcRn. Such Fc variants include
those with substitutions at one or more of Fc region residues: 238,
256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360,
362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc
region residue 434 (U.S. Pat. No. 7,371,826).
[0295] See also Duncan & Winter, Nature 322:738-40 (1988); U.S.
Pat. Nos. 5,648,260; 5,624,821; and WO 94/29351 concerning other
examples of Fc region variants.
[0296] d) Cysteine Engineered Antibody Variants
[0297] In certain embodiments, it may be desirable to create
cysteine engineered antibodies, e.g., a "THIOMAB.TM.," in which one
or more residues of an antibody are substituted with cysteine
residues. In particular embodiments, the substituted residues occur
at sites of the antibody that are available for conjugation. By
substituting those residues with cysteine, reactive thiol groups
are thereby positioned at accessible sites of the antibody and may
be used to conjugate the antibody to other moieties, such as drug
moieties or linker-drug moieties, to create an immunoconjugate, as
described further herein. In certain embodiments, any one or more
of the following residues may be substituted with cysteine: K149
(Kabat numbering) of the light chain; V205 (Kabat numbering) of the
light chain; A 118 (EU numbering) of the heavy chain; A140 (EU
numbering) of the heavy chain; L174 (EU numbering) of the heavy
chain; Y373 (EU numbering) of the heavy chain; and S400 (EU
numbering) of the heavy chain Fc region. In specific embodiments,
the antibodies described herein comprise the HC-A140C (EU
numbering) cysteine substitution. In specific embodiments, the
antibodies described herein comprise the LC-K149C (Kabat numbering)
cysteine substitution. In specific embodiments, the antibodies
described herein comprise the HC-A118C (EU numbering) cysteine
substitution. Cysteine engineered antibodies may be generated as
described, e.g., in U.S. Pat. No. 7,521,541.
[0298] In certain embodiments, the antibody comprises one of the
following heavy chain cysteine substitutions:
TABLE-US-00002 Chain EU Mutation Kabat Mutation (HC/LC) Residue
Site # Site # HC T 114 110 HC A 140 136 HC L 174 170 HC L 179 175
HC T 187 183 HC T 209 205 HC V 262 258 HC G 371 367 HC Y 373 369 HC
E 382 378 HC S 424 420 HC N 434 430 HC Q 438 434
[0299] In certain embodiments, the antibody comprises one of the
following light chain cysteine substitutions:
TABLE-US-00003 Chain EU Mutation Kabat Mutation (HC/LC) Residue
Site # Site # LC I 106 106 LC R 108 108 LC R 142 142 LC K 149 149
LC V 205 205
[0300] A nonlimiting exemplary hu7C2.v2.2.LA light chain (LC) K149C
THIOMAB.TM. has the heavy chain and light chain amino acid
sequences of SEQ ID NOs: 19 and 23, respectively. A nonlimiting
exemplary hu7C2.v2.2.LA heavy chain (HC) A118C THIOMAB.TM. has the
heavy chain and light chain amino acid sequences of SEQ ID NOs: 24
and 18, respectively.
[0301] An exemplary S400C cysteine engineered heavy chain constant
region is shown in SEQ ID NO: 28. The S400C cysteine engineered
heavy chain constant region may be fused to the C-terminus of the
hu7C2.v2.2.LA heavy chain variable region shown in SEQ ID NO: 11.
The resulting hu7C2.v2.2.LA HC S400C heavy chain may be paired with
a hu7C2.v2.2.LA kappa light chain, such as the light chain shown in
SEQ ID NO: 18.
[0302] An exemplary V205C cysteine engineered light chain constant
region is shown in SEQ ID NO: 25. The V205C cysteine engineered
light chain constant region may be fused to the C-terminus of the
hu7C2.v2.2.LA light chain variable region shown in SEQ ID NO: 10.
The resulting hu7C2.v2.2.LA LC V205C light chain may be paired with
a hu7C2.v2.2.LA IgG heavy chain, such as the heavy chain shown in
SEQ ID NO: 19.
[0303] e) Antibody Derivatives
[0304] In certain embodiments, an antibody provided herein may be
further modified to contain additional nonproteinaceous moieties
that are known in the art and readily available. The moieties
suitable for derivatization of the antibody include but are not
limited to water soluble polymers. Non-limiting examples of water
soluble polymers include, but are not limited to, polyethylene
glycol (PEG), copolymers of ethylene glycol/propylene glycol,
carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl
pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane,
ethylene/maleic anhydride copolymer, polyaminoacids (either
homopolymers or random copolymers), and dextran or poly(n-vinyl
pyrrolidone)polyethylene glycol, propropylene glycol homopolymers,
prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated
polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
Polyethylene glycol propionaldehyde may have advantages in
manufacturing due to its stability in water. The polymer may be of
any molecular weight, and may be branched or unbranched. The number
of polymers attached to the antibody may vary, and if more than one
polymer are attached, they can be the same or different molecules.
In general, the number and/or type of polymers used for
derivatization can be determined based on considerations including,
but not limited to, the particular properties or functions of the
antibody to be improved, whether the antibody derivative will be
used in a therapy under defined conditions, etc.
[0305] In another embodiment, conjugates of an antibody and
nonproteinaceous moiety that may be selectively heated by exposure
to radiation are provided. In one embodiment, the nonproteinaceous
moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA
102: 11600-11605 (2005)). The radiation may be of any wavelength,
and includes, but is not limited to, wavelengths that do not harm
ordinary cells, but which heat the nonproteinaceous moiety to a
temperature at which cells proximal to the
antibody-nonproteinaceous moiety are killed.
[0306] B. Recombinant Methods and Compositions
[0307] Antibodies may be produced using recombinant methods and
compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one
embodiment, isolated nucleic acid encoding an anti-HER2 antibody
described herein is provided. Such nucleic acid may encode an amino
acid sequence comprising the VL and/or an amino acid sequence
comprising the VH of the antibody (e.g., the light and/or heavy
chains of the antibody). In a further embodiment, one or more
vectors (e.g., expression vectors) comprising such nucleic acid are
provided. In a further embodiment, a host cell comprising such
nucleic acid is provided. In one such embodiment, a host cell
comprises (e.g., has been transformed with): (1) a vector
comprising a nucleic acid that encodes an amino acid sequence
comprising the VL of the antibody and an amino acid sequence
comprising the VH of the antibody, or (2) a first vector comprising
a nucleic acid that encodes an amino acid sequence comprising the
VL of the antibody and a second vector comprising a nucleic acid
that encodes an amino acid sequence comprising the VH of the
antibody. In one embodiment, the host cell is eukaryotic, e.g. a
Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0,
Sp20 cell). In one embodiment, a method of making an anti-HER2
antibody is provided, wherein the method comprises culturing a host
cell comprising a nucleic acid encoding the antibody, as provided
above, under conditions suitable for expression of the antibody,
and optionally recovering the antibody from the host cell (or host
cell culture medium).
[0308] For recombinant production of an anti-HER2 antibody, nucleic
acid encoding an antibody, e.g., as described above, is isolated
and inserted into one or more vectors for further cloning and/or
expression in a host cell. Such nucleic acid may be readily
isolated and sequenced using conventional procedures (e.g., by
using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of the
antibody).
[0309] Suitable host cells for cloning or expression of
antibody-encoding vectors include prokaryotic or eukaryotic cells
described herein. For example, antibodies may be produced in
bacteria, in particular when glycosylation and Fc effector function
are not needed. For expression of antibody fragments and
polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237,
5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular
Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.,
2003), pp. 245-254, describing expression of antibody fragments in
E. coli.) After expression, the antibody may be isolated from the
bacterial cell paste in a soluble fraction and can be further
purified.
[0310] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for antibody-encoding vectors, including fungi and yeast strains
whose glycosylation pathways have been "humanized," resulting in
the production of an antibody with a partially or fully human
glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414
(2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
[0311] Suitable host cells for the expression of glycosylated
antibody are also derived from multicellular organisms
(invertebrates and vertebrates). Examples of invertebrate cells
include plant and insect cells. Numerous baculoviral strains have
been identified which may be used in conjunction with insect cells,
particularly for transfection of Spodoptera frugiperda cells.
[0312] Plant cell cultures can also be utilized as hosts. See,
e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978,
and 6,417,429 (describing PLANTIBODIES.TM. technology for producing
antibodies in transgenic plants).
[0313] Vertebrate cells may also be used as hosts. For example,
mammalian cell lines that are adapted to grow in suspension may be
useful. Other examples of useful mammalian host cell lines are
monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic
kidney line (293 or 293 cells as described, e.g., in Graham et al.,
J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse
sertoli cells (TM4 cells as described, e.g., in Mather, Biol.
Reprod. 23:243-251 (1980)); monkey kidney cells (CV 1); African
green monkey kidney cells (VERO-76); human cervical carcinoma cells
(HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL
3A); human lung cells (W138); human liver cells (Hep G2); mouse
mammary tumor (MMT 060562); TRI cells, as described, e.g., in
Mather et al., Annals N. Y. Acad. Sci. 383:44-68 (1982); MRC 5
cells; and FS4 cells. Other useful mammalian host cell lines
include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells
(Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and
myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of
certain mammalian host cell lines suitable for antibody production,
see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248
(B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268
(2003).
[0314] C. Assays
[0315] Anti-HER2 antibodies provided herein may be identified,
screened for, or characterized for their physical/chemical
properties and/or biological activities by various assays known in
the art.
[0316] In one aspect, an antibody of the invention is tested for
its antigen binding activity, e.g., by known methods such as ELISA,
BIACore.RTM., FACS, or Western blot.
[0317] In another aspect, competition assays may be used to
identify an antibody that competes with any of the antibodies
described herein for binding to HER2. In certain embodiments, such
a competing antibody binds to the same epitope (e.g., a linear or a
conformational epitope) that is bound by an antibody described
herein. Detailed exemplary methods for mapping an epitope to which
an antibody binds are provided in Morris (1996) "Epitope Mapping
Protocols," in Methods in Molecular Biology vol. 66 (Humana Press,
Totowa, N.J.).
[0318] In an exemplary competition assay, immobilized HER2 is
incubated in a solution comprising a first labeled antibody that
binds to HER2 (e.g., any of the antibodies described herein) and a
second unlabeled antibody that is being tested for its ability to
compete with the first antibody for binding to HER2. The second
antibody may be present in a hybridoma supernatant. As a control,
immobilized HER2 is incubated in a solution comprising the first
labeled antibody but not the second unlabeled antibody. After
incubation under conditions permissive for binding of the first
antibody to HER2, excess unbound antibody is removed, and the
amount of label associated with immobilized HER2 is measured. If
the amount of label associated with immobilized HER2 is
substantially reduced in the test sample relative to the control
sample, then that indicates that the second antibody is competing
with the first antibody for binding to HER2. See Harlow and Lane
(1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y.).
[0319] D. Immunoconjugates
[0320] The invention also provides immunoconjugates comprising any
anti-HER2 antibody provided herein conjugated to one or more
cytotoxic agents, such as chemotherapeutic agents or drugs, growth
inhibitory agents, toxins (e.g., protein toxins, enzymatically
active toxins of bacterial, fungal, plant, or animal origin, or
fragments thereof), or radioactive isotopes (i.e., a
radioconjugate).
[0321] Immunoconjugates allow for the targeted delivery of a drug
moiety to a tumor, and, in some embodiments intracellular
accumulation therein, where systemic administration of unconjugated
drugs may result in unacceptable levels of toxicity to normal cells
(Polakis P. (2005) Current Opinion in Pharmacology 5:382-387).
[0322] Antibody-drug conjugates (ADC) are targeted chemotherapeutic
molecules which combine properties of both antibodies and cytotoxic
drugs by targeting potent cytotoxic drugs to antigen-expressing
tumor cells (Teicher, B. A. (2009) Current Cancer Drug Targets
9:982-1004), thereby enhancing the therapeutic index by maximizing
efficacy and minimizing off-target toxicity (Carter, P. J. and
Senter P. D. (2008) The Cancer Jour. 14(3):154-169; Chari, R. V.
(2008) Ace. Chem. Res. 41:98-107.
[0323] The ADC compounds of the invention include those with
anticancer activity. In some embodiments, the ADC compounds include
an antibody conjugated, i.e. covalently attached, to the drug
moiety. In some embodiments, the antibody is covalently attached to
the drug moiety through a linker. The antibody-drug conjugates
(ADC) of the invention selectively deliver an effective dose of a
drug to tumor tissue whereby greater selectivity, i.e. a lower
efficacious dose, may be achieved while increasing the therapeutic
index ("therapeutic window").
[0324] The drug moiety (D) of the antibody-drug conjugates (ADC)
may include any compound, moiety or group that has a cytotoxic or
cytostatic effect. Drug moieties may impart their cytotoxic and
cytostatic effects by mechanisms including but not limited to
tubulin binding, DNA binding or intercalation, and inhibition of
RNA polymerase, protein synthesis, and/or topoisomerase.
[0325] Exemplary drug moieties include, but are not limited to,
pyrrolobenzodiazepine (PBD), and stereoisomers, isosteres, analogs,
and derivatives thereof that have cytotoxic activity. Nonlimiting
examples of such immunoconjugates are discussed in further detail
below.
[0326] 1. Exemplary Antibody-Drug Conjugates
[0327] An exemplary embodiment of an antibody-drug conjugate (ADC)
compound comprises an antibody (Ab) which targets a tumor cell, a
drug moiety (D), and a linker moiety (L) that attaches Ab to D. In
some embodiments, the antibody is attached to the linker moiety (L)
through one or more amino acid residues, such as lysine and/or
cysteine.
[0328] An exemplary ADC has Formula I:
Ab-(L-D).sub.p I
where p is 1 to about 20. In some embodiments, the number of drug
moieties that can be conjugated to an antibody is limited by the
number of free cysteine residues. In some embodiments, free
cysteine residues are introduced into the antibody amino acid
sequence by the methods described herein. Exemplary ADC of Formula
I include, but are not limited to, antibodies that have 1, 2, 3, or
4 engineered cysteine amino acids (Lyon, R. et al (2012) Methods in
Enzym. 502:123-138). In some embodiments, one or more free cysteine
residues are already present in an antibody, without the use of
engineering, in which case the existing free cysteine residues may
be used to conjugate the antibody to a drug. In some embodiments,
an antibody is exposed to reducing conditions prior to conjugation
of the antibody in order to generate one or more free cysteine
residues.
[0329] a) Exemplary Linkers
[0330] A "Linker" (L) is a bifunctional or multifunctional moiety
that can be used to link one or more drug moieties (D) to an
antibody (Ab) to form an antibody-drug conjugate (ADC) of Formula
I. In some embodiments, antibody-drug conjugates (ADC) can be
prepared using a Linker having reactive functionalities for
covalently attaching to the drug and to the antibody. For example,
in some embodiments, a cysteine thiol of an antibody (Ab) can form
a bond with a reactive functional group of a linker or a
drug-linker intermediate to make an ADC.
[0331] In one aspect, a linker has a functionality that is capable
of reacting with a free cysteine present on an antibody to form a
covalent bond. Nonlimiting exemplary such reactive functionalities
include maleimide, haloacetamides, .alpha.-haloacetyl, activated
esters such as succinimide esters, 4-nitrophenyl esters,
pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides,
acid chlorides, sulfonyl chlorides, isocyanates, and
isothiocyanates. See, e.g., the conjugation method at page 766 of
Klussman, et al (2004), Bioconjugate Chemistry 15(4):765-773, and
the Examples herein.
[0332] In some embodiments, a linker has a functionality that is
capable of reacting with an electrophilic group present on an
antibody. Exemplary such electrophilic groups include, but are not
limited to, aldehyde and ketone carbonyl groups. In some
embodiments, a heteroatom of the reactive functionality of the
linker can react with an electrophilic group on an antibody and
form a covalent bond to an antibody unit. Nonlimiting exemplary
such reactive functionalities include, but are not limited to,
hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine
carboxylate, and arylhydrazide.
[0333] A linker may comprise one or more linker components.
Exemplary linker components include 6-maleimidocaproyl ("MC"),
maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"),
alanine-phenylalanine ("ala-phe"), p-aminobenzyloxycarbonyl (a
"PAB"), N-Succinimidyl 4-(2-pyridylthio) pentanoate ("SPP"), and
4-(N-maleimidomethyl) cyclohexane-1 carboxylate ("MCC"). Various
linker components are known in the art, some of which are described
below.
[0334] A linker may be a "cleavable linker," facilitating release
of a drug. Nonlimiting exemplary cleavable linkers include
acid-labile linkers (e.g., comprising hydrazone),
protease-sensitive (e.g., peptidase-sensitive) linkers, photolabile
linkers, or disulfide-containing linkers (Chari et al., Cancer
Research 52:127-131 (1992); U.S. Pat. No. 5,208,020).
[0335] In certain embodiments, a linker has the following Formula
II:
-A.sub.a-W.sub.w--Y.sub.y-- II
[0336] wherein A is a "stretcher unit", and a is an integer from 0
to 1; W is an "amino acid unit", and w is an integer from 0 to 12;
Y is a "spacer unit", and y is 0, 1, or 2; and Ab, D, and p are
defined as above for Formula I. Exemplary embodiments of such
linkers are described in U.S. Pat. No. 7,498,298, which is
expressly incorporated herein by reference.
[0337] In some embodiments, a linker component comprises a
"stretcher unit" that links an antibody to another linker component
or to a drug moiety. Nonlimiting exemplary stretcher units are
shown below (wherein the wavy line indicates sites of covalent
attachment to an antibody, drug, or additional linker
components):
##STR00007##
[0338] In some embodiments, a linker component comprises an "amino
acid unit". In some such embodiments, the amino acid unit allows
for cleavage of the linker by a protease, thereby facilitating
release of the drug from the immunoconjugate upon exposure to
intracellular proteases, such as lysosomal enzymes (Doronina et al.
(2003) Nat. Biotechnol. 21:778-784). Exemplary amino acid units
include, but are not limited to, dipeptides, tripeptides,
tetrapeptides, and pentapeptides. Exemplary dipeptides include, but
are not limited to, valine-citrulline (vc or val-cit),
alanine-phenylalanine (af or ala-phe); phenylalanine-lysine (fk or
phe-lys); phenylalanine-homolysine (phe-homolys); and
N-methyl-valine-citrulline (Me-val-cit). Exemplary tripeptides
include, but are not limited to, glycine-valine-citrulline
(gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). An amino
acid unit may comprise amino acid residues that occur naturally
and/or minor amino acids and/or non-naturally occurring amino acid
analogs, such as citrulline. Amino acid units can be designed and
optimized for enzymatic cleavage by a particular enzyme, for
example, a tumor-associated protease, cathepsin B, C and D, or a
plasmin protease.
[0339] In some embodiments, a linker component comprises a "spacer"
unit that links the antibody to a drug moiety, either directly or
through a stretcher unit and/or an amino acid unit. A spacer unit
may be "self-immolative" or a "non-self-immolative." A
"non-self-immolative" spacer unit is one in which part or all of
the spacer unit remains bound to the drug moiety upon cleavage of
the ADC. Examples of non-self-immolative spacer units include, but
are not limited to, a glycine spacer unit and a glycine-glycine
spacer unit. In some embodiments, enzymatic cleavage of an ADC
containing a glycine-glycine spacer unit by a tumor-cell associated
protease results in release of a glycine-glycine-drug moiety from
the remainder of the ADC. In some such embodiments, the
glycine-glycine-drug moiety is subjected to a hydrolysis step in
the tumor cell, thus cleaving the glycine-glycine spacer unit from
the drug moiety.
[0340] A "self-immolative" spacer unit allows for release of the
drug moiety. In certain embodiments, a spacer unit of a linker
comprises a p-aminobenzyl unit. In some such embodiments, a
p-aminobenzyl alcohol is attached to an amino acid unit via an
amide bond, and a carbamate, methylcarbamate, or carbonate is made
between the benzyl alcohol and the drug (Hamann et al. (2005)
Expert Opin. Ther. Patents (2005) 15:1087-1103). In some
embodiments, the spacer unit is p-aminobenzyloxycarbonyl (PAB). In
some embodiments, an ADC comprising a self-immolative linker has
the structure:
##STR00008##
[0341] wherein Q is --C.sub.1-C.sub.8 alkyl, --O--(C.sub.1-C.sub.8
alkyl), -halogen, -nitro, or -cyno; m is an integer ranging from 0
to 4; and p ranges from 1 to about 20. In some embodiments, p
ranges from 1 to 10, 1 to 7, 1 to 5, or 1 to 4.
[0342] Other examples of self-immolative spacers include, but are
not limited to, aromatic compounds that are electronically similar
to the PAB group, such as 2-aminoimidazol-5-methanol derivatives
(U.S. Pat. No. 7,375,078; Hay et al. (1999) Bioorg. Med. Chem.
Lett. 9:2237) and ortho- or para-aminobenzylacetals. In some
embodiments, spacers can be used that undergo cyclization upon
amide bond hydrolysis, such as substituted and unsubstituted
4-aminobutyric acid amides (Rodrigues et al (1995) Chemistry
Biology 2:223), appropriately substituted bicyclo[2.2.1] and
bicyclo[2.2.2] ring systems (Storm et al (1972) J. Amer. Chem. Soc.
94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al
(1990) J. Org. Chem. 55:5867). Linkage of a drug to the
.alpha.-carbon of a glycine residue is another example of a
self-immolative spacer that may be useful in ADC (Kingsbury et al
(1984) J. Med. Chem. 27:1447).
[0343] In some embodiments, linker L may be a dendritic type linker
for covalent attachment of more than one drug moiety to an antibody
through a branching, multifunctional linker moiety (Sun et al
(2002) Bioorganic & Medicinal Chemistry Letters 12:2213-2215;
Sun et al (2003) Bioorganic & Medicinal Chemistry
11:1761-1768). Dendritic linkers can increase the molar ratio of
drug to antibody, i.e. loading, which is related to the potency of
the ADC. Thus, where an antibody bears only one reactive cysteine
thiol group, a multitude of drug moieties may be attached through a
dendritic linker.
[0344] Nonlimiting exemplary linkers are shown below in the context
of an ADC of Formula I:
##STR00009##
[0345] Further nonlimiting exemplary ADCs include the
structures:
##STR00010##
[0346] where X is:
##STR00011##
[0347] Y is:
##STR00012##
[0348] each R is independently H or C.sub.1-C.sub.6 alkyl; and n is
1 to 12.
[0349] Typically, peptide-type linkers can be prepared by forming a
peptide bond between two or more amino acids and/or peptide
fragments. Such peptide bonds can be prepared, for example,
according to a liquid phase synthesis method (e.g., E. Schroder and
K. Lubke (1965) "The Peptides", volume 1, pp 76-136, Academic
Press).
[0350] In some embodiments, a linker is substituted with groups
that modulate solubility and/or reactivity. As a nonlimiting
example, a charged substituent such as sulfonate (--SO.sub.3.sup.-)
or ammonium may increase water solubility of the linker reagent and
facilitate the coupling reaction of the linker reagent with the
antibody and/or the drug moiety, or facilitate the coupling
reaction of Ab-L (antibody-linker intermediate) with D, or D-L
(drug-linker intermediate) with Ab, depending on the synthetic
route employed to prepare the ADC. In some embodiments, a portion
of the linker is coupled to the antibody and a portion of the
linker is coupled to the drug, and then the Ab-(linker
portion).sup.a is coupled to drug-(linker portion).sup.b to form
the ADC of Formula I. In some such embodiments, the antibody
comprises more than one (linker portion).sup.a substituents, such
that more than one drug is coupled to the antibody in the ADC of
Formula I.
[0351] The compounds of the invention expressly contemplate, but
are not limited to, ADC prepared with the following linker
reagents: bis-maleimido-trioxyethylene glycol (BMPEO),
N-(.beta.-maleimidopropyloxy)-N-hydroxy succinimide ester (BMPS),
N-(.epsilon.-maleimidocaproyloxy) succinimide ester (EMCS),
N-[.gamma.-maleimidobutyryloxy]succinimide ester (GMBS),
1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl
4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate)
(LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS),
4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl
3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate
(SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB),
N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP),
N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl
4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl
6-[(beta-maleimidopropionamido)hexanoate](SMPH), iminothiolane
(IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB,
sulfo-SMCC, and sulfo-SMPB, and
succinimidyl-(4-vinylsulfone)benzoate (SVSB), and including
bis-maleimide reagents: dithiobismaleimidoethane (DTME),
1,4-Bismaleimidobutane (BMB), 1,4 Bismaleimidyl-2,3-dihydroxybutane
(BMDB), bismaleimidohexane (BMH), bismaleimidoethane (BMOE),
BM(PEG).sub.2 (shown below), and BM(PEG).sub.3 (shown below);
bifunctional derivatives of imidoesters (such as dimethyl
adipimidate HCl), active esters (such as disuccinimidyl suberate),
aldehydes (such as glutaraldehyde), bis-azido compounds (such as
bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives
(such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates
(such as toluene 2,6-diisocyanate), and bis-active fluorine
compounds (such as 1,5-difluoro-2,4-dinitrobenzene). In some
embodiments, bis-maleimide reagents allow the attachment of the
thiol group of a cysteine in the antibody to a thiol-containing
drug moiety, linker, or linker-drug intermediate. Other functional
groups that are reactive with thiol groups include, but are not
limited to, iodoacetamide, bromoacetamide, vinyl pyridine,
disulfide, pyridyl disulfide, isocyanate, and isothiocyanate.
##STR00013##
[0352] Certain useful linker reagents can be obtained from various
commercial sources, such as Pierce Biotechnology, Inc. (Rockford,
Ill.), Molecular Biosciences Inc. (Boulder, Colo.), or synthesized
in accordance with procedures described in the art; for example, in
Toki et al (2002) J. Org. Chem. 67:1866-1872; Dubowchik, et al.
(1997) Tetrahedron Letters, 38:5257-60; Walker, M. A. (1995) J.
Org. Chem. 60:5352-5355; Frisch et al (1996) Bioconjugate Chem.
7:180-186; U.S. Pat. No. 6,214,345; WO 02/088172; US 2003130189;
US2003096743; WO 03/026577; WO 03/043583; and WO 04/032828.
[0353] Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene
triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent
for conjugation of radionucleotide to the antibody. See, e.g.,
WO94/11026.
[0354] b) Exemplary Drug Moieties
[0355] In some embodiments, an ADC comprises a
pyrrolobenzodiazepine (PBD). In some embodiments, PBD dimers
recognize and bind to specific DNA sequences. The natural product
anthramycin, a PBD, was first reported in 1965 (Leimgruber, et al.,
(1965) J. Am. Chem. Soc., 87:5793-5795; Leimgruber, et al., (1965)
J. Am. Chem. Soc., 87:5791-5793). Since then, a number of PBDs,
both naturally-occurring and analogues, have been reported
(Thurston, et al., (1994) Chem. Rev. 1994, 433-465 including dimers
of the tricyclic PBD scaffold (U.S. Pat. Nos. 6,884,799; 7,049,311;
7,067,511; 7,265,105; 7,511,032; 7,528,126; 7,557,099). Without
intending to be bound by any particular theory, it is believed that
the dimer structure imparts the appropriate three-dimensional shape
for isohelicity with the minor groove of B-form DNA, leading to a
snug fit at the binding site (Kohn, In Antibiotics III.
Springer-Verlag, New York, pp. 3-11 (1975); Hurley and
Needham-VanDevanter, (1986) Acc. Chem. Res., 19:230-237). Dimeric
PBD compounds bearing C2 aryl substituents have been shown to be
useful as cytotoxic agents (Hartley et al (2010) Cancer Res.
70(17):6849-6858; Antonow (2010) J. Med. Chem. 53(7):2927-2941;
Howard et al (2009) Bioorganic and Med. Chem. Letters
19(22):6463-6466).
[0356] In some embodiments, PBD compounds can be employed as
prodrugs by protecting them at the N10 position with a nitrogen
protecting group which is removable in vivo (WO 00/12507; WO
2005/023814).
[0357] PBD dimers have been conjugated to antibodies and the
resulting ADC shown to have anti-cancer properties (US
2010/0203007). Nonlimiting exemplary linkage sites on the PBD dimer
include the five-membered pyrrolo ring, the tether between the PBD
units, and the N10-C11 imine group (WO 2009/016516; US 2009/304710;
US 2010/047257; US 2009/036431; US 2011/0256157; WO
2011/130598).
[0358] Nonlimiting exemplary PBD dimer components of ADCs are
center-linked pyrrolobenzodiazepines of Formula A:
##STR00014##
wherein:
[0359] R.sup.2 is
##STR00015##
where R.sup.36a and R.sup.36b are independently selected from H, F,
C.sub.1-4 saturated alkyl, C.sub.2-3 alkenyl, which alkyl and
alkenyl groups are optionally substituted by a group selected from
C.sub.1-4 alkyl amido and C.sub.1-4 alkyl ester; or, when one of
R.sup.36a and R.sup.36b is H, the other is selected from nitrile
and a C.sub.1-4 alkyl ester;
[0360] R.sup.6 and R.sup.9 are independently selected from H, R,
OH, OR, SH, SR, NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and
halo;
[0361] R.sup.7 is independently selected from H, R, OH, OR, SH, SR,
NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and halo;
[0362] Y has the formula:
##STR00016##
[0363] G comprises a reactive group for connecting to an antibody
or G is a linker connected to an antibody;
[0364] n is an integer selected in the range of 0 to 48;
[0365] R.sup.A4 is a C.sub.1-6 alkylene group;
[0366] either [0367] (a) R.sup.10 is H, and R.sup.11 is OH,
OR.sup.A, where R.sup.A is C.sub.1-4 alkyl; or [0368] (b) R.sup.10
and R.sup.11 form a nitrogen-carbon double bond between the
nitrogen and carbon atoms to which they are bound; or [0369] (c)
R.sup.0 is H and R.sup.11 is OSO.sub.zM, where z is 2 or 3 and M is
a monovalent pharmaceutically acceptable cation;
[0370] R and R' are each independently selected from optionally
substituted C.sub.1-12 alkyl, C.sub.3-20 heterocyclyl and
C.sub.5-20 aryl groups, and optionally in relation to the group
NRR', R and R' together with the nitrogen atom to which they are
attached form an optionally substituted 4-, 5-, 6- or 7-membered
heterocyclic ring;
[0371] wherein R.sup.16, R.sup.17, R.sup.19, R.sup.20, R.sup.21 and
R.sup.22 are as defined for R.sup.6, R.sup.7, R.sup.9, R.sup.10,
R.sup.11 and R.sup.2 respectively;
[0372] wherein Z is CH or N;
[0373] wherein T and T'' are independently selected from a single
bond or a C.sub.1-9 alkylene, which chain may be interrupted by one
or more heteroatoms e.g. O, S, N(H), NMe, provided that the number
of atoms in the shortest chain of atoms between X and X' is 3 to 12
atoms; and
[0374] X and X' are independently selected from O, S and N(H).
[0375] In some embodiments, R.sup.9 and R.sup.19 are H.
[0376] In some embodiments, R.sup.6 and R.sup.16 are H.
[0377] In some embodiments, R.sup.7 are R.sup.17 are both
OR.sup.7A, where R.sup.7A is optionally substituted C.sub.1-4
alkyl. In some embodiments, R.sup.7A is Me. In some embodiments,
R.sup.7A is is Ch.sub.2Ph, where Ph is a phenyl group.
[0378] In some embodiments, X is O.
[0379] In some embodiments, T is selected from a single bond,
C.sub.1, and a C.sub.2 alkylene group. In some embodiments, T is a
C.sub.1 alkylene group.
[0380] In some embodiments, R.sup.36a and R.sup.36b are both H. In
some embodiments, R.sup.36a and R.sup.36b are both methyl. In some
embodiments, one of R.sup.36a and R.sup.36b is H, and the other is
selected from C.sub.1-4 saturated alkyl, C.sub.2-3 alkenyl, which
alkyl and alkenyl groups are optionally substituted. In some
embodiments, the group of R.sup.36a and R.sup.36b which is not H is
selected from methyl and ethyl.
[0381] In some embodiments, R.sup.10 is H and R.sup.11 is OH. In
some embodiments, R.sup.10 and R.sup.11 form a nitrogen-carbon
double bond between the nitrogen and carbon atoms to which they are
bound.
[0382] In any of the embodiments described herein, R.sup.16,
R.sup.17, R.sup.19, R.sup.20, R.sup.21, R.sup.22, X' and T' may be
the same as R.sup.6, R.sup.7, R.sup.9, R.sup.10, R.sup.11, R.sup.2,
X and T respectively.
[0383] In some embodiments, G comprises a group selected from (i)
maleimide groups (ii) activated disulfides, (iii) active esters
such as NHS (N-hydroxysuccinimide) esters, HOBt
(N-hydroxybenzotriazole) esters, haloformates, and acid halides;
(iv) alkyl and benzyl halides such as haloacetamides; and (v)
aldehydes, ketones, carboxyl comprises a maleimide group, an
activated disulfide, or an electrophilic functional group. In some
embodiments, G is a linker connected to an antibody, wherein the
linker comprises a moiety derived from an electrophilic functional
group selected from (i) maleimide groups (ii) activated disulfides,
(iii) active esters such as NHS (N-hydroxysuccinimide) esters, HOBt
(N-hydroxybenzotriazole) esters, haloformates, and acid halides;
(iv) alkyl and benzyl halides such as haloacetamides; and (v)
aldehydes, ketones, carboxyl. In some embodiments, G is:
##STR00017##
wherein the wavy line indicates attachment to the remainder of
(A1). In some embodiments, G is:
##STR00018##
wherein the wavy line indicates attachment to the remainder of (A1)
and Ab is an antibody.
[0384] In some embodiments, an ADC comprises a center-linked PBD
comprising the structure:
##STR00019##
wherein Y is defined as above.
[0385] A non-limiting exemplary ADC comprising a center-linked PBD
dimer may be made by conjugating a center-linked PBD drug linker
intermediate (shown below) to an antibody:
##STR00020##
to produce a center-linked PBD antibody-drug conjugate:
##STR00021##
[0386] Another center-linked PBD drug linker intermediate is:
##STR00022##
which is conjugated to an antibody to form an ADC:
##STR00023##
[0387] PBD dimers and ADCs comprising PBD dimers may be prepared
according to methods known in the art. See, e.g., WO 2009/016516;
US 2009/304710; US 2010/047257; US 2009/036431; US 2011/0256157; WO
2011/130598; WO 2013/055987; WO 2014/159981; WO 2014/140862.
[0388] c) Drug Loading
[0389] Drug loading is represented by p, the average number of drug
moieties per antibody in a molecule of Formula I. Drug loading may
range from 1 to 20 drug moieties (D) per antibody. ADCs of Formula
I include collections of antibodies conjugated with a range of drug
moieties, from 1 to 20. The average number of drug moieties per
antibody in preparations of ADC from conjugation reactions may be
characterized by conventional means such as mass spectroscopy,
ELISA assay, and HPLC. The quantitative distribution of ADC in
terms of p may also be determined. In some instances, separation,
purification, and characterization of homogeneous ADC where p is a
certain value from ADC with other drug loadings may be achieved by
means such as reverse phase HPLC or electrophoresis.
[0390] For some antibody-drug conjugates, p may be limited by the
number of attachment sites on the antibody. For example, where the
attachment is a cysteine thiol, as in certain exemplary embodiments
above, an antibody may have only one or several cysteine thiol
groups, or may have only one or several sufficiently reactive thiol
groups through which a linker may be attached. In certain
embodiments, higher drug loading, e.g. p>5, may cause
aggregation, insolubility, toxicity, or loss of cellular
permeability of certain antibody-drug conjugates. In certain
embodiments, the average drug loading for an ADC ranges from 1 to
about 8; from about 2 to about 6; or from about 3 to about 5.
Indeed, it has been shown that for certain ADCs, the optimal ratio
of drug moieties per antibody may be less than 8, and may be about
2 to about 5 (U.S. Pat. No. 7,498,298).
[0391] In certain embodiments, fewer than the theoretical maximum
of drug moieties are conjugated to an antibody during a conjugation
reaction. An antibody may contain, for example, lysine residues
that do not react with the drug-linker intermediate or linker
reagent, as discussed below. Generally, antibodies do not contain
many free and reactive cysteine thiol groups which may be linked to
a drug moiety; indeed most cysteine thiol residues in antibodies
exist as disulfide bridges. In certain embodiments, an antibody may
be reduced with a reducing agent such as dithiothreitol (DTT) or
tricarbonylethylphosphine (TCEP), under partial or total reducing
conditions, to generate reactive cysteine thiol groups. In certain
embodiments, an antibody is subjected to denaturing conditions to
reveal reactive nucleophilic groups such as lysine or cysteine.
[0392] The loading (drug/antibody ratio) of an ADC may be
controlled in different ways, and for example, by: (i) limiting the
molar excess of drug-linker intermediate or linker reagent relative
to antibody, (ii) limiting the conjugation reaction time or
temperature, and (iii) partial or limiting reductive conditions for
cysteine thiol modification.
[0393] It is to be understood that where more than one nucleophilic
group reacts with a drug-linker intermediate or linker reagent,
then the resulting product is a mixture of ADC compounds with a
distribution of one or more drug moieties attached to an antibody.
The average number of drugs per antibody may be calculated from the
mixture by a dual ELISA antibody assay, which is specific for
antibody and specific for the drug. Individual ADC molecules may be
identified in the mixture by mass spectroscopy and separated by
HPLC, e.g. hydrophobic interaction chromatography (see, e.g.,
McDonagh et al (2006) Prot. Engr. Design & Selection
19(7):299-307; Hamblett et al (2004) Clin. Cancer Res.
10:7063-7070; Hamblett, K. J., et al. "Effect of drug loading on
the pharmacology, pharmacokinetics, and toxicity of an anti-CD30
antibody-drug conjugate," Abstract No. 624, American Association
for Cancer Research, 2004 Annual Meeting, March 27-31, 2004,
Proceedings of the AACR, Volume 45, March 2004; Alley, S. C., et
al. "Controlling the location of drug attachment in antibody-drug
conjugates," Abstract No. 627, American Association for Cancer
Research, 2004 Annual Meeting, Mar. 27-31, 2004, Proceedings of the
AACR, Volume 45, March 2004). In certain embodiments, a homogeneous
ADC with a single loading value may be isolated from the
conjugation mixture by electrophoresis or chromatography.
[0394] d) Certain Methods of Preparing Immunoconjugates
[0395] An ADC of Formula I may be prepared by several routes
employing organic chemistry reactions, conditions, and reagents
known to those skilled in the art, including: (1) reaction of a
nucleophilic group of an antibody with a bivalent linker reagent to
form Ab-L via a covalent bond, followed by reaction with a drug
moiety D; and (2) reaction of a nucleophilic group of a drug moiety
with a bivalent linker reagent, to form D-L, via a covalent bond,
followed by reaction with a nucleophilic group of an antibody.
Exemplary methods for preparing an ADC of Formula I via the latter
route are described in U.S. Pat. No. 7,498,298, which is expressly
incorporated herein by reference.
[0396] Nucleophilic groups on antibodies include, but are not
limited to: (i)N-terminal amine groups, (ii) side chain amine
groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine,
and (iv) sugar hydroxyl or amino groups where the antibody is
glycosylated. Amine, thiol, and hydroxyl groups are nucleophilic
and capable of reacting to form covalent bonds with electrophilic
groups on linker moieties and linker reagents including: (i) active
esters such as NHS esters, HOBt esters, haloformates, and acid
halides; (ii) alkyl and benzyl halides such as haloacetamides; and
(iii) aldehydes, ketones, carboxyl, and maleimide groups. Certain
antibodies have reducible interchain disulfides, i.e. cysteine
bridges. Antibodies may be made reactive for conjugation with
linker reagents by treatment with a reducing agent such as DTT
(dithiothreitol) or tricarbonylethylphosphine (TCEP), such that the
antibody is fully or partially reduced. Each cysteine bridge will
thus form, theoretically, two reactive thiol nucleophiles.
Additional nucleophilic groups can be introduced into antibodies
through modification of lysine residues, e.g., by reacting lysine
residues with 2-iminothiolane (Traut's reagent), resulting in
conversion of an amine into a thiol. Reactive thiol groups may also
be introduced into an antibody by introducing one, two, three,
four, or more cysteine residues (e.g., by preparing variant
antibodies comprising one or more non-native cysteine amino acid
residues).
[0397] Antibody-drug conjugates of the invention may also be
produced by reaction between an electrophilic group on an antibody,
such as an aldehyde or ketone carbonyl group, with a nucleophilic
group on a linker reagent or drug. Useful nucleophilic groups on a
linker reagent include, but are not limited to, hydrazide, oxime,
amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and
arylhydrazide. In one embodiment, an antibody is modified to
introduce electrophilic moieties that are capable of reacting with
nucleophilic substituents on the linker reagent or drug. In another
embodiment, the sugars of glycosylated antibodies may be oxidized,
e.g. with periodate oxidizing reagents, to form aldehyde or ketone
groups which may react with the amine group of linker reagents or
drug moieties. The resulting imine Schiff base groups may form a
stable linkage, or may be reduced, e.g. by borohydride reagents to
form stable amine linkages. In one embodiment, reaction of the
carbohydrate portion of a glycosylated antibody with either
galactose oxidase or sodium meta-periodate may yield carbonyl
(aldehyde and ketone) groups in the antibody that can react with
appropriate groups on the drug (Hermanson, Bioconjugate
Techniques). In another embodiment, antibodies containing
N-terminal serine or threonine residues can react with sodium
meta-periodate, resulting in production of an aldehyde in place of
the first amino acid (Geoghegan & Stroh, (1992) Bioconjugate
Chem. 3:138-146; U.S. Pat. No. 5,362,852). Such an aldehyde can be
reacted with a drug moiety or linker nucleophile.
[0398] Exemplary nucleophilic groups on a drug moiety include, but
are not limited to: amine, thiol, hydroxyl, hydrazide, oxime,
hydrazine, thiosemicarbazone, hydrazine carboxylate, and
arylhydrazide groups capable of reacting to form covalent bonds
with electrophilic groups on linker moieties and linker reagents
including: (i) active esters such as NHS esters, HOBt esters,
haloformates, and acid halides; (ii) alkyl and benzyl halides such
as haloacetamides; (iii) aldehydes, ketones, carboxyl, and
maleimide groups.
[0399] Nonlimiting exemplary cross-linker reagents that may be used
to prepare ADC are described herein in the section titled
"Exemplary Linkers." Methods of using such cross-linker reagents to
link two moieties, including a proteinaceous moiety and a chemical
moiety, are known in the art. In some embodiments, a fusion protein
comprising an antibody and a cytotoxic agent may be made, e.g., by
recombinant techniques or peptide synthesis. A recombinant DNA
molecule may comprise regions encoding the antibody and cytotoxic
portions of the conjugate either adjacent to one another or
separated by a region encoding a linker peptide which does not
destroy the desired properties of the conjugate.
[0400] In yet another embodiment, an antibody may be conjugated to
a "receptor" (such as streptavidin) for utilization in tumor
pre-targeting wherein the antibody-receptor conjugate is
administered to the patient, followed by removal of unbound
conjugate from the circulation using a clearing agent and then
administration of a "ligand" (e.g., avidin) which is conjugated to
a cytotoxic agent (e.g., a drug or radionucleotide).
[0401] E. Trastuzumab-MCC-DM1 and Pertuzumab
[0402] Trastuzumab-MCC-DM1 (T-DM1)
[0403] The present invention includes therapeutic treatments with
trastuzumab-MCC-DM1 (T-DM1, also referred to as trastuzumab
emtansine), an antibody-drug conjugate (CAS Reg. No. 139504-50-0),
which has the structure:
##STR00024##
where Tr is trastuzumab linked through linker moiety MCC to the
maytansinoid drug moiety DM1 (U.S. Pat. Nos. 5,208,020; 6,441,163).
The drug to antibody ratio or drug loading is represented by p in
the above structure of trastuzumab-MCC-DM1, and ranges in integer
values from 1 to about 8. Trastuzumab-MCC-DM1 includes all mixtures
of variously loaded and attached antibody-drug conjugates where 1,
2, 3, 4, 5, 6, 7, and 8 drug moieties are covalently attached to
the antibody trastuzumab (U.S. Pat. Nos. 7,097,840; 8,337,856; US
2005/0276812; US 2005/0166993).
[0404] Trastuzumab can be produced by a mammalian cell (Chinese
Hamster Ovary, CHO) suspension culture. The HER2 (or c-erbB2)
proto-oncogene encodes a transmembrane receptor protein of 185 kDa,
which is structurally related to the epidermal growth factor
receptor. Trastuzumab is an antibody that has antigen binding
residues of, or derived from, the murine 4D5 antibody (ATCC CRL
10463, deposited with American Type Culture Collection, 12301
Parklawn Drive, Rockville, Md. 20852 under the Budapest Treaty on
May 24, 1990). Exemplary humanized 4D5 antibodies include
huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5,
huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (trastuzumab, HERCEPTIN) as
in U.S. Pat. No. 5,821,337. In some embodiments, the antibody
portion of T-DM 1 comprises the light and heavy chain amino acid
sequences shown in SEQ ID NO: 30 and SEQ ID NO. 29,
respectively.
[0405] Trastuzumab-MCC-DM1 may be prepared according to Example 1
of U.S. Application Publication No. 20110165155, for example.
[0406] As a general proposition, the initial pharmaceutically
effective amount of trastuzumab-MCC-DM1 administered per dose will
be in the range of about 0.3 to 15 mg/kg/day of patient body
weight.
[0407] A commercial T-DM1 formulation (KADCYLA.RTM.,
ado-trastuzumab emtansine) is a sterile, white to off-white
preservative free lyophilized powder in single-use vials. Each vial
contains 100 mg or 160 mg ado-trastuzumab emtansine. Following
reconstitution, each single-use vial contains ado-trastuzumab
emtansine (20 mg/mL), polysorbate 20 [0.02% (w/v)], sodium
succinate (10 mM), and sucrose [6% (w/v)] with a pH of 5.0 and
density of 1.026 g/mL. The resulting solution containing 20 mg/mL
ado-trastuzumab emtansine is administered by intravenous infusion
following dilution. In some embodiments, ado-trastuzumab emtansine
is administered at a dose of 3.6 mg/kg every three weeks. In some
embodiments, ado-trastuzumab emtansine is administered at a dose of
2.4 mg/kg every week.
[0408] Pertuzumab Compositions
[0409] The pertuzumab composition comprises a mixture of a main
species pertuzumab antibody, as hereinabove defined, and one or
more variants thereof. The preferred embodiment herein of a
pertuzumab main species antibody is one comprising a light chain
amino acid sequence of SEQ ID NO: 32, and a heavy chain amino acid
sequence of SEQ ID NO: 31 (including deamidated and/or oxidized
variants of those sequences). In some embodiments, the composition
comprises a mixture of the main species pertuzumab antibody and an
amino acid sequence variant thereof comprising an amino-terminal
leader extension, e.g., comprising a light chain amino acid
sequence of SEQ ID NO: 34, and a heavy chain amino acid sequence of
SEQ ID NO: 33. Preferably, the amino-terminal leader extension is
on a light chain of the antibody variant (e.g. on one or two light
chains of the antibody variant). The main species HER2 antibody or
the antibody variant may be an full length antibody or antibody
fragment (e.g. Fab of F(ab')2 fragments), but preferably both are
full length antibodies. The antibody variant herein may comprise an
amino-terminal leader extension on any one or more of the heavy or
light chains thereof. Preferably, the amino-terminal leader
extension is on one or two light chains of the antibody. The
amino-terminal leader extension preferably comprises or consists of
VHS--. Presence of the amino-terminal leader extension in the
composition can be detected by various analytical techniques
including, but not limited to, N-terminal sequence analysis, assay
for charge heterogeneity (for instance, cation exchange
chromatography or capillary zone electrophoresis), mass
spectrometry, etc. The amount of the antibody variant in the
composition generally ranges from an amount that constitutes the
detection limit of any assay (preferably N-terminal sequence
analysis) used to detect the variant to an amount less than the
amount of the main species antibody. Generally, about 20% or less
(e.g. from about 1% to about 15%, for instance from 5% to about
15%) of the antibody molecules in the composition comprise an
amino-terminal leader extension. Such percentage amounts are
preferably determined using quantitative N-terminal sequence
analysis or cation exchange analysis (preferably using a
high-resolution, weak cation-exchange column, such as a PROPAC
WCX-10.TM. cation exchange column). Aside from the amino-terminal
leader extension variant, further amino acid sequence alterations
of the main species antibody and/or variant are contemplated,
including but not limited to an antibody comprising a C-terminal
lysine residue on one or both heavy chains thereof, a deamidated
antibody variant, etc.
[0410] Moreover, the main species antibody or variant may further
comprise glycosylation variations, non-limiting examples of which
include antibody comprising a G1 or G2 oligosaccharide structure
attached to the Fc region thereof, antibody comprising a
carbohydrate moiety attached to a light chain thereof (e.g. one or
two carbohydrate moieties, such as glucose or galactose, attached
to one or two light chains of the antibody, for instance attached
to one or more lysine residues), antibody comprising one or two
non-glycosylated heavy chains, or antibody comprising a sialidated
oligosaccharide attached to one or two heavy chains thereof
etc.
[0411] The composition may be recovered from a genetically
engineered cell line, e.g. a Chinese Hamster Ovary (CHO) cell line
expressing the HER2 antibody, or may be prepared by peptide
synthesis.
[0412] For more information regarding exemplary pertuzumab
compositions, see U.S. Pat. Nos. 7,560,111 and 7,879,325 as well as
US 2009/0202546A1.
[0413] A commercial formulation of pertuzumab (PERJETA.RTM.)
contains pertuzumab 420 mg/14 mL (30 mg/mL) in the form of a
preservative-free solution for IV infusion. In some embodiments,
pertuzumab therapy comprises administration of an initial loading
dose of 840 mg, following by administration of a flat maintenance
dose of 420 mg every three weeks.
[0414] F. Methods and Compositions for Diagnostics and
Detection
[0415] In certain embodiments, any of the anti-HER2 antibodies
provided herein is useful for detecting the presence of HER2 in a
biological sample. The term "detecting" as used herein encompasses
quantitative or qualitative detection. A "biological sample"
comprises, e.g., a cell or tissue (e.g., biopsy material, including
cancerous or potentially cancerous breast tissue).
[0416] In one embodiment, an anti-HER2 antibody for use in a method
of diagnosis or detection is provided. In a further aspect, a
method of detecting the presence of HER2 in a biological sample is
provided. In certain embodiments, the method comprises contacting
the biological sample with an anti-HER2 antibody as described
herein under conditions permissive for binding of the anti-HER2
antibody to HER2, and detecting whether a complex is formed between
the anti-HER2 antibody and HER2 in the biological sample. Such
method may be an in vitro or in vivo method. In one embodiment, an
anti-HER2 antibody is used to select subjects eligible for therapy
with an anti-HER2 antibody, e.g. where HER2 is a biomarker for
selection of patients. In a further embodiment, the biological
sample is a cell or tissue.
[0417] In a further embodiment, an anti-HER2 antibody is used in
vivo to detect, e.g., by in vivo imaging, a HER2-positive cancer in
a subject, e.g., for the purposes of diagnosing, prognosing, or
staging cancer, determining the appropriate course of therapy, or
monitoring response of a cancer to therapy. One method known in the
art for in vivo detection is immuno-positron emission tomography
(immuno-PET), as described, e.g., in van Dongen et al., The
Oncologist 12:1379-1389 (2007) and Verel et al., J. Nucl. Med.
44:1271-1281 (2003). In such embodiments, a method is provided for
detecting a HER2-positive cancer in a subject, the method
comprising administering a labeled anti-HER2antibody to a subject
having or suspected of having a HER2-positive cancer, and detecting
the labeled anti-HER2 antibody in the subject, wherein detection of
the labeled anti-HER2 antibody indicates a HER2-positive cancer in
the subject. In certain of such embodiments, the labeled anti-HER2
antibody comprises an anti-HER2 antibody conjugated to a positron
emitter, such as .sup.68Ga, .sup.18F, .sup.64Cu, .sup.86Y,
.sup.76Br, .sup.89Zr, and .sup.124I. In a particular embodiment,
the positron emitter is .sup.89Zr.
[0418] In further embodiments, a method of diagnosis or detection
comprises contacting a first anti-HER2 antibody immobilized to a
substrate with a biological sample to be tested for the presence of
HER2, exposing the substrate to a second anti-HER2 antibody, and
detecting whether the second anti-HER2 is bound to a complex
between the first anti-HER2 antibody and HER2 in the biological
sample. A substrate may be any supportive medium, e.g., glass,
metal, ceramic, polymeric beads, slides, chips, and other
substrates. In certain embodiments, a biological sample comprises a
cell or tissue. In certain embodiments, the first or second
anti-HER2 antibody is any of the antibodies described herein.
[0419] Exemplary disorders that may be diagnosed or detected
according to any of the above embodiments include HER2-positive
cancers, such as HER2-positive breast cancer and HER2-positive
gastric cancer. In some embodiments, HER2-positive cancer has an
immunohistochemistry (IHC) score of 2+ or 3+ and/or an in situ
hybridization (ISH) amplification ratio .gtoreq.2.0.
[0420] In certain embodiments, labeled anti-HER2 antibodies are
provided. Labels include, but are not limited to, labels or
moieties that are detected directly (such as fluorescent,
chromophoric, electron-dense, chemiluminescent, and radioactive
labels), as well as moieties, such as enzymes or ligands, that are
detected indirectly, e.g., through an enzymatic reaction or
molecular interaction. Exemplary labels include, but are not
limited to, the radioisotopes .sup.32P, .sup.14C, .sup.125I,
.sup.3H, and .sup.131I, fluorophores such as rare earth chelates or
fluorescein and its derivatives, rhodamine and its derivatives,
dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and
bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin,
2,3-dihydrophthalazinediones, horseradish peroxidase (HRP),
alkaline phosphatase, .beta.-galactosidase, glucoamylase, lysozyme,
saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and
glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as
uricase and xanthine oxidase, coupled with an enzyme that employs
hydrogen peroxide to oxidize a dye precursor such as HRP,
lactoperoxidase, or microperoxidase, biotin/avidin, spin labels,
bacteriophage labels, stable free radicals, and the like. In
another embodiment, a label is a positron emitter. Positron
emitters include but are not limited to .sup.68Ga, .sup.18F,
.sup.64Cu, .sup.86Y, .sup.76Br, .sup.89Zr, and .sup.124I. In a
particular embodiment, a positron emitter is .sup.89Zr.
[0421] G. Pharmaceutical Formulations
[0422] Pharmaceutical formulations of an anti-HER2 antibody or
immunoconjugate as described herein are prepared by mixing such
antibody or immunoconjugate having the desired degree of purity
with one or more optional pharmaceutically acceptable carriers
(Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
(1980)), in the form of lyophilized formulations or aqueous
solutions. Pharmaceutically acceptable carriers are generally
nontoxic to recipients at the dosages and concentrations employed,
and include, but are not limited to: buffers such as phosphate,
citrate, and other organic acids; antioxidants including ascorbic
acid and methionine; preservatives (such as octadecyldimethylbenzyl
ammonium chloride; hexamethonium chloride; benzalkonium chloride;
benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl
parabens such as methyl or propyl paraben; catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less
than about 10 residues) polypeptides; proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g. Zn-protein complexes); and/or
non-ionic surfactants such as polyethylene glycol (PEG). Exemplary
pharmaceutically acceptable carriers herein further include
insterstitial drug dispersion agents such as soluble neutral-active
hyaluronidase glycoproteins (sHASEGP), for example, human soluble
PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX.RTM.,
Baxter International, Inc.). Certain exemplary sHASEGPs and methods
of use, including rHuPH20, are described in US Patent Publication
Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is
combined with one or more additional glycosaminoglycanases such as
chondroitinases.
[0423] Exemplary lyophilized antibody or immunoconjugate
formulations are described in U.S. Pat. No. 6,267,958. Aqueous
antibody or immunoconjugate formulations include those described in
U.S. Pat. No. 6,171,586 and WO2006/044908, the latter formulations
including a histidine-acetate buffer.
[0424] The formulation herein may also contain more than one active
ingredient as necessary for the particular indication being
treated, preferably those with complementary activities that do not
adversely affect each other.
[0425] Active ingredients may be entrapped in microcapsules
prepared, for example, by coacervation techniques or by interfacial
polymerization, for example, hydroxymethylcellulose or
gelatin-microcapsules and poly-(methylmethacylate) microcapsules,
respectively, in colloidal drug delivery systems (for example,
liposomes, albumin microspheres, microemulsions, nano-particles and
nanocapsules) or in macroemulsions. Such techniques are disclosed
in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
(1980).
[0426] Sustained-release preparations may be prepared. Suitable
examples of sustained-release preparations include semipermeable
matrices of solid hydrophobic polymers containing the antibody or
immunoconjugate, which matrices are in the form of shaped articles,
e.g. films, or microcapsules.
[0427] The formulations to be used for in vivo administration are
generally sterile. Sterility may be readily accomplished, e.g., by
filtration through sterile filtration membranes.
[0428] H. Therapeutic Methods and Compositions
[0429] Any of the anti-HER2 antibodies or immunoconjugates provided
herein may be used in methods, e.g., therapeutic methods.
[0430] In one aspect, an anti-HER2 antibody or immunoconjugate
provided herein is used in a method of inhibiting proliferation of
a HER2-positive cell, the method comprising exposing the cell to
the anti-HER2 antibody or immunoconjugate under conditions
permissive for binding of the anti-HER2 antibody or immunoconjugate
to HER2 on the surface of the cell, thereby inhibiting the
proliferation of the cell. In certain embodiments, the method is an
in vitro or an in vivo method. In further embodiments, the cell is
a breast cancer cell or a gastric cancer cell.
[0431] Inhibition of cell proliferation in vitro may be assayed
using the CellTiter-Glo.TM. Luminescent Cell Viability Assay, which
is commercially available from Promega (Madison, Wis.).
[0432] That assay determines the number of viable cells in culture
based on quantitation of ATP present, which is an indication of
metabolically active cells. See Crouch et al. (1993) J. Immunol.
Meth. 160:81-88, U.S. Pat. No. 6,602,677. The assay may be
conducted in 96- or 384-well format, making it amenable to
automated high-throughput screening (HTS). See Cree et al. (1995)
AntiCancer Drugs 6:398-404. The assay procedure involves adding a
single reagent (CellTiter-Glo.RTM. Reagent) directly to cultured
cells. This results in cell lysis and generation of a luminescent
signal produced by a luciferase reaction. The luminescent signal is
proportional to the amount of ATP present, which is directly
proportional to the number of viable cells present in culture. Data
can be recorded by luminometer or CCD camera imaging device. The
luminescence output is expressed as relative light units (RLU).
[0433] In another aspect, an anti-HER2 antibody or immunoconjugate
for use as a medicament is provided. In further aspects, an
anti-HER2 antibody or immunoconjugate for use in a method of
treatment is provided. In certain embodiments, an anti-HER2
antibody or immunoconjugate for use in treating HER2-positive
cancer is provided. In certain embodiments, the invention provides
an anti-HER2 antibody or immunoconjugate for use in a method of
treating an individual having a HER2-positive cancer, the method
comprising administering to the individual an effective amount of
the anti-HER2 antibody or immunoconjugate. In one such embodiment,
the method further comprises administering to the individual an
effective amount of at least one additional therapeutic agent,
e.g., as described below.
[0434] In a further aspect, the invention provides for the use of
an anti-HER2 antibody or immunoconjugate in the manufacture or
preparation of a medicament. In one embodiment, the medicament is
for treatment of HER2-positive cancer. In a further embodiment, the
medicament is for use in a method of treating HER2-positive cancer,
the method comprising administering to an individual having
HER2-positive cancer an effective amount of the medicament. In one
such embodiment, the method further comprises administering to the
individual an effective amount of at least one additional
therapeutic agent, e.g., as described below.
[0435] In a further aspect, the invention provides a method for
treating HER2-positive cancer. In one embodiment, the method
comprises administering to an individual having such HER2-positive
cancer an effective amount of an anti-HER2 antibody or
immunoconjugate. In one such embodiment, the method further
comprises administering to the individual an effective amount of at
least one additional therapeutic agent, as described below.
[0436] A HER2-positive cancer according to any of the above
embodiments may be, e.g., HER2-positive breast cancer or
HER2-positive gastric cancer. In some embodiments, HER2-positive
cancer has an immunohistochemistry (IHC) score of 2+ or 3+ and/or
an in situ hybridization (ISH) amplification ratio .gtoreq.2.0.
[0437] An "individual," "patient," or "subject" according to any of
the above embodiments may be a human.
[0438] In a further aspect, the invention provides pharmaceutical
formulations comprising any of the anti-HER2 antibodies or
immunoconjugate provided herein, e.g., for use in any of the above
therapeutic methods. In one embodiment, a pharmaceutical
formulation comprises any of the anti-HER2 antibodies or
immunoconjugates provided herein and a pharmaceutically acceptable
carrier. In another embodiment, a pharmaceutical formulation
comprises any of the anti-HER2 antibodies or immunoconjugates
provided herein and at least one additional therapeutic agent,
e.g., as described below.
[0439] Antibodies or immunoconjugates of the invention can be used
either alone or in combination with other agents in a therapy. For
instance, an antibody or immunoconjugate of the invention (e.g., a
hu7C2.v.2.2.LA antibody-drug conjugate (hu7C2 ADC)) may be
co-administered with at least one additional therapeutic agent. In
some embodiments, the additional therapeutic agent is also an
antibody or immunoconjugate that binds to HER2. In some
embodiments, the additional therapeutic agent is (i) an antibody or
immunoconjugate that binds to domain II of HER2, and/or (ii) an
antibody or immunoconjugate that binds to domain IV or HER2. In
some embodiments, the additional therapeutic agent is (i) an
antibody or immunoconjugate that binds to epitope 2C4, and/or (ii)
an antibody or immunoconjugate that binds to epitope 4D5.
[0440] In some embodiments, a hu7C2.v.2.2.LA antibody-drug
conjugate (hu7C2 ADC) is co-administered with one or more
additional therapeutic agents selected from trastuzumab
(Herceptin.RTM.), T-DM1 (Kadcyla.RTM.) and pertuzumab
(Perjeta.RTM.). In some embodiments, an hu7C2 ADC is
co-administered with trastuzumab. In some embodiments, a hu7C2 ADC
is co-administered with T-DM1. In some embodiments, a hu7C2 ADC is
co-administered with pertuzumab. In some embodiments, a hu7C2 ADC
is co-administered with trastuzumab and pertuzumab. In some
embodiments, a hu7C2 ADC is co-administered with T-DM1 and
pertuzumab.
[0441] Such combination therapies noted above encompass combined
administration (where two or more therapeutic agents are included
in the same or separate formulations), and separate administration,
in which case, administration of the antibody or immunoconjugate of
the invention can occur prior to, simultaneously, and/or following,
administration of the additional therapeutic agent and/or adjuvant.
Antibodies or immunoconjugates of the invention can also be used in
combination with radiation therapy.
[0442] An antibody or immunoconjugate of the invention (and any
additional therapeutic agent) can be administered by any suitable
means, including parenteral, intrapulmonary, and intranasal, and,
if desired for local treatment, intralesional administration.
Parenteral infusions include intramuscular, intravenous,
intraarterial, intraperitoneal, or subcutaneous administration.
Dosing can be by any suitable route, e.g. by injections, such as
intravenous or subcutaneous injections, depending in part on
whether the administration is brief or chronic. Various dosing
schedules including but not limited to single or multiple
administrations over various time-points, bolus administration, and
pulse infusion are contemplated herein.
[0443] Antibodies or immunoconjugates of the invention would be
formulated, dosed, and administered in a fashion consistent with
good medical practice. Factors for consideration in this context
include the particular disorder being treated, the particular
mammal being treated, the clinical condition of the individual
patient, the cause of the disorder, the site of delivery of the
agent, the method of administration, the scheduling of
administration, and other factors known to medical practitioners.
The antibody or immunoconjugate need not be, but is optionally
formulated with one or more agents currently used to prevent or
treat the disorder in question. The effective amount of such other
agents depends on the amount of antibody or immunoconjugate present
in the formulation, the type of disorder or treatment, and other
factors discussed above. These are generally used in the same
dosages and with administration routes as described herein, or
about from 1 to 99% of the dosages described herein, or in any
dosage and by any route that is empirically/clinically determined
to be appropriate.
[0444] For the prevention or treatment of disease, the appropriate
dosage of an antibody or immunoconjugate of the invention (when
used alone or in combination with one or more other additional
therapeutic agents) will depend on the type of disease to be
treated, the type of antibody or immunoconjugate, the severity and
course of the disease, whether the antibody or immunoconjugate is
administered for preventive or therapeutic purposes, previous
therapy, the patient's clinical history and response to the
antibody or immunoconjugate, and the discretion of the attending
physician. The antibody or immunoconjugate is suitably administered
to the patient at one time or over a series of treatments.
Depending on the type and severity of the disease, about 1 .mu.g/kg
to 15 mg/kg (e.g. 0.1 mg/kg-10 mg/kg) of antibody or
immunoconjugate can be an initial candidate dosage for
administration to the patient, whether, for example, by one or more
separate administrations, or by continuous infusion. One typical
daily dosage might range from about 1 .mu.g/kg to 100 mg/kg or
more, depending on the factors mentioned above. For repeated
administrations over several days or longer, depending on the
condition, the treatment would generally be sustained until a
desired suppression of disease symptoms occurs. One exemplary
dosage of the antibody or immunoconjugate would be in the range
from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of
about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any
combination thereof) may be administered to the patient. Such doses
may be administered intermittently, e.g. every week or every three
weeks (e.g. such that the patient receives from about two to about
twenty, or e.g. about six doses of the antibody). An initial higher
loading dose, followed by one or more lower doses may be
administered. However, other dosage regimens may be useful. The
progress of this therapy is easily monitored by conventional
techniques and assays.
[0445] It is understood that any of the above formulations or
therapeutic methods may be carried out using both an
immunoconjugate of the invention and an anti-HER2 antibody.
[0446] I. Articles of Manufacture
[0447] Articles of manufacture, or "kits", containing a
hu7C2.v.2.2.LA antibody-drug conjugate (hu7C2 ADC) and
trastuzumab-MCC-DM1 and/or pertuzumab useful for the treatment
methods herein are provided. In some embodiments, the kit comprises
a container comprising a hu7C2 ADC. In some embodiments, the kit
further comprises a container comprising trastuzumab-MCC-DM1. In
some embodiments, the kit further comprises container comprising
pertuzumab. In some embodiments, a kit further comprises a
container comprising trastuzumab-MCC-DM1 and a container comprising
pertuzumab. In some embodiments, the kit comprises two or more of
hu7C2 ADC, trastuzumab-MCC-DM1, and pertuzumab in the same
container. The kit may further comprise a label or package insert,
on or associated with the container. The term"package insert" is
used to refer to instructions customarily included in commercial
packages of therapeutic products, that contain information about
the indications, usage, dosage, administration, contraindications
and/or warnings concerning the use of such therapeutic products.
Suitable containers include, for example, bottles, vials, syringes,
blister pack, etc. The container may be formed from a variety of
materials such as glass or plastic. The container may hold hu7C2
ADC and, optionally, trastuzumab-MCC-DM1 and/or pertuzumab or a
formulation thereof which is effective for use in a treatment
method herein, and may have a sterile access port (for example, the
container may be an intravenous solution bag or a vial having a
stopper pierceable by a hypodermic injection needle). The label or
package insert indicates that the composition is used in a
treatment method as described and claimed herein. The article of
manufacture may also contain a further container comprising a
pharmaceutically acceptable buffer, such as bacteriostatic water
for injection (BWFI), phosphate-buffered saline, Ringer's solution
and dextrose solution. It may further include other materials
desirable from a commercial and user standpoint, including other
buffers, diluents, filters, needles, and syringes.
[0448] The kit may further comprise directions for the
administration of hu7C2 ADC and, optionally, trastuzumab-MCC-DM1
and/or pertuzumab. For example, if the kit comprises a first
composition comprising hu7C2 ADC and a second pharmaceutical
formulation, the kit may further comprise directions for the
simultaneous, sequential or separate administration of the first
and second pharmaceutical compositions to a patient in need
thereof.
[0449] In another embodiment, the kits are suitable for the
delivery of solid oral forms of hu7C2 ADC and, optionally,
trastuzumab-MCC-DM1 and/or pertuzumab, such as tablets or capsules.
Such a kit preferably includes a number of unit dosages. Such kits
can include a card having the dosages oriented in the order of
their intended use. An example of such a kit is a "blister pack".
Blister packs are well known in the packaging industry and are
widely used for packaging pharmaceutical unit dosage forms. If
desired, a memory aid can be provided, for example in the form of
numbers, letters, or other markings or with a calendar insert,
designating the days in the treatment schedule in which the dosages
can be administered.
[0450] According to one embodiment, a kit may comprise (a) a first
container with hu7C2 ADC, and optionally, (b) a second container
with trastuzumab-MCC-DM1 contained therein and/or with pertuzumab
contained therein. In some embodiments, a kit may comprise (a) a
first container with hu7C2 ADC, (b) a second container with
trastuzumab-MCC-DM1 contained therein, and (c) a third container
with pertuzumab contained therein. In some embodiments, the kit may
further comprise a container comprising a
pharmaceutically-acceptable buffer, such as bacteriostatic water
for injection (BWFI), phosphate-buffered saline, Ringer's solution
and dextrose solution. It may further include other materials
desirable from a commercial and user standpoint, including other
buffers, diluents, filters, needles, and syringes.
[0451] Where the kit comprises a composition of hu7C2 ADC and
trastuzumab-MCC-DM1 and/or pertuzumab, the kit may comprise a
container for containing the separate compositions such as a
divided bottle or a divided foil packet, however, the separate
compositions may also be contained within a single, undivided
container. Typically, the kit comprises directions for the
administration of the separate components. The kit form is
particularly advantageous when the separate components are
preferably administered in different dosage forms (e.g., oral and
parenteral), are administered at different dosage intervals, or
when titration of the individual components of the combination is
desired by the prescribing physician.
[0452] One embodiment of an article of manufacture herein comprises
an intravenous (IV) bag containing a stable mixture of a hu7C2 ADC
and pertuzumab and/or T-DM1 suitable for administration to a cancer
patient. Optionally, the mixture is in saline solution; for example
comprising about 0.9% NaCl or about 0.45% NaCl. An exemplary IV bag
is a polyolefin or polyvinyl chloride infusion bag, e.g. a 250 mL
IV bag. According to some embodiments of the invention, the mixture
includes about 420 mg or about 840 mg of pertuzumab and from about
100 mg to about 160 mg T-DM1.
[0453] Optionally, the mixture in the IV bag is stable for up to 24
hours at 5.degree. C. or 30.degree. C. Stability of the mixture can
be evaluated by one or more assays selected from the group
consisting of: color, appearance and clarity (CAC), concentration
and turbidity analysis, particulate analysis, size exclusion
chromatography (SEC), ion-exchange chromatography (IEC), capillary
zone electrophoresis (CZE), image capillary isoelectric focusing
(iCIEF), and potency assay.
III. EXAMPLES
[0454] The following are examples of methods and compositions of
the invention. It is understood that various other embodiments may
be practiced, given the general description provided above.
Example 1: Humanization of Murine Antibody 7C2
[0455] Anti-HER2 murine antibody 7C2 binds to an epitope in domain
I of HER2. See, e.g., PCT Publication No. WO 98/17797. This epitope
is distinct from the epitope bound by trastuzumab, which binds to
domain IV of HER2, and the epitope bound by pertuzumab, which binds
to domain II of HER2. See FIGS. 3, 16, and 18. By binding domain
IV, trastuzumab disrupts ligand-independent HER2-HER3 complexes,
thereby inhibiting downstream signaling (e.g. PI3K/AKT). In
contrast, pertuzumab binding to domain II prevents ligand-driven
HER2 interaction with other HER family members (e.g. HER3, HER1 or
HER4), thus also preventing downstream signal transduction.
[0456] Binding of MAb 7C2 to domain I does not result in
interference of trastuzumab or pertuzumab binding to domains IV and
II, respectively, thereby offering the potential of combining a MAb
7C2 ADC with trastuzumab, trastuzumab emtansine (T-DM-1), and/or
pertuzumab.
[0457] Murine antibody 7C2 (7C2.B9, see PCT Publication No. WO
98/17797) was humanized as follows.
[0458] A. Materials and Methods
[0459] Residue numbers are according to Kabat (Kabat et al.,
Sequences of proteins of immunological interest, 5th Ed., Public
Health Service, National Institutes of Health, Bethesda, Md.
(1991)).
[0460] Direct hypervariable region grafts onto the acceptor human
consensus framework. Variants constructed during the humanization
of 7C2 were assessed in the form of an IgG. The VL and VH domains
from murine 7C2 were aligned with the human VL kappa IV
(VL.sub.KIV) and human VH subgroup I (VH.sub.I) consensus
sequences. Hypervariable regions (HVR) from the murine 7C2 (7C2.B9)
antibody were engineered into VL.sub.KIV and VH.sub.I acceptor
frameworks to generate CDR-graft variants. From the mu7C2 VL
domain, positions 24-34 (L1), 50-56 (L2) and 89-97 (L3) were
grafted into VL.sub.KI. From the mu7C2 VH domain, positions 26-35
(H1), 50-65 (H2) and 95-102 (H3) were grafted into VH.sub.I(FIGS. 1
and 2). The HVR definitions are defined by their sequence
hypervariability (Wu, T. T. & Kabat, E. A. (1970)), their
structural location (Chothia, C. & Lesk, A. M. (1987)) and
their involvement in antigen-antibody contacts (MacCallum et al. J.
Mol. Biol. 262: 732-745 (1996)). To evaluate framework vernier
positions that might be important, selected vernier positions were
mutated back to the murine sequence. The vernier positions include
positions 4 and 49 in VL and positions 37, 67, 69, 71 and 73 in VH.
Three different versions of VL sequences and VH sequences were
synthesized (Blue Heron, Bothell, Wash.) and subsequently subcloned
into mammalian expression vectors. By combining the different
versions of LC with HC, a total of nine different hu7C2 graft
variants (v 1.1, v1.2, v1.3, v2.1, v2.2, v2.3, v3.1, v3.2 and v3.3)
were generated.
[0461] Affinity maturation library. A monovalent Fab-g3 display
phagemid vector with 2 open reading frames under control of a
single phoA promoter was used. The first open reading frame
consists of the stII signal sequence fused to the VL and CL domains
of the acceptor light chain and the second consists of the stII
signal sequence fused to the VH and CH1 domains of the acceptor
heavy chain followed by the minor phage coat protein P3. The HVR
graft variant (7C2.v2.1) was generated by Kunkel mutagenesis using
separate oligonucleotides for each hypervariable region, and
displayed on phage as a Fab.
[0462] To improve affinity, phage libraries containing changes in
each hypervariable region were generated. Sequence diversity was
introduced separately at each position in the hypervariable regions
of 7C2.v2.1 using Kunkel mutagenesis. Positions in the
hypervariable region of 7C2.v2.1 were each fully randomized one at
a time to all possible 20 amino acids using oligonucleotides
encoding NNS. A total of 68 libraries, each consisting of 20
members, were made having a single position located within one of
the hypervariable regions of 7C2 fully randomized. Libraries with
positions in the same hypervariable region were pooled to generate
a total of six libraries.
[0463] Generation of phage libraries. Oligonucleotides designed to
introduce diversity into each hypervariable region as outlined
above were phosphorylated separately in 20 .mu.l reactions
containing 660 ng of oligonucleotide, 50 mM Tris pH 7.5, 10 mM
MgCl.sub.2, 1 mM ATP, 20 mM DTT, and 5 U polynucleotide kinase for
1 h at 37.degree. C.
[0464] To generate the affinity maturation library, 68 individual
Kunkel mutagenesis reactions were performed in a 96-well PCR plate.
From the phosphorylated oligonucleotides reactions (above), 2 .mu.l
was added to 500 ng Kunkel template in 50 mM Tris pH 7.5, 10 mM
MgCl.sub.2 in a final volume of 25 .mu.l. The mixture was annealed
at 90.degree. C. for 1 min, 50.degree. C. for 3 min and then cooled
on ice. The annealed template was then filled in by adding 0.5
.mu.l 10 mM ATP, 0.5 .mu.l 10 mM dNTPs (10 mM each of dATP, dCTP,
dGTP and dTTP), 1 .mu.l 100 mM DTT, 1 .mu.l 10.times.TM buffer (0.5
M Tris pH 7.5, 0.1 M MgCl.sub.2), 80 U T4 ligase, and 4 U T7
polymerase in a total volume of 30 .mu.l for 2 h at room
temperature. These filled-in and ligated products were then each
transformed into XL 1-blue cells. The libraries containing
positions in the same CDR region were pooled and recovered in 10 ml
SOC media for 1 hour at 37.degree. C. Carbenacillin (50 .mu.g/ml)
and M13/KO7 helper phage (MOI 10) were added. The cultures were
incubated for another 30 mins at 37.degree. C. and transferred to
500 ml 2YT containing 50 .mu.g/ml carbenacillin and 50 .mu.g/ml
kanamycin and grown 20 h at 37.degree. C.
[0465] Phage Selections. Her2 extracellular domain (Her2 ECD) was
biotinylated through free amines using NHS-PEG4-Biotin (Pierce).
For biotinylation reactions, a 4-fold molar excess of biotin
reagent was used in PBS. Reactions were followed by dialysis in
PBS.
[0466] Phage were harvested from the cell culture supernatant and
suspended in PBS containing 1% BSA. The phage libraries were
incubated with biotinylated Her2 ECD at room temperature and the
phage bound to biotin-Her2 was then captured for 5 min on
neutrAvidin (10 .mu.g/ml) that had been immobilized in PBS on
MaxiSorp microtiter plates (Nunc) overnight at 4.degree. C.
Microtiter wells were washed extensively with PBS containing 0.05%
Tween 20 (PBST) and bound phage were eluted by incubating the wells
with 20 mM HCl, 500 mM KCl for 30 min. Eluted phage were
neutralized with 1 M Tris, pH 7.5 and amplified using XL1-Blue
cells and M13/KO7 helper phage and grown overnight at 37.degree. C.
in 2YT, 50 .mu.g/ml carbenacillin and 50 .mu.g/ml Kanamycin. The
titers of phage eluted from a target containing well were compared
to titers of phage recovered from a non-target containing well to
assess enrichment. Selection stringency was increased by both
decreasing concentration of biotinylated Her2 ECD (from 5 nM to 0.2
nM) during binding and increasing the competition time (from 0 to
60 min at room temperature) with 1 .mu.M of unlabeled Her2 ECD in
solution.
[0467] Surface plasmon resonance assessment of variants. 7C2
variants were expressed as IgG by 293 transient transfection. IgG
was purified with protein A affinity chromatography. The affinity
of each 7C2 IgG variant for Her2 was determined by surface plasmon
resonance using a BIAcoreT100. Biacore Series S CM5 sensor chips
were immobilized with monoclonal mouse anti-human IgG (Fc) antibody
(Human antibody capture kit, GE Healthcare). Serial 3-fold
dilutions of each 7C2 variant were injected at a flow rate of 30
l/min. Each sample was analyzed with 3-minute association and
10-minute dissociation. After each injection the chip was
regenerated using 3 M MgCl.sub.2. Binding response was corrected by
subtracting the RU from a flow cell capturing an irrelevant IgG at
similar density. A 1:1 Languir model of simultaneous fitting of
k.sub.on and k.sub.off was used for kinetics analysis.
[0468] B. Results and Discussion
[0469] Humanization of 7C2. The human acceptor frameworks used for
humanization of 7C2 are based on the human VL kappa IV consensus
(VL.sub.KIV) and the human VH.sub.I consensus. The VL and VH
domains of murine 7C2 were aligned with the human VL.sub.KIV and
VH.sub.I domains; hypervariable regions were identified and grafted
into the human acceptor framework to generate 7C2.v1.1. The
monovalent affinity of 7C2.v1.1 is decreased 2.5-fold relative to
mu7C2.B9 as assessed by SPR (see Table 2).
TABLE-US-00004 TABLE 2 Affinity of 7C2 CDR grafted antibodies VL
K.sub.D (nM) K4 K4.K49 K4.L4.K49 VH VH1 v1.1 v2.1 v3.1 (15 nM) (20
nM) (16 nM) VH1.V71 v1.2 v2.2 v3.2 (10 nM) (13 nM) (11 nM)
VH1.L37.A67.L69.V71.K73 v1.3 v2.3 v3.3 (9 nM) (11 nM) (10 nM)
[0470] To improve the binding affinity of 7C2.v1.1, positions 4 and
49 in the light chain and positions 37, 67, 69, 71 and 73 in the
heavy chain were changed to residues found at these positions in
mu7C2.B9. Combinations of these altered light and heavy chains with
chains from 7C2.v1.1 were transfected into 293 cells, expressed as
IgG and purified, and assessed for binding to Her2 ECD by SPR (see
Table 2). Variant 7C2.v3.3, which contains 2 altered positions in
light chain and 5 altered positions in heavy chain, had a
monovalent affinity comparable to mu7C2.B9 (see Table 4).
[0471] Affinity maturation libraries were explored in an effort to
recruit further improvements using the framework of 7C2.v2.1, which
contains minimal altered vernier position (Y49K) in light chain.
For each hypervariable region, all 20 amino acids were introduced
separately at individual position using Kunkle mutagenesis (a total
of 68 libraries, each containing 20 members, pooled into six
affinity maturation libraries). The six affinity maturation
libraries were panned for 4 rounds in solution with biotinylated
Her2 ECD. Selection stringency was gradually increased by
decreasing the concentration of biotin-Her2 ECD (from 5 to 0.2 nM)
and increasing the competition time (from 0 to 1 hour at room
temperature) with saturated amount of unlabeled Her2 ECD. A two
thousand fold of phage enrichment was observed for the H2
library.
[0472] A total of 588 clones from the last round were picked for
DNA sequence analysis. Individual sequence changes were identified
in each HVR (see Table 3). The most abundant clones had changes in
VH at position S53 to Met or Leu. The S53M and S53L variants were
expressed as IgG and SPR analysis indicate that S53M and S53L have
comparable affinity to Her2. The S53L variant was selected since
methionine is prone to oxidation during the manufacturing process.
A potential iso-aspartic acid forming site in HVR-H2 was eliminated
with a S55A mutation (see Table 4).
TABLE-US-00005 TABLE 3 Kinetics of affinity-improved variants
k.sub.a k.sub.d K.sub.D Variant HVR-Hl HVR-H2 HVR-H3 (1/Ms) (1/s)
(nM) v2.1 GYWMN MIHPSDSEIRANQKFRD GTYDGGFEY 2.6E+05 4.1E-03 15.5
(SEQ ID (SEQ ID NO: 8) (SEQ ID NO: NO: 15) 17) v2.1.S53M
MIHPMDSEIRANQKFRD 2.7E+05 6.7E-04 2.4 (SEQ ID NO: 20) v2.1.S53L
MIHPLDSEIRANQKFRD 2.5E+05 8.5E-04 3.4 (SEQ ID NO: 21) v2.1.E101K
GTYDGGFKY 2.2E+05 1.5E-03 6.8 (SEQ ID NO: 22)
TABLE-US-00006 TABLE 4 Summary of hu7C2 variant affinities hu7C2
variant K.sub.D (nM) mu7C2.B9 8 hu7C2.v2.2 11 hu7C2.v2.2.LA (S53L,
S55A); 3 HVR-H2 of SEQ ID NO: 16
[0473] An alignment of the human VL.sub.KIV and VH.sub.I domains
and the heavy chain and light chain variable regions of mu7C2.B9
("7C2") and hu7C2.v2.2.LA (referred to in the following examples as
"hu7C2") is shown in FIGS. 1 and 2.
Example 2: Production of hu7C2 Antibody Drug Conjugates
[0474] For larger scale antibody production, antibodies were
produced in CHO cells. Vectors coding for heavy chain and light
chain were transfected into CHO cells and IgG was purified from
cell culture media by protein A affinity chromatography.
[0475] A. Synthesis of Center-Linked PBD Linker Drug
Intermediate
[0476] The center-linked PBD linker drug intermediate
(N-(3-(3,5-bis((((S)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1H--
pyrrolo[2,1-c][1,4]
benzodiazepin-8-yl)oxy)methyl)phenyl)prop-2-yn-1-yl)-1-(3-(2,5-dioxo-2,5--
dihydro-1H-pyrrol-1-yl)propanamido)-3,6,9,12-tetraoxapentadecan-15-amide;
"10") having the following formula:
##STR00025##
was synthesized as follows.
##STR00026##
1. (11S,11aS,11'S,11a'S)-di-tert-butyl
8,8'-(((5-iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-meth-
ylene-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1H-py-
rrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate) (2a)
[0477] 1,3-bis(bromomethyl)-5-iodobenzene (2.00 g, 5.20 mmol) was
added to a stirred solution of Boc/THP-protected PBD capping unit 1
(4.75 g, 10.3 mmol), TBAI (190 mg, 0.52 mmol) and K.sub.2CO.sub.3
(1.42 g, 10.3 mmol) in dry DMF (60 mL). The reaction mixture was
heated to 60.degree. C. and stirred under an argon atmosphere for 3
hours at which point analysis by LC/MS revealed substantial product
formation at retention time 4.15 min (ES+) m/z 1171 ([M+Na].sup.+,
.about.10% relative intensity). The reaction mixture was allowed to
cool to room temperature and the DMF was removed by evaporation in
vacuo. The resulting residue was partitioned between water (50 mL)
and EtOAc (50 mL) and the aqueous phase was extracted with EtOAc
(3.times.20 mL). The combined organic layers were washed with water
(2.times.20 mL), brine (50 mL), dried (MgSO.sub.4), filtered and
evaporated in vacuo to provide the crude product. Purification by
flash chromatography (gradient elution: 50:50 v/v EtOAc/hexane to
80:20 v/v EtOAc/hexane) gave the bis-ether 2a as a white foam (5.42
g, 91% yield).
2. (11S,11aS,11'S,11a'S)-di-tert-butyl
8,8'-(((5-bromo-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-met-
hylene-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1H-p-
yrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate) (2b)
[0478] 1-bromo-3,5-bis(bromomethyl)benzene (1.54 g, 4.53 mmol) was
added to a stirred solution of Boc/THP-protected PBD capping unit 1
(4.20 g, 9.06 mmol), TBAI (167 mg, 0.45 mmol) and K.sub.2CO.sub.3
(1.25 g, 9.06 mmol) in dry DMF (52 mL). The reaction mixture was
heated to 60.degree. C. and stirred under an argon atmosphere for 5
hours at which point analysis by LC/MS revealed substantial product
formation at retention time 4.10 min (ES+) m/z 1101 ([M+H].sup.+,
.about.70% relative intensity). The reaction mixture was allowed to
cool to room temperature and the DMF was removed by evaporation in
vacuo. The resulting residue was partitioned between water (60 mL)
and EtOAc (60 mL) and the aqueous phase was extracted with EtOAc
(3.times.25 mL). The combined organic layers were washed with water
(30 mL), brine (50 mL), dried (MgSO.sub.4), filtered and evaporated
in vacuo to provide the crude product. Purification by flash
chromatography (gradient elution: 50:50 v/v EtOAc/hexane to 100%
EtOAc) gave the bis-ether 2b as a white foam (3.37 g, 68%
yield).
3. (11S,11aS,11'S,11a'S)-di-tert-butyl
8,8'-(((5-chloro-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-me-
thylene-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1H--
pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate) (2c)
[0479] 1,3-bis(bromomethyl)-5-chlorobenzene (1.42 g, 4.80 mmol) was
added to a stirred solution of Boc/THP-protected PBD capping unit 1
(4.42 g, 9.60 mmol), TBAI (177 mg, 0.48 mmol) and K.sub.2CO.sub.3
(1.33 g, 9.60 mmol) in dry DMF (55 mL). The reaction mixture was
heated to 60.degree. C. and stirred under an argon atmosphere for
1.5 hours at which point analysis by LC/MS revealed substantial
product formation at retention time 4.08 min (ES+) m/z 1057
([M+H].sup.+, .about.30% relative intensity). The reaction mixture
was allowed to cool to room temperature and the DMF was removed by
evaporation in vacuo. The resulting residue was partitioned between
water (60 mL) and EtOAc (60 mL) and the aqueous phase was extracted
with EtOAc (3.times.20 mL). The combined organic layers were washed
with water (20 mL), brine (40 mL), dried (MgSO.sub.4), filtered and
evaporated in vacuo to provide the crude product. Purification by
flash chromatography (gradient elution: 50:50 v/v EtOAc/hexane to
80:20 v/v EtOAc/hexane) gave the bis-ether 2c as a white foam (5.10
g, 99% yield).
##STR00027##
[0480] A catalytic amount of Pd(PPh.sub.3).sub.4(5.0 mg, 4.2
.mu.mol) was added to a mixture of the bis-ether 2a (242 mg, 0.21
mmol), propargylamine (41 .mu.L, 35 mg, 0.63 mmol), CuI (1.6 mg,
8.4 .mu.mol), diethylamine (0.42 mL, 309 mg, 4.22 mmol) and
oven-dried 4 .ANG. molecular sieve pellets in dry DMF (1.8 mL) in
an oven-dried sealable vessel. The mixture was degased and flushed
with argon 3 times then heated in a microwave at 100.degree. C. for
3 minutes at which point analysis by LC/MS revealed complete
consumption of starting material and substantial product formation
at retention time 3.18 min (ES+) m/z 1076 ([M+H].sup.+, .about.60%
relative intensity). The reaction mixture was allowed to cool to
room temperature and was then filtered through a sinter to remove
the sieves (washed with DMF). The filtrate was evaporated in vacuo
to provide the unstable crude product 8 which was used immediately
in the next step without purification or analysis.
##STR00028##
[0481] MAL-dPEG.RTM.4-acid (88 mg, 0.21 mmol) was added to a
stirred solution of EDCI (41 mg, 0.21 mmol) and the crude primary
amine 8 in dry DCM (4 mL) at room temperature. The reaction mixture
was stirred under an argon atmosphere for 3 hours at which point
analysis by LC/MS showed a substantial amount of desired product at
retention time 3.58 min (ES+) m/z 1475 ([M+H].sup.+, .about.10%
relative intensity), 1498 ([M+Na].sup.+, .about.5% relative
intensity) accompanied by a side product at retention time 3.85
min. The reaction mixture was diluted with DCM (30 mL) and washed
with H.sub.2O (3.times.10 mL), brine (20 mL), dried (MgSO.sub.4),
filtered and evaporated in vacuo to provide the crude product.
Purification by flash chromatography (gradient elution: 100% DCM to
96:4 v/v DCM/MeOH) gave the maleimide 9 as a foam (67 mg, 22% yield
over 2 steps).
##STR00029##
[0482] A solution of 95:5 v/v TFA/H.sub.2O (1 mL) was added to a
sample of the Boc/THP-protected compound 9 (67 mg, 45.5 .mu.mol) at
0.degree. C. (ice/acetone). After stirring at 0.degree. C. for 1.5
hours, the reaction was deemed complete as judged by LC/MS, desired
product peak at retention time 2.67 min (ES+) m/z 1070
([M+H].sup.+, .about.5% relative intensity). The reaction mixture
was kept cold and added drop wise to a chilled saturated aqueous
solution of NaHCO.sub.3 (50 mL). The mixture was extracted with DCM
(3.times.15 mL) and the combined organic layers washed with brine
(40 mL), dried (MgSO.sub.4), filtered and evaporated in vacuo to
provide the crude product. Purification by flash chromatography
(gradient elution: 100% CHCl.sub.3 to 96:4 v/v CHCl.sub.3/MeOH)
gave 10 as an orange foam (12 mg, 24% yield).
[0483] B. Alternate Synthesis of Center-Linked PBD Linker Drug
Intermediate
[0484] The center-linked PBD linker drug intermediate
(N-(3-(3,5-bis((((S)-7-methoxy-2-methylene-5-oxo-2,3,5,11
a-tetrahydro-1H-pyrrolo[2,1-c][1,4]
benzodiazepin-8-yl)oxy)methyl)phenyl)prop-2-yn-1-yl)-1-(3-(2,5-dioxo-2,5--
dihydro-1H-pyrrol-1-yl)propanamido)-3,6,9,12-tetraoxapentadecan-15-amide;
"10") having the following formula:
##STR00030##
may also be synthesized as follows.
##STR00031##
[0485] EDCI (263 mg, 1.37 mmol) was added to a stirred solution of
t-boc-N-amido-dPEG.RTM..sub.4-acid (26) (500 mg, 1.37 mmol,
Stratech Scientific Limited) and propargylamine (88 .mu.L, 76 mg,
1.37 mmol) in dry DCM (10 mL) at room temperature. The reaction
mixture was stirred under an argon atmosphere for 16 hours at which
point analysis by LC/MS showed a substantial amount of desired
product at retention time 1.26 minutes (ES+) m/z 403 ([M+H].sup.+,
.about.50% relative intensity), 425 ([M+Na].sup.+, .about.100%
relative intensity), note that both starting material and product
had weak UV absorption (214 and 254 nm) and were best detected on
ES+TIC. The reaction mixture was diluted with DCM (100 mL) and
washed with H.sub.2O (30 mL), brine (40 mL), dried (MgSO.sub.4),
filtered and evaporated in vacuo to provide the crude product.
Purification by flash chromatography (gradient elution in 1%
increments: 100% DCM to 98:2 v/v DCM/MeOH) gave the amide 27 as an
oil (392 mg, 71% yield).
[0486] A catalytic amount of Pd(PPh.sub.3).sub.4(23.0 mg, 19.5
.mu.mol) was added to a mixture of the iodoaryl compound 2a (1.02
g, 0.89 mmol), Boc-acetylene 27 (393 mg, 0.98 mmol), CuI (7.4 mg,
39.1 .mu.mol), diethylamine (2.02 mL, 1.43 g, 19.5 mmol) and
oven-dried 4 .ANG. molecular sieve pellets in dry DMF (9 mL) in an
oven-dried sealable vessel. The mixture was degased and flushed
with argon 3 times then heated in a microwave at 100.degree. C. for
26 minutes at which point analysis by LC/MS revealed substantial
product formation at retention time 1.89 minutes (ES+) m/z 1446
([M+Na].sup.+, .about.100% relative intensity, 1424 ([M+H].sup.+,
.about.15% relative intensity). The reaction mixture was allowed to
cool to room temperature and was then filtered through a sinter to
remove the sieves (washed with DMF). The filtrate was evaporated in
vacuo and the resulting residue dissolved in DCM (100 mL) and
washed with H.sub.2O (20 mL), brine (30 mL), dried (MgSO.sub.4),
filtered and evaporated in vacuo to give the crude product.
Purification by flash chromatography (gradient elution in 1%
increments: 100% DCM to 97:3 v/v DCM/MeOH) provided the alkyne 28
as a yellow foam (882 mg, 70% yield).
[0487] TBDMSOTf (1.42 mL, 1.64 g, 6.2 mmol) was added to a stirred
solution of the tri-Boc protected compound 28 (882 mg, 0.62 mmol)
and 2,6-lutidine (0.96 mL, 883 mg, 8.25 mmol) in dry DCM (15 mL) at
room temperature. The reaction mixture was allowed to stir under an
argon atmosphere for 16 hours during which time analysis by LC/MS
revealed formation of the TBS carbamate at retention time 2.09
minutes (ES+) m/z 1504 ([M+Na].sup.+, .about.100% relative
intensity). The reaction mixture was diluted with DCM (60 mL) and
washed with saturated NH.sub.4Cl (2.times.20 mL), H.sub.2O (20 mL),
brine (30 mL), dried (MgSO.sub.4), filtered and evaporated in vacuo
to give the crude TBS carbamate. The product was re-dissolved in
THF (15 mL) and treated with a solution of TBAF (744 .mu.L of a
1.0M solution in THF, 0.744 mmol) at room temperature. The reaction
mixture was allowed to stir for 1 hour at room temperature at which
point analysis by LC/MS revealed substantial product formation at
retention time 1.45 minutes (ES+) m/z 1324 ([M+H].sup.+, .about.60%
relative intensity) along with product corresponding to 1 N10Boc/1
THP cleaved at retention time 1.29 minutes (ES+) m/z 1121
([M+H].sup.+, .about.10% relative intensity), 1138
([M+H.sub.2O].sup.+, .about.20% relative intensity) and product
corresponding to 2 N10 Boc/2 THP cleaved at retention time 1.12
minutes (ES+) m/z 919 ([M+H].sup.+, .about.2.5% relative
intensity), 937 ([M+H.sub.2O].sup.+, .about.3% relative intensity),
955 ([M+2H.sub.2O].sup.+, .about.5% relative intensity). The THF
was removed by evaporation in vacuo and the resulting residue
re-dissolved in DCM (60 mL) and washed with saturated NH.sub.4Cl
(2.times.20 mL), H.sub.2O (20 mL), brine (30 mL), dried
(MgSO.sub.4), filtered and evaporated in vacuo to give the key
amine 29 as a pinkish foam.
##STR00032##
[0488] EDCI (61 mg, 0.32 mmol) was added to a stirred solution of
N-maleoyl-.beta.-alanine (53 mg, 0.32 mmol) and amine 29
(.about.418 mg, 0.32 mmol) in dry DCM (6 mL) at room temperature.
The reaction mixture was stirred under an argon atmosphere for 3
hours at which point analysis by LC/MS showed a substantial amount
of desired product at retention time 1.80 minutes (ES+) m/z 1474
([M+H].sup.+, .about.15% relative intensity), 1497 ([M+Na].sup.+,
.about.100% relative intensity), along with product corresponding
to 1 N10Boc/1 THP cleaved at retention time 1.56 minutes 1272
([M+H].sup.+, .about.80% relative intensity), 1295 ([M+Na].sup.+,
.about.45% relative intensity) and product corresponding to 2 N10
Boc/2 THP cleaved at retention time 1.31 minutes (ES+M+ not
observed). The reaction mixture was diluted with DCM (30 mL) and
washed with H.sub.2O (15 mL), brine (20 mL), dried (MgSO.sub.4),
filtered and evaporated in vacuo to provide the crude product 9 as
a foam.
[0489] A solution of 95:5 v/v TFA/H.sub.2O (5 mL) was added to a
crude sample of the Boc/THP-protected compound 9 (.about.466 mg,
0.32 mmol) at 0.degree. C. (ice/acetone). After stirring at
0.degree. C. for 1 hour the reaction was deemed complete as judged
by LC/MS, desired product peak at retention time 1.32 minutes (ES+)
m/z 1070 ([M+H].sup.+, .about.100% relative intensity). The
reaction mixture was kept cold and added drop-wise to a chilled
saturated aqueous solution of NaHCO.sub.3 (120 mL). The mixture was
extracted with DCM (3.times.40 mL) and the combined organic layers
washed with brine (50 mL), dried (MgSO.sub.4), filtered and
evaporated in vacuo to provide the crude product. Purification by
flash chromatography (gradient elution: 100% CHCl.sub.3 to 96:4 v/v
CHCl.sub.3/MeOH) gave 10 as an orange foam (202 mg, 60% yield):
[.alpha.].sup.21.sub.D=+351.degree. (c=0.47, CHCl.sub.3); LC/MS
(15-minute run), retention time 4.88 minutes (ES+) m/z 1070
([M+H].sup.+, .about.100% relative intensity); .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.66 (d, 2H, J=4.4 Hz), 7.52 (s, 2H),
7.45-7.40 (m, 3H), 6.98-6.94 (m, 1H), 6.80 (s, 2H), 6.66 (s, 2H),
6.55-6.50 (m, 1H), 5.22-5.07 (m, 8H), 4.30-4.22 (m, 6H), 3.96 (s,
6H), 3.91-3.85 (m, 2H), 3.82 (t, 2H, J=7.2 Hz), 3.76 (t, 2H, J=5.8
Hz), 3.65-3.43 (m, 16H), 3.16-3.08 (m, 2H), 2.94 (d, 2H, J=15.7
Hz), 2.54-2.44 (m, 4H).
[0490] C. Conjugation of Linker-Drug Moieties to Antibodies
[0491] Hu7C2 antibody-drug conjugates (ADCs) are produced by
conjugating hu7C2.v.2.2.LA with a heavy chain A118C mutation
(thio-hu7C2-HC A118C) or a light chain K149C mutation
(thio-hu7C2-LC-K149C) to the selected drug-linker moiety (e.g.,
center-linked PBD linker-drug intermediate). As initially isolated,
the engineered cysteine residues in antibodies exist as mixed
disulfides with cellular thiols (e.g., glutathione) and are thus
unavailable for conjugation. Partial reduction of these antibodies
(e.g., with DTT), purification, and reoxidation with
dehydroascorbic acid (DHAA) gives antibodies with free cysteine
sulfhydryl groups available for conjugation, as previously
described, e.g., in Junutula et al. (2008) Nat. Biotechnol.
26:925-932 and US 2011/0301334. Briefly, the antibodies are
combined with the drug-linker moiety to allow conjugation of the
drug-linker moiety to the free cysteine residues of the antibody.
After several hours, the ADCs are purified. The drug load (average
number of drug moieties per antibody) for the ADC was determined
and was in the range of 1.8-1.9. The resulting ADC structures and
the terms used for them below are shown in FIG. 6.
[0492] An example of a method for conjugation of linker-drug
moieties to antibodies is as follows:
[0493] Full length, cysteine engineered monoclonal antibodies
(THIOMABS.TM.-Junutula, et al., 2008b Nature Biotech.,
26(8):925-932; Dornan et al (2009) Blood 114(13):2721-2729; U.S.
Pat. Nos. 7,521,541; 7,723,485; WO2009/052249, Shen et al (2012)
Nature Biotech., 30(2): 184-191; Junutula et al (2008) Jour of
Immun. Methods 332:41-52) expressed in CHO cells are reduced with
about a 20-40 fold excess of TCEP (tris(2-carboxyethyl)phosphine
hydrochloride or DTT (dithiothreitol) in 50 mM Tris pH 7.5 with 2
mM EDTA for 3 hrs at 37.degree. C. or overnight at room
temperature. (Getz et al (1999) Anal. Biochem. 273:73-80; Soltec
Ventures, Beverly, Mass.). The reduced THIOMAB.TM. is diluted and
loaded onto a HiTrap S column in 10 mM sodium acetate, pH 5, and
eluted with PBS containing 0.3M sodium chloride. Alternatively, the
antibody is acidified by addition of 1/20th volume of 10% acetic
acid, diluted with 10 mM succinate pH 5, loaded onto the column and
then washed with 10 column volumes of succinate buffer. The column
is eluted with 50 mM Tris pH7.5, 2 mM EDTA.
[0494] The eluted reduced THIOMAB.TM. is treated with 15 fold molar
excess of DHAA (dehydroascorbic acid) or 200 nM aqueous copper
sulfate (CuSO4). Oxidation of the interchain disulfide bonds is
complete in about three hours or more. Ambient air oxidation is
also effective. The re-oxidized antibody is dialyzed into 20 mM
sodium succinate pH 5, 150 mM NaCl, 2 mM EDTA and stored frozen at
-20.degree. C.
[0495] The deblocked, reoxidized, thio-antibodies (THIOMABS.TM.)
are reacted with 6-8 fold molar excess of the selected drug-linker
moiety (e.g., center-linked PBD linker-drug intermediate) (from a
DMSO stock at a concentration of 20 mM) in 50 mM Tris, pH 8, until
the reaction is complete (16-24 hours) as determined by LC-MS
analysis of the reaction mixture.
[0496] The crude antibody-drug conjugates (ADC) are then applied to
a cation exchange column after dilution with 20 mM sodium
succinate, pH 5. The column is washed with at least 10 column
volumes of 20 mM sodium succinate, pH 5, and the antibody is eluted
with PBS. The antibody drug conjugates are formulated into 20 mM
His/acetate, pH 5, with 240 mM sucrose using gel filtration
columns. The antibody-drug conjugates are characterized by UV
spectroscopy to determine protein concentration, analytical SEC
(size-exclusion chromatography) for aggregation analysis and LC-MS
before and after treatment with Lysine C endopeptidase.
[0497] Size exclusion chromatography is performed using a Shodex
KW802.5 column in 0.2M potassium phosphate pH 6.2 with 0.25 mM
potassium chloride and 15% IPA at a flow rate of 0.75 ml/min.
Aggregation state of the conjugate is determined by integration of
eluted peak area absorbance at 280 nm.
[0498] LC-MS analysis is performed using an Agilent QTOF 6520 ESI
instrument. As an example, an antibody-drug conjugate generated
using this chemistry is treated with 1:500 w/w Endoproteinase Lys C
(Promega) in Tris, pH 7.5, for 30 min at 37.degree. C. The
resulting cleavage fragments are loaded onto a 1000A, 8 um PLRP-S
column heated to 80.degree. C. and eluted with a gradient of 30% B
to 40% B in 5 minutes. Mobile phase A is H.sub.2O with 0.05% TFA
and mobile phase B is acetonitrile with 0.04% TFA. The flow rate is
0.5 ml/min. Protein elution is monitored by UV absorbance detection
at 280 nm prior to electrospray ionization and MS analysis.
Chromatographic resolution of the unconjugated Fc fragment,
residual unconjugated Fab and drugged Fab is usually achieved. The
obtained m/z spectra were deconvoluted using Mass Hunter.TM.
software (Agilent Technologies) to calculate the mass of the
antibody fragments.
Example 3: Efficacy of hu7C2 Antibody Drug Conjugates in MMTV-Her2
Fo5 Transgenic Mammary Tumor Transplant Xenograft Models
[0499] CRL nu/nu mice (Charles River Laboratory) were implanted
with .about.2.times.2 mm fragments of MMTV-Her2 Fo5 transgenic
breast tumors. When tumors reached a mean tumor volume of 100-300
mm.sup.3, animals were grouped into 7 groups of 8 mice each. The
mice received a single administration on day 1 of one of the
following treatments, via intravenous tail vein injection: (1)
vehicle (20 mM L-histidine, 240 mM sucrose, 0.02% Tween-20, pH
5.5), (2) thio-hu7C2-HC-A118C-center-linked-PBD, 0.3 mg/kg; (3)
thio-hu7C2-HC-A118C-center-linked-PBD, 1 mg/kg; (4) thio-hu7C2-LC-K
149C-center-linked-PBD, 0.3 mg/kg; (5) thio-hu7C2-LC-K
149C-center-linked-PBD, 1 mg/kg; (6)
thio-controlAb-HC-A118C-center-linked-PBD, 1 mg/kg; or (7)
thio-controlAb-LC-K149C-center-linked-PBD, 1 mg/kg. The DAR for the
thio-hu7C2-LC-K149C-center-linked-PBD, the thio-hu7C2-HC-A
18C-center-linked-PBD, and the
thio-controlAb-LC-K149C-center-linked-PBD was 1.8. The DAR for the
thio-controlAb-HC-A118C-center-linked-PBD was 1.9.
[0500] Tumor and body weight measurements were taken at least once
per week for the duration of the study. Mice were euthanized when
tumors reached 1000-2000 mm.sup.3 or if the mouse lost 20% or more
of its body weight. Tumor volume was measured in two dimensions
(length and width) using calipers and the tumor volume was
calculated using the formula: Tumor size (mm.sup.3)=(longer
measurement.times.shorter measurement.sup.2).times.0.5.
[0501] The results of that experiment are shown in Table 5 and FIG.
4. Each group contained 8 mice at the beginning of the study.
AUC/day % TGI (tumor growth inhibition) is calculated using the
following formula: %
TGI=100.times.(1-AUCtreatment/Day/AUCvehicle/Day). PR=partial
response, which is defined as more than 50% but less than 100%
reduction in tumor volume, compared with the starting tumor volume,
on any day during the study. CR=complete response, which is defined
as a 100% reduction in tumor volume (no measurable tumor), on any
day during the study.
TABLE-US-00007 TABLE 5 Efficacy of hu7C2 ADCs in MMTV-Her2 Fo5
transgenic mammary tumor xenograft model tumor Last % BW volume,
Day AUC/day % TGI change, last Group last day (N) (lower, upper) PR
CR day (1) vehicle 1640 14 (7) 0 (0, 0) 0 0 5.71 (2) thio-hu7C2-HC-
260 35 (6) 93 (77, 103) 1 0 2.18 A118C-center-linked- PBD, 0.3
mg/kg (3) thio-hu7C2-HC- 115 43 (6) 106 (95, 118) 2 2 5.83
A118C-center-linked- PBD, 1 mg/kg (4) thio-hu7C2-LC- 194 43 (6) 97
(82, 107) 2 0 5.15 K149C-center-linked- PBD, 0.3 mg/kg (5)
thio-hu7C2-LC- 67 43 (8) 111 (101, 123) 5 3 3.53
K149C-center-linked- PBD, 1 mg/kg (6) thio-controlAb-HC- 794 22 (8)
54 (10, 79) 0 0 7.66 A118C-center-linked- PBD, 1 mg/kg (7)
thio-controlAb-LC- 512 26 (6) 72 (39, 89) 0 0 4.62
K149C-center-linked- PBD, 1 mg/kg
[0502] As shown in Table 5, thio-hu7C2-LC-K149C-center-linked-PBD
showed 5 partial responses and 3 complete responses at 1 mg/kg and
2 partial responses at 0.3 mg/kg. Thio-hu7C2-HC-A118C-disulfide-PBD
showed 2 partial responses and 2 complete responses at 1 mg/kg and
1 partial response at 0.3 mg/kg.
Example 4: Efficacy of hu7C2 Antibody Drug Conjugates in KPL-4
Human Breast Cancer Transgenic Mammary Tumor Transplant Xenograft
Models
[0503] Female C.B-17 SCID-beige mice (Charles River Laboratory)
were each inoculated in the thoracic mammary fat pad area with 3
million KPL-4 cells suspended in HBSS/matrigel (1:1 ratio). When
the xenograft tumors reached an average tumor volume of 100-300 mm3
(referred to as Day 0), animals were randomized into 5 groups of 8
mice each. The mice received a single administration on day 1 of
one of the following treatments, via intravenous tail vein
injection: (1) vehicle (20 mM L-histidine, 240 mM sucrose, 0.02%
Tween-20, pH 5.5), (2) thio-hu7C2-LC-K149C-center-linked-PBD, 0.3
mg/kg; (3) thio-hu7C2-LC-K149C-center-linked-PBD, 1 mg/kg; (4)
thio-hu7C2-LC-K149C-center-linked-PBD, 3 mg/kg; (5)
thio-controlAb-LC-K149C-center-linked-PBD, 3 mg/kg. The DAR for the
thio-hu7C2-LC-K149C-center-linked-PBD was 1.7 and the DAR for the
control was 1.8.
[0504] Tumors and body weights of mice were measured 1-2 times a
week throughout the study. Mice were promptly euthanized when body
weight loss was >20% of their starting weight. Tumor volume was
measured in two dimensions (length and width) using calipers and
the tumor volume was calculated using the formula: Tumor size
(mm3)=(longer measurement.times.shorter measurement
2).times.0.5.
[0505] The results of that experiment are shown in Table 6 and FIG.
5. Each group contained 8 mice at the beginning of the study.
AUC/day % TGI (tumor growth inhibition) is calculated using the
following formula: %
TGI=100.times.(1-AUCtreatment/Day/AUCvehicle/Day). PR=partial
response, which is defined as more than 50% but less than 100%
reduction in tumor volume, compared with the starting tumor volume,
on any day during the study. CR=complete response, which is defined
as a 100% reduction in tumor volume (no measurable tumor), on any
day during the study.
TABLE-US-00008 TABLE 6 Efficacy of hu7C2 ADCs in KPL-4 Human Breast
Cancer Transgenic Mammary Tumor Transplant Xenograft Models tumor
Last AUC/day % % BW volume, last Day TGI change, last Group day (N)
(lower, upper) PR CR day (1) vehicle 1095 22 (8) 0 (0, 0) 0 0 -5.89
(2) thio-hu7C2-HC- 550 25 (8) 58 (-14, 87) 0 0 -2.45
A149C-center-linked- PBD, 0.3 mg/kg (3) thio-hu7C2-HC- 641 25 (7)
55 (-28, 90) 0 0 -5.7 A149C-center-linked- PBD, 1 mg/kg (4)
thio-hu7C2-HC- 79 25 (8) 120 (108, 147) 5 1 -5.94
A149C-center-linked- PBD, 3 mg/kg (5) thio-controlAb-LC- 247 25 (6)
107 (87, 128) 1 0 -14.99 K149C-center-linked- PBD, 3 mg/kg
[0506] As shown in Table 6, thio-hu7C2-LC-K149C-center-linked-PBD
showed 5 partial responses and 1 complete response at 1 mg/kg.
[0507] In this study, anti-Her2 ADC demonstrated dose-dependent
inhibition of tumor growth, resulting in tumor regression at 3
mg/kg dose.
Example 3: Crystal Structure of 7C2 Fab Bound to HER2
Methods
[0508] Expression, purification, and crystallization of the
7C2/HER2 complex--7C2 Fab was expressed in E. coli and purified
using Protein G sepharose affinity resin (GE), SP sepharose cation
exchange chromatography, and size exclusion chromatography (SEC).
HER2 extracellular domain (ECD) was expressed in CHO cells and
purified by affinity chromatography using trastuzumab antibody
linked to controlled pore glass beads, followed by DEAE anion
exchange and size exclusion chromatography.
[0509] The complex between Fab 7C2 and HER2 ECD was purified by
SEC. The complex was deglycosylated using a combination of enzymes
(Endo F1, F2, F3, Endo H and PNGase), followed by purification by
SEC into 0.1M NaCl, 20 mM HEPES pH 7.2 and 2% glycerol. The complex
was crystallized resulting in thick plates after one week in
hanging drops using equal parts of protein at 10 mg/mL and
reservoir (30% v/v PEG 550 monomethylether, 0.1M Sodium citrate
tribasic dihydrate pH 5.0) and treated briefly with reservoir prior
to immersion in liquid nitrogen.
[0510] The diffraction data for the complex extending to 2.7 .ANG.
resolution were collected at .about.110 K at SSRL beam line 11-1.
The diffraction images were integrated and scaled using the program
HKL2000 and elements of the CCP4 suite. See Winn et al., 2011, Acta
Crystallogr D. Biol. Crystallogr. 67: 235-42.
[0511] The structure was solved by molecular replacement (MR) using
program Phaser. See McCoy et al., 2005, Acta Crystallogr D. Biol.
Crystallogr. 61: 458-64. The MR search models include the HER2 ECD
domain derived from a crystal structure of HER2/Herceptin Fab
complex (PDB code: 1N8Z), Fab constant domain (PDB code: 1N8Z) and
a predicted model for the variable domain generated by the program
Modeller. See Fiser et al., 2003, Methods Enzymol., 374: 461-91.
The structure was refined with programs REFMAC5 (Marshudov et al.,
2011, Acta Crystallogr D. Biol. Crystallogr. 67: 355-67) and
PHENIX.refine (Adams et al., 2010, Acta Crystallogr D. Biol.
Crystallogr. 66 (pt. 2): 213-21) using the maximum likelihood
target functions, anisotropic individual B-factors, and TLS
refinement. The data and refinement statistics are summarized in
Table 7.
TABLE-US-00009 TABLE 7 Statistics of x-ray diffraction data
collection and structure refinement (values in parentheses are for
last resolution shell) Data collection SSRL 11-1 Space group
C222.sub.1 Cell parameters (.ANG.) a = 136.8, b = 171.9, c = 162.5
Resolution (.ANG.) 50-2.75 (2.85-2.75) Rsym 0.112 (0.689) Number of
observations 319169 Unique reflections 49078 Redundancy 6.5 (5.5)
Completeness (%) 98.8 (92.2) <I>/<.sigma.I> 20 (2.2)
Vm(A.sup.3/Da) 4.2 Refinement Resolution (.ANG.) 48.33-2.75 Number
of reflections 49053 R, Rfree 0.23, 0,25 Number of residues 1047
Number of waters 109 Number of atoms 8039 RMSD bonds (.ANG.) 0.007
RMSD angles ('') 1.2 Mean bonded .DELTA.B (.ANG..sup.2) 5.5
Ramachandran analysis (%) 93/6/1 Number of TLS groups 3
<B>.sup.e (.ANG..sup.2) 7C2/HER2 88
Results
[0512] The crystal structure of the 7C2 Fab/HER2 complex was
determined at 2.75 .ANG. resolution. Each asymmetric unit cell
contains one Fab/HER2 complex. The structure revealed that the 7C2
Fab binds to domain I of HER2 ECD (FIG. 11A). The binding epitope
is distinct from those in the previously characterized complexes of
HER2 ECD with Fab fragments of therapeutic antibodies trastuzumab
(Tmab) or pertuzumab (Pmab), which are located at domains IV and
II, respectively. See, e.g., Cho et al., 2003, Nature, 421: 756-60;
Eigenbrot et al., 2010, PNAS, 107: 15039-44; and Franklin et al.,
2004, Caner Cell, 5: 17-28. Indeed, an overlay of the 7C2 Fab/HER2
ECD complex structure with the structures of Tmab/HER2 ECD complex
and Pmab/HER2 ECD complex shows that the three Fabs have
independent, non-overlapping epitopes and would not spatially
interfere with each other binding to HER2 (FIG. 11A). A
superposition of the HER2 ECD structures within the Tmab/HER2 ECD
complex, Pmab/HER2 ECD complex and 7C2 Fab/HER2 ECD complex showed
a minimal structural differences (FIG. 11B). This observation
suggested that the HER2 ECD is relatively rigid, which is
consistent with previous reports in the literature. See, e.g., Cho
et al., 2003, Nature, 421: 756-60; Eigenbrot et al., 2010, PNAS,
107: 15039-44; and Franklin et al., 2004, Caner Cell, 5: 17-28.
[0513] The 7C2 Fab binds to the loop 163-175 and the loop 185-189
within the HER2 domain I (i.e., amino acids 163-175 and 185-189 of
mature HER2, e.g., SEQ ID NO: 39; domain I is shown in SEQ ID NO:
35). The binding buries .about.1160 .ANG..sup.2 of solvent
accessible surface area on each side of the interface. There is an
intricate network of hydrophobic, hydrogen bonding and ionic
interactions. Certain residues that are involved in binding are
labeled in FIG. 11C. The side chain of His171 makes contacts with
the heavy chain residues His52 and Asp55. The HER2 residues Ser186,
Ser187 and Glu188 form hydrogen bonding with the D102 from heavy
chain and the two Tyr residues (Tyr36 and Tyr54) from the light
chain.
[0514] The 7C2 binding epitope partially overlaps with that from a
previously reported anti-HER2 antibody, chA21 (FIG. 11D). See Zhou
et al., 2011, JBC, 286: 31676-83. Both epitopes include a loop in
domain I (residues 163-187). Interestingly, the residue His171
plays a role in the interaction with both antibodies. However, the
chA21 binding epitope spans .about.1820 .ANG..sup.2 of solvent
accessible surface area, which is .about.660 .ANG..sup.2 bigger
than the 7C2 epitope and includes two additional N-terminal loops,
residues 100-105 and residues 135-144.
[0515] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, the descriptions and examples should not be
construed as limiting the scope of the invention. The disclosures
of all patent and scientific literature cited herein are expressly
incorporated in their entirety by reference.
TABLE-US-00010 Table of Sequences SEQ NAME SEQUENCE ID NO Human
Her2 MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY 1
precursor QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR
(UniProtKB/ IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK
Swiss-Prot: GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK
P04626.1); aa 1- GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC
AAGCTGPKHS 22 signal DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT
FGASCVTACP sequence; aa 23- YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR
CEKCSKPCAR VCYGLGMEHL 1255 mature REVRAVTSAN IQEFAGCKKI FGSLAFLPES
FDGDPASNTA PLQPEQLQVF Her2 ETLEEITGYL YISAWPDSLP DLSVFQNLQV
IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH
QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC VEECRVLQGL
PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC PSGVKPDLSY
MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG ILLVVVLGVV
FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL RKVKVLGSGA
FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL
TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN
VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT HQSDVWSYGV
TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM IDSECRPRFR
ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF
FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL
GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ GGAAPQPHPP
PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV mature human
TQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL ELTYLPTNAS 39 HER2
LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG DPLNNTTPVT
GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR
ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS
DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP YNYLSTDVGS
CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN IQEFAGCKKI
FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP DLSVFQNLQV
IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH
QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC VEECRVLQGL
PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC PSGVKPDLSY
MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG ILLVVVLGVV
FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL RKVKVLGSGA
FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL
TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN
VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT HQSDVWSYGV
TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM IDSECRPRFR
ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF
FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL
GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP
SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ GGAAPQPHPP
PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV Murine 7C2.B9
DIVLTQSPAS LVVSLGQRAT ISCRASQSVS GSRFTYMHWY QQKPGQPPKL 2 (mu7C2)
light LIKYASILES GVPARFSGGG SGTDFTLNIH PVEEDDTATY YCQHSWEIPP chain
variable WTFGGGTKLE IK region Mu7C2 heavy QVQLQQPGAE LVRPGASVKL
SCKASGYSFT GYWMNWLKQR PGQGLEWIGM 3 chain variable IHPSDSEIRA
NQKFRDKATL TVDKSSTTAY MQLSSPTSED SAVYYCARGT region YDGGFEYWGQ
GTTLTVSS Mu7C2 HVR-L1 RASQSVSGSRFTYMH 4 Mu7C2 HVR-L2 YASILES 5
Mu7C2 HVR-L3 QHSWEIPPWT 6 Mu7C2 HVR-H1 GYWMN 7 Mu7C2 HVR-H2
MIHPSDSEIRANQKFRD 8 Mu7C2 HVR-H3 GTYDGGFEY 9 Humanized DIVMTQSPDS
LAVSLGERAT INCRASQSVS GSRFTYMHWY QQKPGQPPKL 10 7C2.v2.2.LA
LIKYASILES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQHSWEIPP ("hu7C2")
light WTFGQGTKVE IK chain variable region Hu7C2 heavy EVQLVQSGAE
VKKPGASVKV SCKASGYSFT GYWMNWVRQA PGQGLEWIGM 11 chain variable
IHPLDAEIRA NQKFRDRVTI TVDTSTSTAY LELSSLRSED TAVYYCARGT region
YDGGFEYWGQ GTLVTVSS Hu7C2 HVR-L1 RASQSVSGSRFTYMH 12 Hu7C2 HVR-L2
YASILES 13 Hu7C2 HVR-L3 QHSWEIPPWT 14 Hu7C2 HVR-H1 GYWMN 15 Hu7C2
HVR-H2 MIHPLDAEIRANQKFRD 16 (Hu7C2.v2.1.S53L, S55A HVR-H2) Hu7C2
HVR-H3 GTYDGGFEY 17 Humanized DIVMTQSPDS LAVSLGERAT INCRASQSVS
GSRFTYMHWY QQKPGQPPKL 18 7C2.v2.2.LA LIKYASILES GVPDRFSGSG
SGTDFTLTIS SLQAEDVAVY YCQHSWEIPP (hu7C2) kappa WTFGQGTKVE
IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK light chain VQWKVDNALQ
SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
Hu7C2IgG1 EVQLVQSGAE VKKPGASVKV SCKASGYSFT GYWMNWVRQA PGQGLEWIGM 19
heavy chain IHPLDAEIRA NQKFRDRVTI TVDTSTSTAY LELSSLRSED TAVYYCARGT
YDGGFEYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN
SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS
CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV
DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA
KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
Hu7C2.v2.1.S53M MIHPMDSEIRANQKFRD 20 HVR-H2 Hu7C2.v2.1.S53L
MIHPLDSEIRANQKFRD 21 HVR-H2 Hu7C2.v2.1.E101K GTYDGGFKY 22 HVR-H3
Humanized DIVMTQSPDS LAVSLGERAT INCRASQSVS GSRFTYMHWY QQKPGQPPKL 23
7C2.v2.2.LA LIKYASILES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQHSWEIPP
(hu7C2) K149C WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL
LNNFYPREAK kappa light chain VQWCVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC Hu7C2 A118C EVQLVQSGAE
VKKPGASVKV SCKASGYSFT GYWMNWVRQA PGQGLEWIGM 24 IgG1 heavy chain
IHPLDAEIRA NQKFRDRVTI TVDTSTSTAY LELSSLRSED TAVYYCARGT YDGGFEYWGQ
GTLVTVSSCS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT
FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC
PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT
KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK V205C cysteine TVAAPSVFIF
PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN 25 engineered light
SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH QGLSSPCTKS chain
constant FNRGEC region (Ig.kappa.) A118C cysteine CSTKGPSVFP
LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV 26 engineered heavy
HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP chain
constant KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS
region (IgG1) HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT
VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC
LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV
MHEALHNHYT QKSLSLSPGK K149C cysteine TVAAPSVFIF PPSDEQLKSG
TASVVCLLNN FYPREAKVQW CVDNALQSGN 27 engineered light SQESVTEQDS
KDSTYSLSST LTLSKADYEK HKVYACEVTH QGLSSPVTKS chain constant FNRGEC
region (Ig.kappa.) S400C cysteine ASTKGPSVFP LAPSSKSTSG GTAALGCLVK
DYFPEPVTVS WNSGALTSGV 28 engineered heavy HTFPAVLQSS GLYSLSSVVT
VPSSSLGTQT YICNVNHKPS NTKVDKKVEP chain constant KSCDKTHTCP
PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS region (IgG1)
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA
LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP
ENNYKTTPPV LDCDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
Sequence CWU 1
1
4311255PRTHomo sapiens 1Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu
Leu Leu Ala Leu Leu1 5 10 15Pro Pro Gly Ala Ala Ser Thr Gln Val Cys
Thr Gly Thr Asp Met Lys 20 25 30Leu Arg Leu Pro Ala Ser Pro Glu Thr
His Leu Asp Met Leu Arg His 35 40 45Leu Tyr Gln Gly Cys Gln Val Val
Gln Gly Asn Leu Glu Leu Thr Tyr 50 55 60Leu Pro Thr Asn Ala Ser Leu
Ser Phe Leu Gln Asp Ile Gln Glu Val65 70 75 80Gln Gly Tyr Val Leu
Ile Ala His Asn Gln Val Arg Gln Val Pro Leu 85 90 95Gln Arg Leu Arg
Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr 100 105 110Ala Leu
Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro 115 120
125Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
130 135 140Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn
Pro Gln145 150 155 160Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp
Ile Phe His Lys Asn 165 170 175Asn Gln Leu Ala Leu Thr Leu Ile Asp
Thr Asn Arg Ser Arg Ala Cys 180 185 190His Pro Cys Ser Pro Met Cys
Lys Gly Ser Arg Cys Trp Gly Glu Ser 195 200 205Ser Glu Asp Cys Gln
Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys 210 215 220Ala Arg Cys
Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys225 230 235
240Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
245 250 255His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala
Leu Val 260 265 270Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn
Pro Glu Gly Arg 275 280 285Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala
Cys Pro Tyr Asn Tyr Leu 290 295 300Ser Thr Asp Val Gly Ser Cys Thr
Leu Val Cys Pro Leu His Asn Gln305 310 315 320Glu Val Thr Ala Glu
Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys 325 330 335Pro Cys Ala
Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu 340 345 350Val
Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys 355 360
365Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp
370 375 380Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln
Val Phe385 390 395 400Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr
Ile Ser Ala Trp Pro 405 410 415Asp Ser Leu Pro Asp Leu Ser Val Phe
Gln Asn Leu Gln Val Ile Arg 420 425 430Gly Arg Ile Leu His Asn Gly
Ala Tyr Ser Leu Thr Leu Gln Gly Leu 435 440 445Gly Ile Ser Trp Leu
Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly 450 455 460Leu Ala Leu
Ile His His Asn Thr His Leu Cys Phe Val His Thr Val465 470 475
480Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr
485 490 495Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala
Cys His 500 505 510Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly
Pro Thr Gln Cys 515 520 525Val Asn Cys Ser Gln Phe Leu Arg Gly Gln
Glu Cys Val Glu Glu Cys 530 535 540Arg Val Leu Gln Gly Leu Pro Arg
Glu Tyr Val Asn Ala Arg His Cys545 550 555 560Leu Pro Cys His Pro
Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys 565 570 575Phe Gly Pro
Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp 580 585 590Pro
Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu 595 600
605Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln
610 615 620Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp
Asp Lys625 630 635 640Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu
Thr Ser Ile Ile Ser 645 650 655Ala Val Val Gly Ile Leu Leu Val Val
Val Leu Gly Val Val Phe Gly 660 665 670Ile Leu Ile Lys Arg Arg Gln
Gln Lys Ile Arg Lys Tyr Thr Met Arg 675 680 685Arg Leu Leu Gln Glu
Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly 690 695 700Ala Met Pro
Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu705 710 715
720Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys
725 730 735Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val
Ala Ile 740 745 750Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn
Lys Glu Ile Leu 755 760 765Asp Glu Ala Tyr Val Met Ala Gly Val Gly
Ser Pro Tyr Val Ser Arg 770 775 780Leu Leu Gly Ile Cys Leu Thr Ser
Thr Val Gln Leu Val Thr Gln Leu785 790 795 800Met Pro Tyr Gly Cys
Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg 805 810 815Leu Gly Ser
Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly 820 825 830Met
Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala 835 840
845Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe
850 855 860Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His
Ala Asp865 870 875 880Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu
Glu Ser Ile Leu Arg 885 890 895Arg Arg Phe Thr His Gln Ser Asp Val
Trp Ser Tyr Gly Val Thr Val 900 905 910Trp Glu Leu Met Thr Phe Gly
Ala Lys Pro Tyr Asp Gly Ile Pro Ala 915 920 925Arg Glu Ile Pro Asp
Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro 930 935 940Pro Ile Cys
Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met945 950 955
960Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
965 970 975Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln
Asn Glu 980 985 990Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe
Tyr Arg Ser Leu 995 1000 1005Leu Glu Asp Asp Asp Met Gly Asp Leu
Val Asp Ala Glu Glu Tyr 1010 1015 1020Leu Val Pro Gln Gln Gly Phe
Phe Cys Pro Asp Pro Ala Pro Gly 1025 1030 1035Ala Gly Gly Met Val
His His Arg His Arg Ser Ser Ser Thr Arg 1040 1045 1050Ser Gly Gly
Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu 1055 1060 1065Glu
Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser 1070 1075
1080Asp Val Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu
1085 1090 1095Gln Ser Leu Pro Thr His Asp Pro Ser Pro Leu Gln Arg
Tyr Ser 1100 1105 1110Glu Asp Pro Thr Val Pro Leu Pro Ser Glu Thr
Asp Gly Tyr Val 1115 1120 1125Ala Pro Leu Thr Cys Ser Pro Gln Pro
Glu Tyr Val Asn Gln Pro 1130 1135 1140Asp Val Arg Pro Gln Pro Pro
Ser Pro Arg Glu Gly Pro Leu Pro 1145 1150 1155Ala Ala Arg Pro Ala
Gly Ala Thr Leu Glu Arg Pro Lys Thr Leu 1160 1165 1170Ser Pro Gly
Lys Asn Gly Val Val Lys Asp Val Phe Ala Phe Gly 1175 1180 1185Gly
Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln Gly Gly Ala 1190 1195
1200Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala Phe Asp
1205 1210 1215Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly
Ala Pro 1220 1225 1230Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu
Asn Pro Glu Tyr 1235 1240 1245Leu Gly Leu Asp Val Pro Val 1250
12552112PRTMus musculus 2Asp Ile Val Leu Thr Gln Ser Pro Ala Ser
Leu Val Val Ser Leu Gly1 5 10 15Gln Arg Ala Thr Ile Ser Cys Arg Ala
Ser Gln Ser Val Ser Gly Ser 20 25 30Arg Phe Thr Tyr Met His Trp Tyr
Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45Lys Leu Leu Ile Lys Tyr Ala
Ser Ile Leu Glu Ser Gly Val Pro Ala 50 55 60Arg Phe Ser Gly Gly Gly
Ser Gly Thr Asp Phe Thr Leu Asn Ile His65 70 75 80Pro Val Glu Glu
Asp Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp 85 90 95Glu Ile Pro
Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105
1103118PRTMus musculus 3Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu
Val Arg Pro Gly Ala1 5 10 15Ser Val Lys Leu Ser Cys Lys Ala Ser Gly
Tyr Ser Phe Thr Gly Tyr 20 25 30Trp Met Asn Trp Leu Lys Gln Arg Pro
Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Met Ile His Pro Ser Asp Ser
Glu Ile Arg Ala Asn Gln Lys Phe 50 55 60Arg Asp Lys Ala Thr Leu Thr
Val Asp Lys Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser
Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Thr
Tyr Asp Gly Gly Phe Glu Tyr Trp Gly Gln Gly Thr 100 105 110Thr Leu
Thr Val Ser Ser 115415PRTMus musculus 4Arg Ala Ser Gln Ser Val Ser
Gly Ser Arg Phe Thr Tyr Met His1 5 10 1557PRTMus musculus 5Tyr Ala
Ser Ile Leu Glu Ser1 5610PRTMus musculus 6Gln His Ser Trp Glu Ile
Pro Pro Trp Thr1 5 1075PRTMus musculus 7Gly Tyr Trp Met Asn1
5817PRTMus musculus 8Met Ile His Pro Ser Asp Ser Glu Ile Arg Ala
Asn Gln Lys Phe Arg1 5 10 15Asp99PRTMus musculus 9Gly Thr Tyr Asp
Gly Gly Phe Glu Tyr1 510112PRTArtificial sequenceSynthetic
polypeptide 10Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val
Ser Leu Gly1 5 10 15Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser
Val Ser Gly Ser 20 25 30Arg Phe Thr Tyr Met His Trp Tyr Gln Gln Lys
Pro Gly Gln Pro Pro 35 40 45Lys Leu Leu Ile Lys Tyr Ala Ser Ile Leu
Glu Ser Gly Val Pro Asp 50 55 60Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser65 70 75 80Ser Leu Gln Ala Glu Asp Val
Ala Val Tyr Tyr Cys Gln His Ser Trp 85 90 95Glu Ile Pro Pro Trp Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
11011118PRTArtificial sequenceSynthetic polypeptide 11Glu Val Gln
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30Trp
Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40
45Gly Met Ile His Pro Leu Asp Ala Glu Ile Arg Ala Asn Gln Lys Phe
50 55 60Arg Asp Arg Val Thr Ile Thr Val Asp Thr Ser Thr Ser Thr Ala
Tyr65 70 75 80Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Gly Thr Tyr Asp Gly Gly Phe Glu Tyr Trp
Gly Gln Gly Thr 100 105 110Leu Val Thr Val Ser Ser
1151215PRTArtificial sequenceSynthetic peptide 12Arg Ala Ser Gln
Ser Val Ser Gly Ser Arg Phe Thr Tyr Met His1 5 10
15137PRTArtificial sequenceSynthetic peptide 13Tyr Ala Ser Ile Leu
Glu Ser1 51410PRTArtificial sequenceSynthetic peptide 14Gln His Ser
Trp Glu Ile Pro Pro Trp Thr1 5 10155PRTArtificial sequenceSynthetic
peptide 15Gly Tyr Trp Met Asn1 51617PRTArtificial sequenceSynthetic
peptide 16Met Ile His Pro Leu Asp Ala Glu Ile Arg Ala Asn Gln Lys
Phe Arg1 5 10 15Asp179PRTArtificial sequenceSynthetic peptide 17Gly
Thr Tyr Asp Gly Gly Phe Glu Tyr1 518219PRTArtificial
sequenceSynthetic polypeptide 18Asp Ile Val Met Thr Gln Ser Pro Asp
Ser Leu Ala Val Ser Leu Gly1 5 10 15Glu Arg Ala Thr Ile Asn Cys Arg
Ala Ser Gln Ser Val Ser Gly Ser 20 25 30Arg Phe Thr Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45Lys Leu Leu Ile Lys Tyr
Ala Ser Ile Leu Glu Ser Gly Val Pro Asp 50 55 60Arg Phe Ser Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser65 70 75 80Ser Leu Gln
Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Trp 85 90 95Glu Ile
Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
110Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
Asn Phe 130 135 140Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp
Asn Ala Leu Gln145 150 155 160Ser Gly Asn Ser Gln Glu Ser Val Thr
Glu Gln Asp Ser Lys Asp Ser 165 170 175Thr Tyr Ser Leu Ser Ser Thr
Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190Lys His Lys Val Tyr
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205Pro Val Thr
Lys Ser Phe Asn Arg Gly Glu Cys 210 21519448PRTArtificial
sequenceSynthetic polypeptide 19Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30Trp Met Asn Trp Val Arg Gln
Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Met Ile His Pro Leu
Asp Ala Glu Ile Arg Ala Asn Gln Lys Phe 50 55 60Arg Asp Arg Val Thr
Ile Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Leu Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg
Gly Thr Tyr Asp Gly Gly Phe Glu Tyr Trp Gly Gln Gly Thr 100 105
110Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
115 120 125Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly 130 135 140Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
Val Ser Trp Asn145 150 155 160Ser Gly Ala Leu Thr Ser Gly Val His
Thr Phe Pro Ala Val Leu Gln 165 170 175Ser Ser Gly Leu Tyr Ser Leu
Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190Ser Leu Gly Thr Gln
Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205Asn Thr Lys
Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220His
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser225 230
235 240Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg 245 250 255Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro 260 265 270Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala 275 280 285Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val 290 295 300Ser Val Leu Thr Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr305 310 315 320Lys Cys Lys Val
Ser Asn Lys
Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335Ile Ser Lys Ala Lys
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350Pro Pro Ser
Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365Leu
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375
380Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
Asp385 390 395 400Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser 405 410 415Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
Ser Val Met His Glu Ala 420 425 430Leu His Asn His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys 435 440 4452017PRTArtificial
sequenceSynthetic peptide 20Met Ile His Pro Met Asp Ser Glu Ile Arg
Ala Asn Gln Lys Phe Arg1 5 10 15Asp2117PRTArtificial
sequenceSynthetic peptide 21Met Ile His Pro Leu Asp Ser Glu Ile Arg
Ala Asn Gln Lys Phe Arg1 5 10 15Asp229PRTArtificial
sequenceSynthetic peptide 22Gly Thr Tyr Asp Gly Gly Phe Lys Tyr1
523219PRTArtificial sequenceSynthetic polypeptide 23Asp Ile Val Met
Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10 15Glu Arg Ala
Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Ser Gly Ser 20 25 30Arg Phe
Thr Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45Lys
Leu Leu Ile Lys Tyr Ala Ser Ile Leu Glu Ser Gly Val Pro Asp 50 55
60Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser65
70 75 80Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser
Trp 85 90 95Glu Ile Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 105 110Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu 115 120 125Gln Leu Lys Ser Gly Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe 130 135 140Tyr Pro Arg Glu Ala Lys Val Gln
Trp Cys Val Asp Asn Ala Leu Gln145 150 155 160Ser Gly Asn Ser Gln
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175Thr Tyr Ser
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190Lys
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200
205Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210
21524448PRTArtificial sequenceSynthetic polypeptide 24Glu Val Gln
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 20 25 30Trp
Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40
45Gly Met Ile His Pro Leu Asp Ala Glu Ile Arg Ala Asn Gln Lys Phe
50 55 60Arg Asp Arg Val Thr Ile Thr Val Asp Thr Ser Thr Ser Thr Ala
Tyr65 70 75 80Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Gly Thr Tyr Asp Gly Gly Phe Glu Tyr Trp
Gly Gln Gly Thr 100 105 110Leu Val Thr Val Ser Ser Cys Ser Thr Lys
Gly Pro Ser Val Phe Pro 115 120 125Leu Ala Pro Ser Ser Lys Ser Thr
Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140Cys Leu Val Lys Asp Tyr
Phe Pro Glu Pro Val Thr Val Ser Trp Asn145 150 155 160Ser Gly Ala
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175Ser
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185
190Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
195 200 205Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
Lys Thr 210 215 220His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
Gly Gly Pro Ser225 230 235 240Val Phe Leu Phe Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg 245 250 255Thr Pro Glu Val Thr Cys Val
Val Val Asp Val Ser His Glu Asp Pro 260 265 270Glu Val Lys Phe Asn
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285Lys Thr Lys
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300Ser
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr305 310
315 320Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr 325 330 335Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu 340 345 350Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
Val Ser Leu Thr Cys 355 360 365Leu Val Lys Gly Phe Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser 370 375 380Asn Gly Gln Pro Glu Asn Asn
Tyr Lys Thr Thr Pro Pro Val Leu Asp385 390 395 400Ser Asp Gly Ser
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415Arg Trp
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425
430Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 44525106PRTArtificial sequenceSynthetic polypeptide 25Thr
Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln1 5 10
15Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20 25 30Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser 35 40 45Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
Ser Thr 50 55 60Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp
Tyr Glu Lys65 70 75 80His Lys Val Tyr Ala Cys Glu Val Thr His Gln
Gly Leu Ser Ser Pro 85 90 95Cys Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 10526330PRTArtificial sequenceSynthetic polypeptide 26Cys Ser
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25
30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro
Ser Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val Val Val Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170
175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn 195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu225 230 235 240Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285Leu
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295
300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr305 310 315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
33027106PRTArtificial sequenceSynthetic polypeptide 27Thr Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln1 5 10 15Leu Lys
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 20 25 30Pro
Arg Glu Ala Lys Val Gln Trp Cys Val Asp Asn Ala Leu Gln Ser 35 40
45Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
50 55 60Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
Lys65 70 75 80His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu
Ser Ser Pro 85 90 95Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100
10528330PRTArtificial sequenceSynthetic polypeptide 28Ala Ser Thr
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10 15Ser Thr
Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30Phe
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40
45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys 85 90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 100 105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro 115 120 125Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys 130 135 140Val Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150 155 160Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185
190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly 210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu Glu225 230 235 240Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr 245 250 255Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Cys Asp Gly Ser Phe Phe 275 280 285Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr305 310
315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
33029449PRTArtificial sequenceSynthetic polypeptide 29Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val
50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp
Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser Ala Ser
Thr Lys Gly Pro Ser Val 115 120 125Phe Pro Leu Ala Pro Ser Ser Lys
Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser145 150 155 160Trp Asn Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175Leu
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185
190Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
Cys Asp 210 215 220Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
Leu Leu Gly Gly225 230 235 240Pro Ser Val Phe Leu Phe Pro Pro Lys
Pro Lys Asp Thr Leu Met Ile 245 250 255Ser Arg Thr Pro Glu Val Thr
Cys Val Val Val Asp Val Ser His Glu 260 265 270Asp Pro Glu Val Lys
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285Asn Ala Lys
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300Val
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys305 310
315 320Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
Glu 325 330 335Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
Gln Val Tyr 340 345 350Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
Asn Gln Val Ser Leu 355 360 365Thr Cys Leu Val Lys Gly Phe Tyr Pro
Ser Asp Ile Ala Val Glu Trp 370 375 380Glu Ser Asn Gly Gln Pro Glu
Asn Asn Tyr Lys Thr Thr Pro Pro Val385 390 395 400Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415Lys Ser
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425
430Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445Gly30214PRTArtificial sequenceSynthetic polypeptide
30Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr
Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155
160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys
21031448PRTArtificial sequenceSynthetic polypeptide 31Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25
30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg
Phe 50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr
Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp
Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser Ala Ser
Thr Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Ser Ser Lys
Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155 160Asn Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170
175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
Lys Pro 195 200 205Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
Ser Cys Asp Lys 210 215 220Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Leu Leu Gly Gly Pro225 230 235 240Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295
300Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
Glu305 310 315 320Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
Pro Ile Glu Lys 325 330 335Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Thr 340 345 350Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn Gln Val Ser Leu Thr 355 360 365Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu385 390 395 400Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410
415Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly 435 440 44532214PRTArtificial sequenceSynthetic polypeptide
32Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile
Gly 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Tyr Tyr Ile Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro
Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val
Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155
160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys
21033449PRTArtificial sequenceSynthetic polypeptide 33Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30Thr
Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe
50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr
Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser Ala Ser Thr
Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Ser Ser Lys Ser
Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140Gly Cys Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155 160Asn Ser Gly
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175Gln
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185
190Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
Asp Lys 210 215 220Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro225 230 235 240Ser Val Phe Leu Phe Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser 245 250 255Arg Thr Pro Glu Val Thr Cys
Val Val Val Asp Val Ser His Glu Asp 260 265 270Pro Glu Val Lys Phe
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285Ala Lys Thr
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300Val
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu305 310
315 320Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
Lys 325 330 335Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr Thr 340 345 350Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
Gln Val Ser Leu Thr 355 360 365Cys Leu Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu 370 375 380Ser Asn Gly Gln Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu385 390 395 400Asp Ser Asp Gly
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415Ser Arg
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425
430Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445Lys34217PRTArtificial sequenceSynthetic polypeptide
34Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala1
5 10 15Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp
Val 20 25 30Ser Ile Gly Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala
Pro Lys 35 40 45Leu Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val
Pro Ser Arg 50 55 60Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser65 70 75 80Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
Cys Gln Gln Tyr Tyr Ile 85 90 95Tyr Pro Tyr Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys Arg Thr 100 105 110Val Ala Ala Pro Ser Val Phe
Ile Phe Pro Pro Ser Asp Glu Gln Leu 115 120 125Lys Ser Gly Thr Ala
Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 130 135 140Arg Glu Ala
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly145 150 155
160Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
165 170 175Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
Lys His 180 185 190Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu
Ser Ser Pro Val 195 200 205Thr Lys Ser Phe Asn Arg Gly Glu Cys 210
21535195PRTHomo sapiens 35Thr Gln Val Cys Thr Gly Thr Asp Met Lys
Leu Arg Leu Pro Ala Ser1 5 10 15Pro Glu Thr His Leu Asp Met Leu Arg
His Leu Tyr Gln Gly Cys Gln 20 25 30Val Val Gln Gly Asn Leu Glu Leu
Thr Tyr Leu Pro Thr Asn Ala Ser 35 40 45Leu Ser Phe Leu Gln Asp Ile
Gln Glu Val Gln Gly Tyr Val Leu Ile 50 55 60Ala His Asn Gln Val Arg
Gln Val Pro Leu Gln Arg Leu Arg Ile Val65 70 75 80Arg Gly Thr Gln
Leu Phe Glu Asp Asn Tyr Ala Leu Ala Val Leu Asp 85 90 95Asn Gly Asp
Pro Leu Asn Asn Thr Thr Pro Val Thr Gly Ala Ser Pro 100 105 110Gly
Gly Leu Arg Glu Leu Gln Leu Arg Ser Leu Thr Glu Ile Leu Lys 115 120
125Gly Gly Val Leu Ile Gln Arg Asn Pro Gln Leu Cys Tyr Gln Asp Thr
130 135 140Ile Leu Trp Lys Asp Ile Phe His Lys Asn Asn Gln Leu Ala
Leu Thr145 150 155 160Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys His
Pro Cys Ser Pro Met 165 170 175Cys Lys Gly Ser Arg Cys Trp Gly Glu
Ser Ser Glu Asp Cys Gln Ser 180 185 190Leu Thr Arg 19536124PRTHomo
sapiens 36Thr Val Cys Ala Gly Gly Cys Ala Arg Cys Lys Gly Pro Leu
Pro Thr1 5 10 15Asp Cys Cys His Glu Gln Cys Ala Ala Gly Cys Thr Gly
Pro Lys His 20 25 30Ser Asp Cys Leu Ala Cys Leu His Phe Asn His Ser
Gly Ile Cys Glu 35 40 45Leu His Cys Pro Ala Leu Val Thr Tyr Asn Thr
Asp Thr Phe Glu Ser 50 55 60Met Pro Asn Pro Glu Gly Arg Tyr Thr Phe
Gly Ala Ser Cys Val Thr65 70 75 80Ala Cys Pro Tyr Asn Tyr Leu Ser
Thr Asp Val Gly Ser Cys Thr Leu 85 90 95Val Cys Pro Leu His Asn Gln
Glu Val Thr Ala Glu Asp Gly Thr Gln 100 105 110Arg Cys Glu Lys Cys
Ser Lys Pro Cys Ala Arg Val 115 12037169PRTHomo sapiens 37Cys Tyr
Gly Leu Gly Met Glu His Leu Arg Glu Val Arg Ala Val Thr1 5 10 15Ser
Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys Lys Ile Phe Gly Ser 20 25
30Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp Pro Ala Ser Asn Thr
35 40 45Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe Glu Thr Leu Glu
Glu 50 55 60Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro Asp Ser Leu
Pro Asp65 70 75 80Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg Gly
Arg Ile Leu His 85 90 95Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu
Gly Ile Ser Trp Leu 100 105 110Gly Leu Arg Ser Leu Arg Glu Leu Gly
Ser Gly Leu Ala Leu Ile His 115 120 125His Asn Thr His Leu Cys Phe
Val His Thr Val Pro Trp Asp Gln Leu 130 135 140Phe Arg Asn Pro His
Gln Ala Leu Leu His Thr Ala Asn Arg Pro Glu145 150 155 160Asp Glu
Cys Val Gly Glu Gly Leu Ala 16538142PRTHomo sapiens 38Cys His Gln
Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr1 5 10 15Gln Cys
Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu 20 25 30Glu
Cys Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg 35 40
45His Cys Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val
50 55 60Thr Cys Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His
Tyr65 70 75 80Lys Asp Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly
Val Lys Pro 85 90 95Asp Leu Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp
Glu Glu Gly Ala 100 105 110Cys Gln Pro Cys Pro Ile Asn Cys Thr His
Ser Cys Val Asp Leu Asp 115 120 125Asp Lys Gly Cys Pro Ala Glu Gln
Arg Ala Ser Pro Leu Thr 130 135 140391233PRTHomo sapiens 39Thr Gln
Val Cys Thr Gly Thr Asp Met Lys Leu Arg Leu Pro Ala Ser1 5 10 15Pro
Glu Thr His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys Gln 20 25
30Val Val Gln Gly Asn Leu Glu Leu Thr Tyr Leu Pro Thr Asn Ala Ser
35 40 45Leu Ser Phe Leu Gln Asp Ile Gln Glu Val Gln Gly Tyr Val Leu
Ile 50 55 60Ala His Asn Gln Val Arg Gln Val Pro Leu Gln Arg Leu Arg
Ile Val65 70 75 80Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr Ala Leu
Ala Val Leu Asp 85 90 95Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro Val
Thr Gly Ala Ser Pro 100 105 110Gly Gly Leu Arg Glu Leu Gln Leu Arg
Ser Leu Thr Glu Ile Leu Lys 115 120 125Gly Gly Val Leu Ile Gln Arg
Asn Pro Gln Leu Cys Tyr Gln Asp Thr 130 135 140Ile Leu Trp Lys Asp
Ile Phe His Lys Asn Asn Gln Leu Ala Leu Thr145 150 155 160Leu Ile
Asp Thr Asn Arg Ser Arg Ala Cys His Pro Cys Ser Pro Met 165 170
175Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser Ser Glu Asp Cys Gln Ser
180 185 190Leu Thr Arg Thr Val Cys Ala Gly Gly Cys Ala Arg Cys Lys
Gly Pro 195 200 205Leu Pro Thr Asp Cys Cys His Glu Gln Cys Ala Ala
Gly Cys Thr Gly 210 215 220Pro Lys His Ser Asp Cys Leu Ala Cys Leu
His Phe Asn His Ser Gly225 230 235 240Ile Cys Glu Leu His Cys Pro
Ala Leu Val Thr Tyr Asn Thr Asp Thr 245 250 255Phe Glu Ser Met Pro
Asn Pro Glu Gly Arg Tyr Thr Phe Gly Ala Ser 260 265 270Cys Val Thr
Ala Cys Pro Tyr Asn Tyr Leu Ser Thr Asp Val Gly Ser 275 280 285Cys
Thr Leu Val Cys Pro Leu His Asn Gln Glu Val Thr Ala Glu Asp 290 295
300Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys Pro Cys Ala Arg Val
Cys305 310 315 320Tyr Gly Leu Gly Met Glu His Leu Arg Glu Val Arg
Ala Val Thr Ser 325 330 335Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys
Lys Ile Phe Gly Ser Leu 340 345 350Ala Phe Leu Pro Glu Ser Phe Asp
Gly Asp Pro Ala Ser Asn Thr Ala 355 360 365Pro Leu Gln Pro Glu Gln
Leu Gln Val Phe Glu Thr Leu Glu Glu Ile 370 375 380Thr Gly Tyr Leu
Tyr Ile Ser Ala Trp Pro Asp Ser Leu Pro Asp Leu385 390 395 400Ser
Val Phe Gln Asn Leu Gln Val Ile Arg Gly Arg Ile Leu His Asn 405 410
415Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu Gly Ile Ser Trp Leu Gly
420 425 430Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly Leu Ala Leu Ile
His His 435 440 445Asn Thr His Leu Cys Phe Val His Thr Val Pro Trp
Asp Gln Leu Phe 450 455 460Arg Asn Pro His Gln Ala Leu Leu His Thr
Ala Asn Arg Pro Glu Asp465 470 475 480Glu Cys Val Gly Glu Gly Leu
Ala Cys His Gln Leu Cys Ala Arg Gly 485 490 495His Cys Trp Gly Pro
Gly Pro Thr Gln Cys Val Asn Cys Ser Gln Phe 500 505 510Leu Arg Gly
Gln Glu Cys Val Glu Glu Cys Arg Val
Leu Gln Gly Leu 515 520 525Pro Arg Glu Tyr Val Asn Ala Arg His Cys
Leu Pro Cys His Pro Glu 530 535 540Cys Gln Pro Gln Asn Gly Ser Val
Thr Cys Phe Gly Pro Glu Ala Asp545 550 555 560Gln Cys Val Ala Cys
Ala His Tyr Lys Asp Pro Pro Phe Cys Val Ala 565 570 575Arg Cys Pro
Ser Gly Val Lys Pro Asp Leu Ser Tyr Met Pro Ile Trp 580 585 590Lys
Phe Pro Asp Glu Glu Gly Ala Cys Gln Pro Cys Pro Ile Asn Cys 595 600
605Thr His Ser Cys Val Asp Leu Asp Asp Lys Gly Cys Pro Ala Glu Gln
610 615 620Arg Ala Ser Pro Leu Thr Ser Ile Ile Ser Ala Val Val Gly
Ile Leu625 630 635 640Leu Val Val Val Leu Gly Val Val Phe Gly Ile
Leu Ile Lys Arg Arg 645 650 655Gln Gln Lys Ile Arg Lys Tyr Thr Met
Arg Arg Leu Leu Gln Glu Thr 660 665 670Glu Leu Val Glu Pro Leu Thr
Pro Ser Gly Ala Met Pro Asn Gln Ala 675 680 685Gln Met Arg Ile Leu
Lys Glu Thr Glu Leu Arg Lys Val Lys Val Leu 690 695 700Gly Ser Gly
Ala Phe Gly Thr Val Tyr Lys Gly Ile Trp Ile Pro Asp705 710 715
720Gly Glu Asn Val Lys Ile Pro Val Ala Ile Lys Val Leu Arg Glu Asn
725 730 735Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr
Val Met 740 745 750Ala Gly Val Gly Ser Pro Tyr Val Ser Arg Leu Leu
Gly Ile Cys Leu 755 760 765Thr Ser Thr Val Gln Leu Val Thr Gln Leu
Met Pro Tyr Gly Cys Leu 770 775 780Leu Asp His Val Arg Glu Asn Arg
Gly Arg Leu Gly Ser Gln Asp Leu785 790 795 800Leu Asn Trp Cys Met
Gln Ile Ala Lys Gly Met Ser Tyr Leu Glu Asp 805 810 815Val Arg Leu
Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys 820 825 830Ser
Pro Asn His Val Lys Ile Thr Asp Phe Gly Leu Ala Arg Leu Leu 835 840
845Asp Ile Asp Glu Thr Glu Tyr His Ala Asp Gly Gly Lys Val Pro Ile
850 855 860Lys Trp Met Ala Leu Glu Ser Ile Leu Arg Arg Arg Phe Thr
His Gln865 870 875 880Ser Asp Val Trp Ser Tyr Gly Val Thr Val Trp
Glu Leu Met Thr Phe 885 890 895Gly Ala Lys Pro Tyr Asp Gly Ile Pro
Ala Arg Glu Ile Pro Asp Leu 900 905 910Leu Glu Lys Gly Glu Arg Leu
Pro Gln Pro Pro Ile Cys Thr Ile Asp 915 920 925Val Tyr Met Ile Met
Val Lys Cys Trp Met Ile Asp Ser Glu Cys Arg 930 935 940Pro Arg Phe
Arg Glu Leu Val Ser Glu Phe Ser Arg Met Ala Arg Asp945 950 955
960Pro Gln Arg Phe Val Val Ile Gln Asn Glu Asp Leu Gly Pro Ala Ser
965 970 975Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu Leu Glu Asp Asp
Asp Met 980 985 990Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu Val Pro
Gln Gln Gly Phe 995 1000 1005Phe Cys Pro Asp Pro Ala Pro Gly Ala
Gly Gly Met Val His His 1010 1015 1020Arg His Arg Ser Ser Ser Thr
Arg Ser Gly Gly Gly Asp Leu Thr 1025 1030 1035Leu Gly Leu Glu Pro
Ser Glu Glu Glu Ala Pro Arg Ser Pro Leu 1040 1045 1050Ala Pro Ser
Glu Gly Ala Gly Ser Asp Val Phe Asp Gly Asp Leu 1055 1060 1065Gly
Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His Asp 1070 1075
1080Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu
1085 1090 1095Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys
Ser Pro 1100 1105 1110Gln Pro Glu Tyr Val Asn Gln Pro Asp Val Arg
Pro Gln Pro Pro 1115 1120 1125Ser Pro Arg Glu Gly Pro Leu Pro Ala
Ala Arg Pro Ala Gly Ala 1130 1135 1140Thr Leu Glu Arg Pro Lys Thr
Leu Ser Pro Gly Lys Asn Gly Val 1145 1150 1155Val Lys Asp Val Phe
Ala Phe Gly Gly Ala Val Glu Asn Pro Glu 1160 1165 1170Tyr Leu Thr
Pro Gln Gly Gly Ala Ala Pro Gln Pro His Pro Pro 1175 1180 1185Pro
Ala Phe Ser Pro Ala Phe Asp Asn Leu Tyr Tyr Trp Asp Gln 1190 1195
1200Asp Pro Pro Glu Arg Gly Ala Pro Pro Ser Thr Phe Lys Gly Thr
1205 1210 1215Pro Thr Ala Glu Asn Pro Glu Tyr Leu Gly Leu Asp Val
Pro Val 1220 1225 123040117PRTHomo sapiens 40Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Tyr Ile His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Trp
Ile Asn Pro Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe 50 55 60Gln
Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Asp Thr Ala Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
Leu 100 105 110Val Thr Val Ser Ser 11541114PRTHomo sapiens 41Asp
Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10
15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
20 25 30Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Gln 35 40 45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser
Gly Val 50 55 60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr65 70 75 80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val
Tyr Tyr Cys Gln Gln 85 90 95Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Gln
Gly Thr Lys Val Glu Ile 100 105 110Lys Arg42113PRTMus musculus
42Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Val Val Ser Leu Gly1
5 10 15Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Gly
Ser 20 25 30Arg Phe Thr Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln
Pro Pro 35 40 45Lys Leu Leu Ile Lys Tyr Ala Ser Ile Leu Glu Ser Gly
Val Pro Ala 50 55 60Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr
Leu Asn Ile His65 70 75 80Pro Val Glu Glu Asp Asp Thr Ala Thr Tyr
Tyr Cys Gln His Ser Trp 85 90 95Glu Ile Pro Pro Trp Thr Phe Gly Gly
Gly Thr Lys Leu Glu Ile Lys 100 105 110Arg43113PRTArtificial
sequenceSynthetic polypeptide 43Asp Ile Val Met Thr Gln Ser Pro Asp
Ser Leu Ala Val Ser Leu Gly1 5 10 15Glu Arg Ala Thr Ile Asn Cys Arg
Ala Ser Gln Ser Val Ser Gly Ser 20 25 30Arg Phe Thr Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45Lys Leu Leu Ile Lys Tyr
Ala Ser Ile Leu Glu Ser Gly Val Pro Asp 50 55 60Arg Phe Ser Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser65 70 75 80Ser Leu Gln
Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Trp 85 90 95Glu Ile
Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
110Arg
* * * * *